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Abstract 
The Roles of F-box and Leucine-Rich Repeat Protein 4 (FBXL4)  
in Mitochondrial Encephalopathy and T-cell Acute Lymphoblastic Leukemia 
 Julie Erika Haydu  
 
The F-box and leucine-rich repeat factor (FBXL4) locus is altered in two distinct diseases, a 
pediatric mitochondrial encephalopathy associated with early death, and the highly aggressive 
hematological malignancy T-cell Acute Lymphoblastic Leukemia (T-ALL). As an F-box protein, FBXL4 is 
predicted to target specific protein substrates for proteasomal degradation. Notably, not much is known 
about the roles of FBXL4 in homeostasis or disease, and thus I generated conditional Fbxl4 knockout 
mice to characterize the contributions of Fbxl4 to mitochondrial encephalopathy and to T-ALL. 
Homozygous mutations in FBXL4 are associated with pediatric-onset mitochondrial 
encephalopathy, but the molecular and cellular mechanisms driving disease pathogenesis are unknown. 
Here, I show that constitutive loss of Fbxl4 recapitulates key features of human mitochondrial 
encephalopathy, including microcephaly, failure to thrive, and perinatal lethality. Moreover, Fbxl4 
inactivation drives profound metabolic alterations in the perinatal period. On the cellular level, loss of 
Fbxl4 results in mitochondria DNA depletion and disrupts oxidative phosphorylation and mitochondria 
membrane potential. Isolation of the FBXL4 protein complex reveals that FBXL4 interacts with a diverse 
set of mitochondrial factors crucial for normal mitochondrial function. 
FBXL4 is recurrently deleted in T-ALL as part of large heterozygous deletions affecting the long 
arm of chromosome 6 (6q-). Interestingly, I identified a leukemia patient with a focal deletion 
encompassing just the FBXL4 locus, and thus I hypothesized that FBXL4 may function as a novel 
hemizygous tumor suppressor in T-ALL. Moreover, given that Fbxl4 is differentially expressed during T-
cell development, I postulated that Fbxl4 may contribute to the process of T-cell maturation. Notably, 
using conditional Fbxl4 knockout mice, I found that Fbxl4 is dispensable in hematopoietic stem cells 
(HSCs) and during T-cell development. Moreover, conditional inactivation of Fbxl4 in HSCs or in early T-
cell progenitors does not lead to leukemia development. Heterozygous inactivation of Fbxl4 to 
recapitulate the context of 6q- does not alter the kinetics of NOTCH1-induced T-ALL. Strikingly, 
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homozygous inactivation of Fbxl4 prolongs survival in NOTCH1-induced T-ALL, an effect that can be 
partially explained on the cellular level by increased apoptosis and cell death and impaired mitochondrial 
dynamics in Fbxl4-null T-ALL tumor cells. 
Overall, these findings underscore the importance of FBXL4 in development, metabolism, and 
mitochondrial dynamics, and may be used to develop novel therapies for patients with mitochondrial 
encephalopathy associated with FBXL4 mutations and for patients with 6q- T-ALL.
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Chapter 1. Introduction 
1.A. Ubiquitin-Mediated Protein Turnover 
Intracellular protein turnover is crucial for homeostasis. In general, the mechanisms of protein 
degradation are highly regulated and energy-dependent processes. The majority of protein degradation in 
eukaryotes is mediated by the ubiquitin proteasome system (UPS), which provides multiple layers of 
regulation and specificity to the process of protein turnover (Ravid and Hochstrasser 2008). 
 
1.A.i. Ubiquitin Proteasome System  
The UPS is responsible for the degradation of most cellular proteins (Schwartz and Ciechanover 
2009). The covalent attachment of ubiquitin, a highly conserved 76-amino acid residue polypeptide, 
directs target proteins for proteolysis (Weissman 2001). Covalently linked chains of ubiquitin are 
generated on substrates through a multi-step enzymatic process. Chains of four or more ubiquitin 
molecules, linked together through Lys48 or Lys11 of each subsequent ubiquitin moiety, direct substrates 
to the 26S proteasome (Weissman 2001, Nalepa, Rolfe et al. 2006, Skaar, Pagan et al. 2013). The 26S 
proteasome is a large macromolecular complex of proteases and regulatory subunits that specifically 
degrades ubiquitin-conjugated proteins via an ATP-dependent process (Xie 2010). 
 Ubiquitin conjugation requires sequential action of a ubiquitin-activating enzyme (E1), one of many 
ubiquitin-conjugating enzymes (E2s), and one of many ubiquitin ligases (E3) (Schwartz and Ciechanover 
2009). Notably, ubiquitin ligases provide substrate specificity to this process as they physically interact 
with the target substrate. The two main classes of ubiquitin ligases are HECT-domain and RING-finger 
domain proteins (Weissman 2001, Nalepa, Rolfe et al. 2006). Many RING-finger type ubiquitin ligases 
contain a cullin subunit and are thus called Cullin RING ubiquitin Ligases (CRLs). Mammals have six 
typical CRLs and two atypical cullin-based ligases (Figure 1.1). In general, CRLs consist of a cullin 
backbone that serves as a scaffold for a RING-finger protein such as RBX1 or RBX2, an E2 enzyme, and 





 The SKP1-CUL1-F-box (SCF) or CRL1 ubiquitin ligase complex is the best characterized Cullin 
Ring ubiquitin Ligase (Figure 1.1) (Petroski and Deshaies 2005). In the SCF complex, CUL1 acts as a 
molecular platform by interacting at its amino terminus with SKP1 and at its carboxyl terminus with a 
RING-finger protein such as RBX1 and a specific E2 enzyme. The F-box protein is the variable 
component of the SCF complex and binds SKP1 through an N-terminal F-box domain and to specific 
protein substrates through variable C-terminal protein-protein interaction domains (Figure 1.1) (Jin, 
Cardozo et al. 2004, Petroski and Deshaies 2005, Skaar, Pagan et al. 2013). 
 
1.A.ii. Mammalian Family of F-box Proteins 
The human genome encodes sixty-nine F-box proteins, each of which contains a 40 amino acid 
F-box domain capable of binding to SKP1 to create a link to CUL1 (Cenciarelli, Chiaur et al. 1999, 
Winston, Koepp et al. 1999, Jin, Cardozo et al. 2004). F-box proteins can be further divided into three 
major categories based on their substrate interaction domains. In more detail, FBXWs contain WD40 
repeats, FBXLs contain leucine-rich repeats, and FBXOs contain other types of protein interaction 
domains (Jin, Cardozo et al. 2004). An F-box protein typically recognizes a short amino acid sequence 
called a degron within a particular substrate that is usually post-translationally modified, most often 
through phosphorylation (Skaar, D'Angiolella et al. 2009). It is notable that of the sixty-nine human F-box 
proteins, only a few have been matched with specific substrates (Frescas and Pagano 2008, Skaar, 
Pagan et al. 2013). 
F-box proteins participate in essential cellular processes, including cell cycle progression, 
response to DNA damage, and survival (Frescas and Pagano 2008, Crusio, King et al. 2010, Skaar, 
Pagan et al. 2013). For example, FBXO1/CCNF is important in controlling centrosome homeostasis and 
mitotic fidelity in dividing cells through coordinated degradation of its substrate CP110 (D'Angiolella, 
Donato et al. 2010). On the other hand, FBXO31 acts a regulator of the G1/S transition and degrades its 
Figure 1.1. The cullin-RING ligase family. There are six typical CRLs and two atypical 
cullin-based ligases. Complex assembly is modular, as a cullin backbone orients a RING-
finger protein such as RBX1 or RBX2 and an E2 enzyme, as well as various substrate-
interaction components. The substrate interaction factors are SKP1 and an F-box protein for 
CRL1; Elongin C, Elongin B, and a SOCS box protein for CRL2 and CRL5; a BTB protein 
for CRL3; and DDB1 and DCAF proteins for CRL4A and CRL4B. CRL7 uses SKP1 and a 
single F-box protein (FBXW8), and the substrate adaptors for CRL9 are currently unknown. 
Figure is adapted (Skaar, Pagan et al. 2013). 
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substrate cyclin D1 to induce G1 arrest in cells exposed to DNA damage (Santra, Wajapeyee et al. 2009). 
Additionally, the proapoptotic BH3-only factor BimEL is specifically targeted for ubiquitin-mediated 
degradation by the F-box protein βTrCP (Dehan, Bassermann et al. 2009). 
In recent years, non-canonical, SCF-independent functions have been described for several F-
box proteins, thus broadening the cellular mechanisms of this protein family (Nelson, Randle et al. 2013). 
For example, the F-box protein FBXO18 has both E3 ubiquitin ligase activity and activity as a DNA 
helicase that helps maintain genomic stability through regulating homologous recombination (Kim, Kim et 
al. 2002, Kim, Kim et al. 2004, Fugger, Mistrik et al. 2009). On the other hand, the F-box protein FBXO38 
has been shown to interact via its F-box domain with Kruppel-like transcription factor 7 (KLF7) and acts 
as a transcriptional cofactor with KLF7 at the promoter of the cell cycle inhibitor p21WAF1/Cip1 (Smaldone, 
Laub et al. 2004). Notably, although FBXO38 can bind to SKP1, SCF-dependent functions for FBXO38 
have not yet been elucidated (Nelson, Randle et al. 2013). Overall, about 12% of F-box proteins have 
been linked to roles beyond the canonical activity of ubiquitination, and this number is expected to expand 
with further investigation (Nelson, Randle et al. 2013). 
Altered F-box protein function is associated with human disease. For illustration, FBXO7 
mutations cause an early-onset, autosomal recessive parkinsonian-pyramidal syndrome that results in 
progressive neurodegeneration with extrapyramidal and pyramidal system involvement (Di Fonzo, Dekker 
et al. 2009).!On the other hand, the F-box proteins βTrCP and FBXL3 regulate circadian rhythms, in part 
through degrading the substrates PER1, PER2, CRY1, and CRY2, and alterations in this process have 
been linked to mood and sleep disorders (Toh, Jones et al. 2001, Shirogane, Jin et al. 2005, Busino, 
Bassermann et al. 2007, Godinho, Maywood et al. 2007, Siepka, Yoo et al. 2007, Takahashi, Hong et al. 
2008, Keers, Pedroso et al. 2012). 
Dysregulation of F-box protein function also contributes to cancer.  FBXW7 is recurrently mutated 
in human cancers, most frequently in 35% of cholangiocarcinomas, 31% of T-cell acute lymphoblastic 
leukemias, 9% of colon tumors, 9% of endometrium tumors, and 6% of stomach tumors (Akhoondi, Sun 
et al. 2007). Moreover, the F-box protein SKP2 is overexpressed in a broad range of cancers and is 
associated with a poor prognosis. SKP2 overexpression leads to inactivation of its substrate 
CDKN1B/p27 by SKP2-mediated degradation and thus aberrant promotion of S-phase entry (Frescas and 
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Pagano 2008). SKP2 also degrades other anti-proliferative substrates such as CDKN1A/p21 and 
CDKN1C/p57, further contributing its function as an oncoprotein (Frescas and Pagano 2008, Skaar, 
D'Angiolella et al. 2009). Recently, FBXO11 has been shown to degrade the BCL6 oncoprotein, and 
mutations and deletions in FBXO11 have been proposed to contribute to lymphomagenesis in Diffuse 
Large B-cell Lymphoma (DLBCL) through BCL6 stabilization (Duan, Cermak et al. 2012). 
Notably, analysis of the roles and mechanisms of F-box proteins disrupted in human disease and 
in cancer is likely to provide important insights into the underlying pathology and may lead to new 
treatments. 
 
1.A.ii.a. F-box and Leucine Rich Repeat Protein 4  (FBXL4) 
F-box and Leucine Rich Repeat Protein 4 (FBXL4) is one of the sixty-nine mammalian F-box 
proteins. The FBXL4 gene is highly conserved, with FBXL4 orthologs present in Drosophila melanogaster 
(fruit fly), Danio rerio (zebrafish), Anolis carolinensis (lizard), Gallus gallus (chicken), and Mus Musculus 
(mouse). Notably, the mouse Fbxl4 gene shares 88.5% nucleotide and 93.4% amino acid similarity with 
the human FBXL4 gene. In Drosophila, FBXL4 participates in calcium-mediated visual cortex signaling. In 
this pathway, the calcium sensor calmodulin stimulates the transcriptional activator dCAMTA, and then 
dCAMTA directly induces dFbxl4 expression, which leads to deactivation of the visual G protein-coupled 
receptor rhodopsin and termination of the photoresponse (Han, Gong et al. 2006, Skaar, Pagan et al. 
2009). However, the cellular roles and mechanisms of FBXL4 are relatively unknown.  
Protein domain analysis reveals that FBXL4 contains a putative Mitochondrial Localization 
Sequence and an F-box domain in its N-terminus, and seven leucine-rich repeats in its C-terminus 
(Figure 1.2). As an F-box protein, FBXL4 is predicted to function as a substrate recognition module in 
ubiquitin-mediated proteolysis, interacting with SKP1 of the SCF complex via its F-box domain and 
binding specific substrates through its leucine-rich repeats (Jin, Cardozo et al. 2004). To date, the only 
substrate proposed for FBXL4 is the nuclear histone demethylase KDM4A/JMJD2A (Van Rechem, Black 
et al. 2011). Notably, given that FBXL4 predominantly localizes with mitochondria (Figure 1.3), 








1.B. Mitochondria in Health and Disease 
The origins of mitochondria stretch back two billion years to the engulfment of a prokaryotic cell 
by a eukaryotic cell, initiating an evolutionary process that continues today (Ricchetti, Fairhead et al. 1999, 
McInnes 2013). Mitochondria are crucial metabolic hubs, tasked with generating energy through the 
currency of ATP in response to cellular demands (Koopman, Willems et al. 2012, McInnes 2013). In 
addition to their critical roles in metabolism, mitochondria contribute to a diverse set of important 
biological processes, including programmed cell death (apoptosis), calcium buffering, production of 
reactive oxygen species, and adaptive thermogenesis (Koopman, Willems et al. 2012). Thus, proper 
Figure 1.2. FBXL4 protein structure. The 621 amino acids of FBXL4 encode a 70-
kilodalton protein. The N-terminus of FBXL4 contains a Mitochondria Localization Sequence 
(MLS) and an F-box domain (FBOX). The C-terminal of FBXL4 contains seven leucine-rich 
repeats (L), which are predicted to serve as a scaffold for protein-protein interactions (Jin, 
Cardozo et al. 2004). 
!
Figure 1.3. FBXL4 localizes to mitochondria. Immunofluorescence of HEK-293T cells 
transfected with empty vector and pDsRed2-Mito, encoding a red fluorescent protein 
targeted to mitochondria (top panels) or with a vector encoding a GFP-FBXL4 fusion protein 
and dsRed2-Mito (bottom panels). Scale bars represent 10 microns.  
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mitochondrial function is imperative for cellular and organismal integrity, and mitochondrial dysfunction 
has far reaching implications, including cell death.  
 
1.B.i. Mitochondria Structure and Function 
The mitochondrion is a double membrane-bound organelle, with outer and inner membranes 
enclosing the intermembrane space and an aqueous innermost compartment called the mitochondrial 
matrix (Figure 1.4) (Koopman, Willems et al. 2012). While the outer membrane is predominantly smooth, 
the inner membrane is comprised of many folds (cristae) that protrude into the matrix (Figure 1.4). The 
cristae contain the membrane-bound complexes of oxidative phosphorylation and the majority of the 
soluble electron transport proteins such as cytochrome c (Figure 1.4) (Youle and van der Bliek 2012). 
Importantly, cristae increase the inner membrane surface area and have a dynamic structure that may 
play a role in mitochondrial metabolism (Benard and Rossignol 2008, Dieteren, Gielen et al. 2011). In fact, 
both mitochondrial external and internal morphology is dynamic and depends on cell type and metabolic 
state (Benard and Rossignol 2008). 
 
 
Figure 1.4. Mitochondria structure. The intermembrane space (IMS) is between the 
mitochondrial outer membrane (MOM) and the mitochondrial inner membrane (MIM). The 
MIM encloses the mitochondrial matrix and has many protrusions called cristae, which 
increase the surface area for electron transport. Inset: The five multi-protein complexes (CI-
CV), as well as coenzyme Q10 (CoQ10) and cytochrome c (CytC), of the electron transport 
chain are located in the MIM. In oxidative phosphorylation, the complexes accept electrons 
from NADH and FADH2, and use the energy released from passing electrons along the 
electron transport chain to pump protons (H+) into the IMS. Then, protons are energetically 
favored to then flow through complex V in a process coupled to ATP synthesis. The terminal 
electron acceptor is molecular oxygen (O2), forming water (H2O). Voltage-dependent anion 
channels (VDACs) ensure that the MOM is ion-impermeable. Figure is adapated (Koopman, 
Willems et al. 2012). 
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Net mitochondrial structure, far from static, is linked to the balance between mitochondrial motility, 
fission, and fusion (Youle and van der Bliek 2012). Mitochondria cannot be synthesized de novo, and thus 
new mitochondria must come from existing mitochondria. Fission is the breaking apart of a mitochondrion 
to form two physically separate mitochondria, and fusion is the joining together of mitochondrial 
membranes and compartments to produce a single larger mitochondrion (McInnes 2013). Following 
mitochondrial fission, yeast and mammals are capable of a mitochondrial quality control mechanism 
called mitophagy by which mitochondria can be selectively eliminated from cells (Youle and Narendra 
2011). Thus, when mitochondria are damaged, depending on the level of damage, fusion may promote 
complementation between damaged and healthy mitochondria within the same cell to rescue the defects. 
On the other hand, mitophagy may be used to eliminate mitochondria that are damaged beyond repair. 
Proper functioning of the fission and fusion pathways is crucial for mitochondrial function (Youle and van 
der Bliek 2012). 
Mitochondria contain their own DNA as a 16.5-kilobasepair circular DNA molecule (mtDNA). The 
mitochondrial genome contains thirteen genes encoding subunits of the respiratory chain, as well as 
twenty-two transfer RNA genes and two genes encoding ribosomal RNAs that are important for 
mitochondrial protein translation (Uziel, Ghezzi et al. 2011). Generally, mitochondria contain between two 
and ten mtDNA molecules, depending on their current fission-fusion status (Wallace 1994). Within a cell, 
there are typically thousands of copies of the mitochondria genome (Debray, Lambert et al. 2008). 
Mitochondrial DNA has a relatively high mutation rate, in part due to its small genome size, the lack of 
mutation-suppressing elements such as intron sequences, and its close proximity to DNA-damaging 
agents such as reactive oxygen species (Lightowlers, Chinnery et al. 1997, McInnes 2013). The 
transmission of mtDNA between generations is exclusively maternal. If there happens to be a mutation in 
the mtDNA, variations in the mutation load between cells and organs within an individual, called 
heteroplasmy, can arise due to random distribution of mtDNA molecules at cell division during 
development and selection for or against cells with a high load of mutant mtDNA. In these cases, it is 
believed that mitochondrial dysfunction occurs upon reaching a certain threshold of mutant mtDNA, which 
can depend on tissue-specific energy needs (Debray, Lambert et al. 2008). Interestingly, more than one 
thousand nuclear gene products also contribute to mitochondrial structure and function and when 
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dysregulated can contribute to mitochondrial disease, underscoring the complex interplay between the 
mitochondrial and nuclear genomes (Pagliarini, Calvo et al. 2008). 
Mitochondria produce ATP through a process called oxidative phosophorylation (OXPHOS). 
Initially, glucose is converted to pyruvate through glycolysis in the cytosol, and then pyruvate can be 
turned into lactate or taken up by mitochondria, where it is converted to acetyl coenzyme A (acetyl CoA). 
In the mitochondrial matrix, acetyl CoA enters the tricarboxylic acid (TCA) cycle to generate the reduced, 
electron-rich forms of nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2). 
Fatty acids and glutamine can also feed into the TCA as substrates. Next, NADH and FADH2 are oxidized 
as they donate electrons to the oxidative phosphorylation system, also known as the electron transport 
chain (ETC), which is a series of five coupled protein complexes embedded in the inner mitochondrial 
membrane (Figure 1.4). NADH donates electrons at complex I, and FADH2 donates electrons at complex 
II. These electrons are shuttled to complex III by coenzyme Q10 (CoQ10) and then to complex IV by 
cytochrome c. At complex IV, the electrons are donated to molecular oxygen to yield water. The energy 
released by electron transport is used at complexes I, III, and IV to push protons from the mitochondrial 
matrix to the intermembrane space, generating a proton gradient across the inner mitochondrial 
membrane. This proton gradient results in a matrix-directed proton-motive force, as well as sets the 
mitochondria membrane potential. Finally, complex V harnesses the proton motive force to produce ATP, 
which is transported to the cytosol by the action of the adenine nucleotide translocator. Importantly, the 
proton motive force and mitochondria membrane potential are important for other mitochondrial functions, 
including transportation of ions, exchange and import of metabolites and proteins, and mitochondrial 
fusion. Thus, defective oxidative phosphorylation can lead to multiple problems in the cell (Koopman, 
Willems et al. 2012, McInnes 2013). 
Mitochondria are the sites of several important metabolic processes, many of which serve to 
provide substrates for oxidative phosphorylation and thus energy production. The degradation of fatty 
acids through beta-oxidation in the mitochondria results in acetyl CoA entering the TCA cycle to produce 
NADH and FADH2, which are used by the electron transport chain for ATP production. In more detail, 
once fatty acids are processed through the mitochondria and enter the mitochondrial matrix via the 
actions of palmitoyl transferase I, cartinine acyl translocase, and palmitoyl transferase II, the reactions of 
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beta-oxidation are catalyzed by multiple enzymes within the mitochondrial matrix (Bartlett and Eaton 
2004). Fatty acid catabolism is an important energy source in humans, and thus defects in beta-oxidation, 
or defects in the electron transport process, can lead to ATP deficiency (Debray, Lambert et al. 2008, 
McInnes 2013). Moreover, in times of impaired glucose oxidation, high energy-compounds called ketone 
bodies are produced in the liver and kidneys as a byproduct of fatty acid oxidation and are then 
transported by the blood to other tissues, where they are processed and can enter into the TCA cycle and 
thus contribute to ATP production (Fukao, Lopaschuk et al. 2004). Under certain conditions, amino acids 
obtained from protein breakdown can also contribute to ketone body production and are thus classified as 
ketogenic amino acids (Fukao, Lopaschuk et al. 2004). Some amino acids are also able to contribute to 
glucose production and are thus classified as glucogenic amino acids (Nuttall, Ngo et al. 2008). Notably, 
several enzymes and metabolites localized to mitochondria contribute to gluconeogenesis, the process by 
which new glucose is produced from non-carbohydrate substrates including pyruvate, lactate, glycerol, 
and glucogenic amino acids (Nuttall, Ngo et al. 2008). 
Beyond roles in metabolism and energy production, mitochondria contribute to multiple biological 
processes. In apoptosis, a form of programmed cell death involving the activation of specialized cysteine 
proteases called caspases, mitochondrial outer membrane permeabilization (MOMP) is required for 
effector caspase activation (Spencer and Sorger 2011). Mitochondria also play a role in ion homestasis, 
as mitochondria balance exchanging metabolites and other compounds with the cytoplasm with 
preserving the protonmotive force across the inner mitochondrial membrane that sustains oxidative 
phosphorylation. Thus, as the majority of metabolites transported into mitochondria are anions, these 
compounds are typically symported with protons or antiported against hydroxyl anions in order to harness 
the protonmotive force in their accumulation (Cardoso, Queliconi et al. 2010). At the same time, 
mitochondria are also important in adaptive thermogenesis, a process by which substrate oxidation can 
be uncoupled from ADP phosphorylation by dissipating the protonmotive force. For example, in response 
to an extended cold exposure, adaptive thermogenesis in brown adipose tissue can be used to generate 
heat (Azzu and Brand 2010) Mitochondria also contribute to calcium buffering by storing and releasing 
calcium ions and thus exerting an important control over intracellular signaling (Romagnoli, Aguiari et al. 
2007, Pizzo, Drago et al. 2012). Mitochondria also participate in the production and regulation of reactive 
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oxygen species, which are agents of oxidative damage but can also be regulators of various biological 
processes (Murphy, Holmgren et al. 2011). Recently, mitochondria have been shown to contribute in 
several ways to the innate immune response, including roles as signaling network platforms and in 
effector responses (West, Shadel et al. 2011). Finally, mitochondria participate in the synthesis of 
important cellular compounds, including urea (Adeva, Souto et al. 2012), porphyrins (Hamza 2006), and 
steroid hormones (Jefcoate 2002). 
 
1.B.ii. Consequences of Mitochondrial Dysfunction 
Given the critical roles mitochondria play in energy production and in other key biological 
processes, it is not surprising that abnormalities of mitochondria function are implicated in a variety of 
human diseases, with the pathological implications depending on the particular mitochondrial functions 
disrupted (Koopman, Willems et al. 2012, Schapira 2012). Generally speaking, in primary mitochondrial 
disease, the problem originates in mitochondria (Schapira 2012), while secondary mitochondrial disease 
arises from an outside influence that impinges on mitochondria function, such as viral infections or off-
target drug effects (Cohen 2010, Finsterer and Segall 2010, Wang, Liu et al. 2011). 
Primary mitochondrial disease arises from a variety of sources. For example, an individual may 
have a mtDNA mutation that affects a gene encoding a subunit of one of the electron transport chain 
complexes. On the other hand, an individual may have a mutation in a nuclear-encoded gene that leads 
to disordered maintenance of mtDNA, resulting in deletions or depletion of mtDNA for instance (Schapira 
2012). Alternatively, an individual may have a mutation in a nuclear-encoded gene with a gene product 
localized predominantly at mitochondria that results in mitochondria dysfunction (Pagliarini, Calvo et al. 
2008, Koopman, Willems et al. 2012). Culprit mutations can be present in the germline, or mutations may 
arise de novo, for example from reactive oxygen species-mediated damage of mtDNA or from faulty 
repair of mtDNA or nuclear DNA (Schapira 2012). However, it must be noted that in many cases, the 
underlying genetic defects remain unknown, especially due to the large amount of clinical and genetic 
heterogeneity among patients and the still growing body of information about genes important in 
mitochondrial function (Tucker, Compton et al. 2010). While individual cases of genetically determined 
disorders of mitochondrial function are relatively rare, the collective prevalence is 1 in 5,000 across all 
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ages, and these diseases pose a significant burden on human health, especially as they remain incurable 
(Falk and Sondheimer 2010). 
Mitochondrial dysfunction is also associated with more common diseases, including cancer 
(Cairns, Harris et al. 2011), obesity (Tseng, Cypess et al. 2010), and diabetes (Sleigh, Raymond-Barker 
et al. 2011), as well as with a wide range of neurological disorders, including Alzheimer’s disease 
(Coskun, Wyrembak et al. 2012), Parkinson’s disease (McCoy and Cookson 2012), Huntington’s disease 
(Mochel and Haller 2011), and epilepsy (Lonnqvist, Paetau et al. 2009). In these conditions, mitochondrial 
abnormalities may be secondary to the underlying disease pathology, altered mitochondria structure or 
function may drive pathology, or a combination of these events may occur. In many cases, the precise 
contribution of mitochondrial dysfunction to disease pathogenesis remains unknown and is an area of 
ongoing research (Koopman, Willems et al. 2012, Schapira 2012). 
 
1.B.ii.a. Altered Mitochondrial Dynamics in Cancer 
Almost 100 years ago, Otto Warburg first noted that cancer cells take up glucose at a much 
higher rate than normal cells and secrete the majority of this glucose-derived carbon as lactate, rather 
than oxidizing it completely via mitochondrial respiration (DeBerardinis, Lum et al. 2008). This shift from 
ATP production through oxidative phosphorylation to ATP production through glycolysis, even under 
normal oxygen conditions, is known as the “Warburg effect” and has been studied extensively. However, 
there is some debate about the most important selective advantages conveyed to tumor cells via 
glycolytic metabolism (Cairns, Harris et al. 2011). Notably, the increased glycolysis in tumor cells does 
not appear to be an adaptation to cope with a lack of ATP produced by oxidative phosphorylation, as the 
majority of tumors retain oxidative phosphorylation capacity and consume oxygen at rates similar to 
normal tissue (Weinhouse 1976, Frezza and Gottlieb 2009), and notably, in some systems, intact 
mitochondrial function is important for cellular transformation (Funes, Quintero et al. 2007, Fogal, 
Richardson et al. 2010, Weinberg, Hamanaka et al. 2010). Interestingly, glycolysis has the capacity to 
produce ATP at a higher rate than oxidative phosphorylation and would thus be advantageous to rapidly-
proliferating tumor cells, precluding limitations in glucose supplies (Cairns, Harris et al. 2011). Moreover, it 
has been proposed that glycolysis serves as an adaptive mechanism to hypoxic conditions during the 
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early avascular stages of tumorigenesis, as glycolysis generates ATP in the absence of oxygen. In 
addition, adaption to the acidic microenvironment produced by the excess lactate generation in the 
context of glycolysis may further drive the glycolytic phenotype (Gatenby and Gillies 2004). Finally, recent 
reports indicate that aerobic glycolysis confers a biosynthetic advantage for tumor cells, as a high flux of 
substrates through glycolysis permits for effective shunting of carbon to crucial biosynthetic pathways 
required for cell proliferation, including the production of nucleotides, lipids, and NADPH (DeBerardinis, 
Lum et al. 2008). 
Notably, multiple genes with crucial functions in mitochondrial metabolic pathways are altered in 
cancer. For example, loss of function mutations in succinate dehydrogenase (SDH), an oxioreductase 
complex that participates in the electron transport chain and in the TCA cycle, are associated with 
dominantly-inherited familial paraganglioma (Baysal, Ferrell et al. 2000). Mutations have been noted in all 
4 SDH subunits (Baysal 2008), as well as in SDH5, a protein important for the incorporation of the flavin 
adenine dinucleotide cofactor of SDH (Hao, Khalimonchuk et al. 2009). Moreover, the TCA cycle enzyme 
fumarate hydratase (FH) is mutated in familial syndromes associated with increased susceptibility to renal 
cell cancer and leiomyomatosis (tumors of smooth muscle affecting the uterus and the skin) (Tomlinson, 
Alam et al. 2002). SDH- and FH-deficient tumors display loss of the wild-type allele in combination with 
the inherited mutant allele and thus SDH and FH are proposed to function as tumor suppressors 
(DeBerardinis and Thompson 2012). On the other hand, two isoforms of NADP+-dependent isocitrate 
dehydrogenase, IDH1 and IDH2, are mutated in gliomas and glioblastomas (Parsons, Jones et al. 2008, 
Yan, Parsons et al. 2009) and in acute myelogenous leukemia (Mardis, Ding et al. 2009). IDH1 and IDH2 
mutations are somatically acquired, within the enzyme active site, and only affect a single allele. Normally, 
IDH1 and IDH2 oxidize isocitrate to α-ketoglutarate and reduce NADP+ to NADPH in the process (Cairns, 
Harris et al. 2011). However, mutations in IDH1 or IDH2 appear to confer new properties to the enzymes, 
including production of large amounts of (D)-2-hydroxyglutarate (2-HG), which may act as an 
oncometabolite, in part through altering the function of enzymes important in histone and DNA 
methylation (DeBerardinis and Thompson 2012). Notably, the mechanisms underlying tumorigenesis in 
the context of mutated metabolism genes are likely multifactorial and represent areas of active research 
(DeBerardinis and Thompson 2012). 
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Mitochondria have emerged as potential therapeutic targets in cancer, particularly given that 
cancer cell mitochondria display structural and functional differences from normal mitochondria, coupled 
with the finding that tumor cells exhibit extensive metabolic reprogramming that may result in increased 
susceptibility to perturbations of mitochondrial function (Fulda, Galluzzi et al. 2010). For example, evasion 
of apoptosis is a hallmark of cancer and a major source of treatment failure (Fulda 2009, Hanahan and 
Weinberg 2011), and therefore pro-apoptotic treatments are attractive cancer therapies, such as the BH3 
mimetic ABT-737, which cooperates with conventional chemotherapies and radiotherapy in hematological 
malignancies and solid tumors (van Delft, Wei et al. 2006, Kang, Kang et al. 2007, Hann, Daniel et al. 
2008, Kutuk and Letai 2008, Mason, Vandenberg et al. 2008, Tagscherer, Fassl et al. 2008). Interestingly, 
the susceptibly of cancer cells to ABT-737 as a single agent depends on the expression profile of BCL-2 
family proteins, and in fact, tumor cells with relatively high BCL-2 expression levels are particularly 
sensitive to ABT-737 treatment (Oltersdorf, Elmore et al. 2005, Konopleva, Contractor et al. 2006, Mason, 
Vandenberg et al. 2008). Moreover, agents that induce the overproduction of mitochondrial reactive 
oxygen species have been tested in various cancers, including menadione, which can induce objective 
clinical responses in advanced hepatoceullar carcinoma (Sarin, Kumar et al. 2006), and motexafin 
gadolinium in combination with brain radiotherapy, which prolongs the time for neurological progression 
for patients with lung cancer and documented brain metastasis (Mehta, Shapiro et al. 2009). Finally, 
compounds predicted to take advantage of the altered mitochondrial metabolism in cancer have been 
proposed as novel treatments, including specifically targeting the aerobic glycolysis characteristic of 
cancer cells through inhibition of mitochondrial pyruvate dehydrogenase kinase (PDK) with 
dicholoroacetate (Bonnet, Archer et al. 2007), or via inhibition of lactate dehydrogenase A (Fantin, St-
Pierre et al. 2006). Importantly, targeting mitochondria in cancer cells is a promising avenue of research 
that may be able to evade resistance mechanisms elicited by conventional chemotherapeutics via directly 
targeting mitochondria and thus circumventing upstream signaling events (Fulda, Galluzzi et al. 2010). 
 
1.B.ii.b. Mitochondrial Dysfunction in Neurological Disorders 
Mitochondria dysregulation is also an important factor in neurological conditions such as 
Alzheimer’s, Parkinson’s, and Huntington’s diseases (Koopman, Willems et al. 2012, Schapira 2012). In 
! 15 
some cases, mutations in mitochondrial proteins contribute to disease pathology, such as mutations in 
the genes encoding parkin and PINK1 in Parkinson’s disease that appear to interfere with the efficiency of 
mitophagy and result in the accumulation of damaged mitochondria (Schapira, Agid et al. 2009, Gegg, 
Cooper et al. 2010). On the other hand, mitochondrial defects can be secondary to the primary disease 
process, such as in Huntington’s disease, where mitochondrial calcium dysregulation, reduced respiration, 
and increased sensitivity to free radical-mediated damage are secondary to mutant huntingtin protein 
(Kaltenbach, Romero et al. 2007, Lim, Fedrizzi et al. 2008, Orr, Li et al. 2008, Wang, Lim et al. 2009). In 
Alzheimer’s disease, polymorphisms in the TOMM40 gene, which encodes an outer mitochondrial 
membrane protein, are a risk factor for disease development and age of onset (Roses, Lutz et al. 2010). 
Moreover, altered mitochondrial morphology and function and defects in mtDNA have been observed in 
some patients with Alzheimer’s disease (Schapira 2012). Interestingly, triple transgenic mice with amyloid 
and tangle pathology similar to Alzheimer’s disease patients exhibit significant mitochondrial 
abnormalities, including reduced oxidative phosphorylation, depressed mitochondrial membrane potential, 
and increased free radical production (Rhein, Song et al. 2009).  
 
1.B.ii.c. Primary Mitochondrial Disease 
Primary mitochondrial disorders encompass a sizeable and diverse group of conditions with 
pathological implications across multiple organ systems (Koopman, Willems et al. 2012, Schapira 2012, 
McInnes 2013). Mitochondrial disease can occur in adults or children (Haas, Parikh et al. 2007, Cohen 
2013), but in general, the manifestations of pediatric mitochondrial disease tend to be progressive and 
more frequently fatal when compared to adult onset disease (Menezes, Riley et al. 2014). The remainder 
of this section will focus on primary mitochondrial disease with a pediatric onset.   
The estimated prevalence of pediatric-onset mitochondrial disease is 1 in 5,000 (Debray, Lambert 
et al. 2008). While about 10-15% of pediatric mitochondrial diseases are caused by mutations in mtDNA, 
it appears that the majority of pediatric-onset mitochondrial disorders are due to defects in nuclear-
encoded genes that produce proteins localized to mitochondria (Thorburn 2004, Debray, Lambert et al. 
2008, Falk and Sondheimer 2010, Tucker, Compton et al. 2010, Uziel, Ghezzi et al. 2011). These 
statistics fit with the observation that mtDNA encodes thirty-seven mitochondrial factors, while nuclear 
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DNA encodes more than one thousand mitochondrial factors (Pagliarini, Calvo et al. 2008, Koopman, 
Willems et al. 2012). Importantly, despite an ever-growing list of genes implicated in mitochondria disease, 
causative mutations are not identified in about 50% of cases (Tucker, Compton et al. 2010). 
 
1.B.ii.c.(1). Clinical Picture of Primary Mitochondrial Disease 
The clinical signs and symptoms of mitochondrial disease stem from loss of normal mitochondrial 
function, especially impaired cellular energy production via oxidative phosphorylation (OXPHOS) 
(Koopman, Willems et al. 2012). Since nearly all cells require proper OXPHOS activity to survive, virtually 
any organ can be affected by mitochondrial disease (Debray, Lambert et al. 2008). However, cell types 
with relatively high energy demands, such as muscle cells and neurons, are more sensitive to decreased 
ATP production. Thus, almost all presentations of mitochondrial disease involve neurological symptoms, 
often with muscle weakness (Tucker, Compton et al. 2010, Uziel, Ghezzi et al. 2011). Primary 
mitochondrial diseases with a neurological component are also known as mitochondrial encephalopathies 
and constitute the bulk of primary mitochondrial disease (Tucker, Compton et al. 2010). 
A large degree of phenotypic variability exists in the clinical presentation of mitochondrial disease, 
giving rise to the mnemonic “any age, any symptom, any organ” (Munnich, Rotig et al. 1996). One reason 
for this variability is that mitochondria tend to be specialized for particular functions across different cell 
types and tissues. For example, heart mitochondria predominantly produce energy in the form of ATP, 
while liver mitochondria are generally more biosynthetic (McInnes 2013). Various tissues and cell types 
can also differ in ATP demand, the method of ATP production, the source of substrates for oxidative 
phosphorylation, the rate of oxidative phosphorylation, and general mitochondrial dynamics (Koopman, 
Willems et al. 2012). In addition, clinical evidence of mitochondrial impairment may only be elicited under 
a stress such as starvation, exercise, or an infection driving cellular metabolic demand in a particular 
tissue or cell type that exceeds a certain threshold (Koopman, Willems et al. 2012). Thus, mitochondrial 
dysfunction in one tissue or cell type may have different consequences than dysfunction in another tissue 
or cell type (Koopman, Willems et al. 2012, McInnes 2013). Moreover, another source of clinical variability 
comes from heteroplasmy due to uneven distribution of damaged mitochondria across the cells 
comprising different tissues (Debray, Lambert et al. 2008, Koopman, Willems et al. 2012, Youle and van 
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der Bliek 2012). In these cases, it is believed that mitochondrial dysfunction occurs upon reaching a 
certain threshold of mutant mtDNA or damaged mitochondria, which may depend on the energy needs of 
the particular tissue (Debray, Lambert et al. 2008). Finally, the underlying clinical phenotype may be 
obscured by or complicated by compensatory mechanisms, such as production of new mitochondria, 
mitophagy of damaged mitochondria, increased expression of gene products involved in the OXPHOS 
system, and a switch to a more glycolytic process of ATP production (Koopman, Willems et al. 2012). 
In general, the clinical spectrum of mitochondrial disease is heavily concentrated on tissues with 
characteristically high ATP requirements, particularly the brain, heart, eye, kidney, and skeletal muscle, 
as well as the ears, endocrine glands, liver, bone marrow, and gastrointestinal tract (Chi, Lee et al. 2010). 
In fact, it appears that most of the mutations associated with mitochondrial disease result in decreased 
activity of the OXPHOS system and thus decreased ATP production in a direct or indirect manner 
(McInnes 2013). 
Although clinical evaluation of mitochondrial disease is challenging, as patient presentation is 
variable and often overlaps with other conditions, there are a constellation of signs and symptoms highly 
suggestive of mitochondrial disease, as well as signs and symptoms compatible with mitochondrial 
disease given other concurrent findings (Table 1.1) (Debray, Lambert et al. 2008). Moreover, fibroblasts 
from a patient’s skin are typically cultured and tested for various biochemical parameters of mitochondrial 
function, including respiratory complex activity, which can be helpful in diagnosis (Debray, Lambert et al. 
2008). Sometimes, biochemical findings, such as increased succinate in succinate dehydrogenase 
deficiency, can be diagnostic (Table 1.1) (Debray, Lambert et al. 2008). Of note, the detection of ragged 
red fibers on muscle biopsy, which represent the disordered accumulation of mitochondria, is highly 
suggestive of mitochondrial disease (Table 1.1) (McInnes 2013). Finally, lactic acidosis is a hallmark of 
mitochondrial dysfunction (Table 1.1), but it should be noted that blood lactate levels can be highly 
variable in individual patients and may not be elevated in proven mitochondrial disease or may only be 
elevated with stress (Debray, Mitchell et al. 2007). Notably, cerebrospinal fluid (CSF) lactate level is more 
reliable than blood lactate level as a diagnostic marker for mitochondrial disease, particularly in patients 





1.B.ii.c.(2). Causes of Primary Mitochondrial Disease 
Over the past two decades, mutations in over thirty mtDNA-encoded genes and in more than two 
hundred nuclear DNA-encoded gene have been linked to human mitochondrial disease (Figure 1.5) 
(Tucker, Compton et al. 2010, Koopman, Willems et al. 2012). In general, these mutations affect genes 
involved in OXPHOS complex function, assembly, and regulation; maintenance, replication, and 
expression of mtDNA; function of the mitochondria membrane; and the activity of mitochondria-related 
chaperone and protein import processes (Figure 1.5) (Tucker, Compton et al. 2010, Koopman, Willems 
et al. 2012, Schapira 2012). However, in many cases, although mutations may be identified in a particular 
gene, the mitochondrial roles and mechanisms of the encoded protein remains unknown (Figure 1.5) 
(Tucker, Compton et al. 2010, Koopman, Willems et al. 2012). 
Table 1.1. Clinical features of pediatric mitochondrial disease. The unexplained 
presence of one or more of the signs or symptoms in (1) puts mitochondrial disease high on 
the differential. The presence of each unexplained sign or symptom in (2) raises the clinical 
suspicion of mitochondrial disease, particularly if multiple organs are involved and/or if one 
or more clinical features from (2) occur concomitantly with clinical features from (1). Table is 




Importantly, causative mutations are not identified in 50% of patients who present with 
mitochondrial disease (Kirby and Thorburn 2008). The lack of a genetic diagnosis in these cases is 
multifactorial. First, there is a large amount of genetic heterogeneity among patients due to the ever-
increasing number of gene products required for OXPHOS, and actually in only a few families are 
mutations in OXPHOS responsible for the observed mitochondrial pathology. Second, the correlation 
between genotype and phenotype in mitochondrial disease is often confusing, as there only a handful of 
clinical presentations that suggest a particular mitochondrial disease, and most presentations are in fact 
Figure 1.5. Genes associated with mitochondrial disease. The current list of genes 
mutated in mitochondrial disease is summarized here by the mitochondrial sub-localization 
of each gene product. Genes encoded by nuclear DNA are shown in black, while genes 
encoded by mtDNA are indicated in green. Partial mitochondrial localization refers to genes 
that locate to mitochondria but also localize to other cellular compartments. 
Submitochondrial localization refers to genes that have not yet been localized to a particular 
mitochondrial compartment. Genes encoded by mtDNA important in mtDNA expression are 
shown under a separate heading. Figure is adapted (Tucker, Compton et al. 2010, 
Koopman, Willems et al. 2012). 
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associated with mutations in multiple causative genes. Therefore, in most patients there is not a clear 
candidate gene to sequence and in fact many potential candidate genes should be sequenced, which can 
be costly and time consuming. Third, as the full compendium of gene products important in the function of 
the OXPHOS system remain to be elucidated, it is possible for a patient to have a mutation in a gene with 
no known role in mitochondria, which precludes its sequencing (Tucker, Compton et al. 2010). 
Although it is evident that mutations in genes encoding mitochondrial factors lead to impaired 
mitochondrial function, in many cases it remains to be elucidated how specific genetic alterations induce 
dysfunction at the level of cells, organs, or the organism. Thus, there is a dire need for studies using 
relevant cellular and animal models of mitochondrial disease to define the molecular mechanisms of 
disease and to develop effective treatments for patients (Koopman, Willems et al. 2012). 
 
1.B.ii.c.(3). Treatment of Primary Mitochondrial Disorders 
The complications of mitochondrial disease typically impact multiple organ systems and confer 
significant morbidity and mortality. There are currently no cures for mitochondrial disease and in most 
cases, treatment remains limited to symptomatic management (Gardner, Craven et al. 2007, Debray, 
Lambert et al. 2008, Falk and Sondheimer 2010). Few clinical trials exist for this group of diseases, and in 
general clinical trials are challenging due to heterogeneity in phenotypic presentation and disease 
evolution, even in groups of patients with the same underlying genetic alteration (Menezes, Riley et al. 
2014). Prognostic counseling for patients is difficult because of the high variability in disease severity 
between individual patients (Debray, Lambert et al. 2008). Overall, the prognosis of mitochondrial disease 
is quite poor, with a generally progressive clinical course that results in significant morbidity, decreased 
quality of life, and premature death (Uziel, Ghezzi et al. 2011). 
In general, very few specific treatments exist for mitochondrial disease, outside of symptomatic 
management (Uziel, Ghezzi et al. 2011). Although some physicians prescribe prophylactic “mitochondrial 
cocktails” containing antioxidant and vitamin co-factors, these treatments are generally of unproven 
efficacy (Debray, Lambert et al. 2008). Notably, some patients with defective biosynthesis of CoQ partially 
respond to oral CoQ10 supplementation (Uziel, Ghezzi et al. 2011). Moreover, studies have shown that 
patients with pyruvate dehydrogenase (PDH) deficiency may benefit from thiamine supplementation, a 
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ketogenic diet, or the use of dichloroacetate (Wexler, Hemalatha et al. 1997, Naito, Ito et al. 1998, 
Fouque, Brivet et al. 2003). Dichloracetate has been shown in mitochondrial disease to lower lactate 
nonspecifically and may be helpful during short term treatment of severe acidotic crises, yet the long term 
use of dichloracetate results in peripheral neuropathy (Stacpoole, Kerr et al. 2006). Moreover, a recent 
study in a small number of patients with mitochondrial disease and decreased 5-methyltetrahydrofolate 
levels in the cerebrospinal fluid, likely due to defective ATP-dependent cerebral transport of folate, 
exhibited clinically significant improvement with oral folinic acid (Pineda, Ormazabal et al. 2006, 
Ramaekers, Weis et al. 2007). Finally, gene therapy approaches to treat mitochondrial disease have in 
general been hindered by the challenge of importing the restorative protein product into mitochondria 
(Taylor 2005). Importantly, there is a growing need for the development of clinically relevant mouse 
models of mitochondrial disease to drive the development of therapies for patients with these devastating 
diseases (Menezes, Riley et al. 2014). 
 
1.B.ii.c.(4). FBXL4 Mutations in Pediatric Mitochondrial Encephalopathy 
Recently, a novel pediatric onset mitochondrial encephalopathy was linked to mutations in FBXL4, 
a gene encoded by nuclear DNA (Bonnen, Yarham et al. 2013, Gai, Ghezzi et al. 2013). Mitochondrial 
DNA Depletion Syndrome 13 (OMIM 615471) is associated with homozygous FBXL4 mutations that are 
proposed to inactivate the FBXL4 gene product (Figure 1.6, Table 1.2). Patients with FBXL4 mutations 
typically present months after birth with encephalopathy, hypotonia, lactic acidosis, and severe global 
developmental delay. Variable features of the disease include dysmorphism, skeletal abnormalities, 
microcephaly, poor growth, difficulty swallowing, gastrointestinal dysmotility, renal tubular acidosis, 
seizures, cataracts, cardiomyopathy, and episodic metabolic failure. Several patients died in infancy due 
to metabolic decompensation during a concomitant infection. The surviving patients from these studies 
are now in late childhood and are typically nonverbal, unable to sit autonomously, exhibit muscle wasting 
and severe truncal ataxia; and in several cases suffer from epileptic seizures and/or choreoathetoid 
movements. At the cellular level, FBXL4 mutations are associated with mitochondrial respiratory chain 
deficiency, decreased mitochondria membrane potential, mtDNA depletion, and fragmentation of the 
mitochondrial network. Re-expression of FBXL4 rescued some aspects of the cellular phenotype, 
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including membrane potential, complex IV activity, mtDNA content, and oxygen consumption rate, 
suggesting FBXL4 mutations are pathogenic in this disease (Bonnen, Yarham et al. 2013, Gai, Ghezzi et 
al. 2013). 
The FBXL4 gene encodes an F-box and leucine-rich repeat factor with a mitochondrial 
localization and a predicted role in targeting specific proteins for proteasomal degradation (Bai, Sen et al. 
1996, Cenciarelli, Chiaur et al. 1999, Winston, Koepp et al. 1999, Jin, Cardozo et al. 2004). The FBXL4 
mutations described in pediatric mitochondrial encephalopathy are generally frameshift or truncating 
mutations predicted to disrupt the C-terminal end of the protein, or point mutations clustered in the 
leucine-rich repeats (Figure 1.6, Table 1.2). Interestingly, these different types of mutations in FBXL4 are 
postulated to converge on disruption of the leucine-rich repeats, which are predicted to serve as protein-
protein interaction domains with specific substrates (Jin, Cardozo et al. 2004). Notably, the molecular and 
cellular functions of FBXL4 and its role in mitochondrial encephalopathy remain largely unknown. 
 
 
Figure 1.6. Landscape of FBXL4 mutations in pediatric mitochondrial 
encephalopathy. Mutations in FBXL4 are aligned to the FBXL4 protein structure. 
Frameshift mutations (fs), nonsense mutations (*), and nonsynomous point mutations are 
indicated adjacent to the original amino acid code and position. Figure is adapted (Bonnen, 





1.C. T-cell Acute Lymphoblastic Leukemia  
 T-lineage acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy that 
arises from lymphoid progenitor cells expressing immunophenotypic T-cell markers (Ferrando, Neuberg 
et al. 2002). T-ALL requires treatment with intensified chemotherapy (Pui, Robison et al. 2008). Despite 
recent progress in clinical outcomes in this disease, studies of long-term effects of chemotherapy in 
patients with T-ALL show that recent gains in leukemia-free survival have been achieved at the cost of 
significant increases in the rates of life-threatening and debilitating toxicities (Aifantis, Raetz et al. 2008). 
Thus, there is a critical need for improved understanding of the pathogenesis of T-ALL concomitant with 
the development of novel anti-leukemic drugs (Pui, Mullighan et al. 2012). 
 
1.C.i. Hematopoesis  
1.C.i.a. An Overview of Hematopoesis 
As T-ALL arises from developing T-cells, an understanding of hematopoesis and the process of 
T-cell maturation are important to the study of T-ALL. Hematopoietic stem cells (HSCs), capable of multi-
Table 1.2. Summary of FBXL4 mutations in pediatric mitochondrial encephalopathy. 
This table shows the mutations detected in the FBXL4 cDNA and the corresponding 
changes in the FBXL4 protein for each subject sequenced. Frameshift mutations (fs), 
nonsense mutations (*), and nonsynomous point mutations are indicated adjacent to the 
original amino acid. In all cases, patients exhibited biallelic alterations in FBXL4, either two 
of the same mutation (homozygous) or two different mutations (compound heterozygous). 
Table is adapted (Bonnen, Yarham et al. 2013, Gai, Ghezzi et al. 2013). 
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lineage reconstitution and long-term self-renewal, exist in the bone marrow and give rise to all blood cell 
lineages. HSCs do not express markers present on lineage (Lin)-committed hematopoietic cells but do 
express high levels of stem-cell antigen 1 (Sca1) and Kit and thus are also known as LSK cells (Lin- 
Sca1+ Kit+). Notably, only some LSK HSCs are capable of long term repopulating activity, thus HSCs can 
be additionally divided into long term (LT)-HSCs and short-term (ST)-HSCs. ST-HSCs only have limited 
self-renewal potential. Self-renewing HSCs give rise to multipotent progenitors (MPPs) through 
asymmetric cell division, and MPPs in turn are capable of producing all hematopoietic lineages. MPPs 
give rise to progenitor cells with more restricted lineage potential, including common lymphoid progenitors 
(CLPs) and common myeloid progenitors (CMPs) (Forsberg, Bhattacharya et al. 2006, Wilson and 
Trumpp 2006). Ultimately, CLPs give rise to cells that produce B-cells, T-cells, and natural killer cells, 
while CMPs give rise to cells that produce erythrocytes, megakaryocytes, dendritic cells, monocytes, and 
granulocytes, including neutrophils, basophils, and eosinophils (Novershtern, Subramanian et al. 2011). 
 
1.C.i.b. The Process of T-cell Development 
T-cell development is a coordinated, tightly controlled process (Figure 1.7). Multipotent blood 
progenitor cells transit from the bone marrow to the thymus to begin an extended differentiation process, 
gradually acquiring T-cell characteristics while losing their developmental plasticity (Rothenberg, Moore et 
al. 2008, Koch and Radtke 2011). Early thymic/T-cell precursors (ETPs) are the most immature 
intrathymic progenitors that have been identified. In addition to efficient T lymphoid potential, ETPs 
possess natural killer, dendritic, and myeloid cell potential (Bell and Bhandoola 2008, Wada, Masuda et al. 
2008). 
Once entering the thymus, ETP or double negative 1 (DN1) cells migrate through distinct thymic 
microenvironments, concomitantly differentiating from CD4- CD8- double negative (DN) to CD4+ CD8+ 
double positive (DP) to C4+ or CD8+ single positive (SP) cells (Figure 1.7) (Aifantis, Raetz et al. 2008, 
Rothenberg, Moore et al. 2008, Koch and Radtke 2011). Development through the initial “pro-T-cell” 
stages, from ETP to double negative 3 (DN3), is independent of the T-cell Receptor (TCR) and is 
coordinated with migration through specific thymic microenvironments. In more detail, ETPs and DN2 
cells proliferate extensively while gaining T-cell characteristics through interactions with thymic stromal 
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cells. Once T-cells reach the DN3 stage, proliferation slows and TCR gene rearrangement increases. 
Following successful in-frame rearrangement at the T-cell receptor β locus, pre-T-cells acquire surface 
expression of the pre-TCR that promotes differentiation to the DN4 stage. TCR-β expression allows the 
cells to undergo β selection, turning on expression of CD4 and CD8 to become double positive (DP cells) 
and ultimately gaining cell-surface TCR-αβ complexes. The expression of cell-surface TCR-αβ complexes 
allows the cells to undergo positive selection and negative selection to culminate in the production of 
mature CD4+ or CD8+ TCR+ αβ T-cells (Figure 1.7). On the other hand, DN3 T-cells that successfully 
recombine TCRγ- and δ- chains, in contrast to β-chains, are selected as γδ T-cells (Figure 1.7). Notably, 
multiple genes required for T-cell development in the bone marrow and thymus are also known 
oncogenes in T-ALL, including NOTCH1, IL7R, and MYB (Aifantis, Raetz et al. 2008, Rothenberg, Moore 







1.C.ii. Clinical Picture of T-ALL 
T-ALL, a malignant tumor of lymphoid progenitor cells, comprises 10-15% of pediatric and 25% of 
adult acute lymphoblastic leukemia cases (Van Vlierberghe and Ferrando 2012). The hallmark of T-ALL is 
infiltration of the bone marrow with immature lymphoblasts expressing immunophenotypic T-cell markers 
(Ferrando 2009). Clinically, T-ALL patients typically have very high white blood cell counts, mediastinal 
masses with pleural effusions, and an elevated risk of central nervous system infiltration at diagnosis (Pui, 
Relling et al. 2004). Currently, 5-year relapse-free survival rates for T-ALL are over 75% in pediatric and 
over 50% in adult patients (Pui, Relling et al. 2004). However, despite intensified therapy, 25% of children 
and 50% of adult T-ALL cases show primary resistant disease or respond only transiently to 
chemotherapy and relapse (Pui, Robison et al. 2008). The outcome of T-ALL patients with primary 
resistant or relapsed leukemia remains poor (Goldberg, Silverman et al. 2003, Oudot, Auclerc et al. 2008). 
Thus, T-ALL is an important clinical problem. 
 
1.C.iii. Genetic Mechanisms of T-ALL 
T-ALL is a heterogeneous disease in which multiple oncogenic and tumor suppressor pathways 
coordinately disrupt the regulatory programs controlling cell proliferation, differentiation, and survival 
during thymocyte development. The most prominent oncogenic mechanism in T-cell transformation is 
activation of the NOTCH1 signaling pathway (Weng, Ferrando et al. 2004). Moreover, deletions of the 
CDKN2A locus in chromosome band 9p21, encompassing the p16/INKF4A and/or p14/ARF tumor 
suppressor genes, occur in more than 70% of T-ALLs (Hebert, Cayuela et al. 1994, Ferrando, Neuberg et 
Figure 1.7. T-cell development proceeds through distinct thymic microenvironments. 
Early T-cell precursors (ETPs) from the bone marrow enter the thymus through blood 
vessels at the cortico-medullary junction. ETPs commit to the T-cell lineage as they 
progress through the CD4- CD8- double negative stages (DN2, DN3, and DN4). Successful 
recombination at the TCR-β locus leads to pre-TCR surface expression, which promotes 
differentiation to the DN4 stage. Pre-TCR-selected cells become CD4+ CD8+ double 
positive (DP) cells and then undergo the processes of positive and negative selection. 
Positive selection ensures the survival and maturation of developing T-cells that exhibit the 
appropriate degree of interaction between their TCR and peptide-MHC complexes on thymic 
epithelial cells, while negative selection removes developing T-cells that react too strongly 
against self-antigens. Selected cells leave the thymus as single positive CD4+ or CD8+ αβ 
T-cells. Notably, if a DN3 cell successfully recombines TCRγ- and δ- chains instead of β-
chains, it is selected as a γδ T-cell. Figure is adapted (Aifantis, Raetz et al. 2008) and 
(Rothenberg, Moore et al. 2008). 
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al. 2002). T-ALLs also characteristically exhibit the translocation and aberrant expression of transcription 
factor oncogenes, typically through chromosomal rearrangements that place these transcription factors 
under the control of strong T-cell specific enhancers in the TCRβ (7q34) or TCRα-TCRδ (14q11) loci 
(Ferrando and Look 2000). These oncogenic transcription factors include the basic helix-loop-helix 
(bHLH) family members TAL1, TAL2, LYL1 and BHLHB1, LIM-only domain (LMO) genes including LMO1 
and LMO2, and the homeobox (HOX) genes TLX1/HOX11, TLC2/HOX11L2, NKX2.1, NKX2.2, and 
NKX2.5, as well as MYC, MYB, and TAN1, a truncated and constitutively activated form of the NOTCH1 
receptor (Tosello and Ferrando 2013). Other recurrent genetic lesions in T-ALL affect genes encoding 
factors important in signal transduction, chromatin remodeling, cell cycle control, and cell growth (Van 
Vlierberghe and Ferrando 2012). Notably, the number and diversity of genetic lesions identified in T-ALL 
continues to expand, especially with the ubiquity of next generation sequencing (Pui, Mullighan et al. 
2012). 
 
1.C.iii.a. NOTCH1 Pathway Activation in T-ALL 
More than 50% of T-ALLs exhibit activating mutations in the NOTCH pathway, making NOTCH1 
the most prominent T-ALL-specific oncogene (Weng, Ferrando et al. 2004). The NOTCH1 receptor is a 
transmembrane protein that functions as a ligand-activated transcription factor. Physiologic NOTCH1 
signaling is triggered by interaction of the receptor with ligands of the Delta/Serrate/LAG-2 (DSL) family of 
ligands (Delta-like 1, 3, and 4; Jagged 1 and 2) on nearby cells (Van Vlierberghe and Ferrando 2012). 
The ligand-NOTCH1 receptor interaction induces a conformational change in the heterodimerization 
(HD)-LNR repeats complex of NOTCH1 to expose the otherwise cryptic C-terminal part of the HD domain 
to protease cleavage by ADAM10 and ADAM17 metalloproteases at the cell surface (Brou, Logeat et al. 
2000, Mumm and Kopan 2000, Mumm, Schroeter et al. 2000, Bozkulak and Weinmaster 2009, van 
Tetering, van Diest et al. 2009). This initial cut at the so-called S2 site in the extracellular portion of the 
receptor primes NOTCH1 for further proteolytic processing at the S3 site in the transmembrane region by 
the γ-secretase complex (Brou, Logeat et al. 2000, Mumm and Kopan 2000, Mumm, Schroeter et al. 
2000). Upon γ-secretase cleavage, the intracellular portion of NOTCH1 (ICN1) is released from the 
membrane and translocates to the nucleus, where it interacts with RBPJ/CSL DNA-binding protein, 
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recruits members of the mastermind (MAML) family of co-activators, and p300, and triggers the 
expression of target genes (Van Vlierberghe and Ferrando 2012). 
NOTCH1 mutations in T-ALL generally result in increased processing of the receptor at the 
membrane or in enhanced stability of the activated intracellular form of NOTCH1 in the nucleus, inducing 
ligand-independent activation of the receptor. Commonly, mutations in NOTCH1 affect the HD domain, 
leading to altered conformation of the HD-LNR domains and disruption of the NRR, a highly shielded 
domain that normally blocks S2 cleavage in the absence of ligand (Malecki, Sanchez-Irizarry et al. 2006). 
Moreover, mutations that enhance the stability of activated intracellular NOTCH1 occur frequently in T-
ALL, include truncating or nonsense mutations in the C-terminal PEST domain of NOTCH1 that disrupt 
the recognition sequence required for proteasomal degradation of ICN1 by the FBXW7/SCF complex in 
the nucleus (Weng, Ferrando et al. 2004), or mutations in FBXW7 that impair the ability of this F-box 
factor to recognize and target ICN1 for proteasomal  degradation (O'Neil, Grim et al. 2007, Thompson, 
Buonamici et al. 2007). Interestingly, HD and PEST domain mutations often occur in cis within a single 
NOTCH1 allele (Aster, Blacklow et al. 2011). Alternative mechanisms of NOTCH1 activation in T-ALL 
include insertions in the extracellular juxtamembrane region of the receptor that displace the HD-LNR 
complex and its S2 site and lead to deprotected S2 cleavage (Sulis, Williams et al. 2008), as well as 
deletion of the 5’ exons of the NOTCH1 locus, abrogating the negative regulatory control of the 
extraceullar domain of the protein and thus leading to constitutively active NOTCH1 polypeptides (Haydu, 
De Keersmaecker et al. 2012). Rare balanced chromosomal translocations truncate the NOTCH1 locus 
on chromosome 9 and place it under the control of the strong T-cell enhancer elements in the TCRβ locus 
on chromosome 7 (Ellisen, Bird et al. 1991). 
 
1.C.iii.b. Deletion of the Long Arm of Chromosome 6 in T-ALL 
Deletion of the long arm of chromosome 6 (6q-) occurs in approximately 20% of acute 
lymphoblastic leukemia cases (Strefford, Worley et al. 2007), and is associated with T-cell 
immunophenotype and either an intermediate or poor outcome (Sinclair, Sorour et al. 2004). These are 
often large, heterogeneous deletions, yet no consensus region or common target gene(s) have been 
identified (Sinclair, Sorour et al. 2004). Previous studies of 6q- in acute leukemias have failed to identify 
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recurrent mutations in the corresponding genes on the patient’s intact chromosome 6, suggesting that 
haploinsufficiency for one or more genes in this region may itself be leukemogenic (Taborelli, Tibiletti et al. 
2006). The mechanism of 6q- may resemble the mechanism of deletion of the long arm of chromosome 5 
(5q-) in myelodysplastic syndrome (MDS), where several hemizygously-deleted genes play important 
roles in MDS pathogenesis in the absence of mutations or epigenetic silencing of the remaining allele, 
suggesting a haploinsufficient mechanism of action (Look 2005, Ebert 2009). 
Strikingly, our high-resolution array comparative genomics hybridization (aCGH) analysis of 
chromosome 6 in pediatric T-ALL reveals a focal deletion at the FBXL4 locus (Figure 1.8). This deletion 
is approximately 20 kB in size and removes the proximal promoter and first exon of the FBXL4 gene 
(Figure 1.8). Interestingly, the FBXL4 gene, located at 6q16.2, is contained in several regions of minimal 
deletion previously defined in studies of 6q- patients (Burkhardt, Moericke et al. 2008). In total, 5/14 
patients in our study (35.7%) exhibited deletions encompassing the region of 6q harboring FBXL4, with 
the overall deleted regions extending from 6q12 to 6q23.2 (Figure 1.8). Mutational analysis of FBXL4 in 
6q- patients showed no mutations in FBXL4 and expression analysis showed absence of epigenetic 
FBXL4 silencing which is consistent with a possible haploinsufficiency model for 6q- in leukemia 









Recently, a study in T-cell lymphoblastic lymphoma, a disease closely related to T-ALL, used 
microsatellite marker analysis to describe a common minimally deleted region encompassing just two 
genes, one of which is FBXL4 (Figure 1.9) (Bonn, Rohde et al. 2013). Taken together, these results 




1.C.iv. Treatment of T-ALL 
Conventional treatment for T-ALL typically consists of a remission-induction phase, an 
intensification (or consolidation) phase, and continuation therapy to eliminate residual disease. Moreover, 
central nervous system (CNS) treatment is performed early on to prevent relapse due the sequestration 
of leukemic cells in this location (Pui and Evans 2006, Pui, Robison et al. 2008). The aim of the 
remission-induction phase is to eliminate more than 99% of the initial leukemic cell burden and to restore 
normal hematopoesis. For most standard-risk patient cases, provided patients receive intensified post-
remission treatment, a three drug induction regimen is sufficient, although children with high risk or very 
Figure 1.8. FBXL4 is recurrently deleted in T-ALL. The heterozygous 6q deletions are in 
light green for each patient. One patient has a homozygous deletion (dark green) within a 
heterogzygous deletion, but there are no genes in this region. To the right, raw aCGH data 


















Figure 1.9. FBXL4 is in the commonly deleted region in T-cell Lymphoblastic 
Lymphoma. A recently published study mapping 6q deletions in 118 T-cell Lymphoblastic 
Lymphoma patients by microsatellite marker analysis defined a narrow region of minimal 
deletion (darkest gray) that contains FBXL4. This figure is adapted from Figure S5 (Bonn, 
Rohde et al. 2013). 
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high-risk T-ALL and almost all adult cases are treated with four or more drugs for remission-induction. 
The most common three-drug regimen includes a glucocorticoid such as prednisone or dexamethasone, 
vincristine, and asparaginase or anthracycline. Following the restoration of normal hematopoesis, the 
goal of intensification treatment is to eliminate drug-resistant residual leukemia cells to reduce the risk of 
relapse.  Although a general consensus agrees that the intensification phase is important, the best 
treatment regimens and duration of treatment remains an area of debate. Finally, continuation treatment 
is required for T-ALL patients to prevent or forestall relapse (Pui, Robison et al. 2008). Although it has 
been shown that some childhood patients only require one year of continuation therapy (Toyoda, Manabe 
et al. 2000), there is no prospective way to identify these patients and thus all patients receive 
chemotherapy for twenty-four to thirty months, with the mainstay of treatment consisting of daily 
mercaptopurine and weekly methotrexate (Pui, Robison et al. 2008). Notably, allogeneic hematopoietic 
stem-cell transplant, the most intensive treatment for T-ALL, benefits several subgroups of patients with 
high-risk ALL, but comes with considerable morbidity and mortality (Pui, Robison et al. 2008). On the 
other hand, autologous transplant, which has several practical advantages to allogeneic hematopoietic 
stem-cell transplant, fails to enhance outcome in either adult of pediatric acute lymphoblastic leukemia 
(Dhedin, Dombret et al. 2006, Ribera, Ortega et al. 2007). 
Following the identification of NOTCH1 activating mutations in T-ALL, efforts have been made to 
develop anti-NOTCH1 therapies. For example, the γ-secretase complex, which is responsible for the 
proteolytic processing and activation of NOTCH1 signaling, can be abrogated with small molecule 
inhibitors (GSIs) (Pollack and Lewis 2005). Studies in T-ALL cell lines have shown that GSIs rapidly clear 
activated NOTCH1 protein and downregulate NOTCH1 target genes, as well as reduce growth and 
proliferation by inducing G1 cell cycle arrest and decreasing cell size (Weng, Ferrando et al. 2004, 
Palomero, Barnes et al. 2006). However, in early clinical trials, GSIs were found to have limited 
antileukemic activity against human T-ALL, and there were reports of dose-limiting gastrointestinal toxicity 
(Deangelo, Stone et al. 2006). However, combination therapy of GSIs with glucocorticoids, a mainstay of 
T-ALL therapy, restores glucocorticoid sensitivity in glucocorticoid-resistant T-ALL and inhibits GSI-
induced gut toxicity (Real, Tosello et al. 2009). The use of GSIs in T-ALL continues to be an area of 
ongoing research (Aster and Blacklow 2012) and illustrates how understanding the genetic mechanisms 
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of T-ALL can drive drug development, with the goal of designing highly effective anti-leukemia therapies 
with decreased off-target toxicity. 
 
1.D. Specific Aims 
Genetic alterations in FBXL4 are implicated in two very different diseases. First, the FBXL4 gene 
is mutated in early-onset pediatric mitochondrial encephalopathy, for which no treatments or cures exist 
(Figure 1.6, Table 1.2) (Bonnen, Yarham et al. 2013, Gai, Ghezzi et al. 2013). Second, FBXL4 is 
recurrently deleted in intermediate and poor prognosis T-ALL as part of 6q- (Burkhardt, Moericke et al. 
2008), and we recently identified a T-ALL patient with a focal FBXL4 deletion (Figure 1.8). Interestingly, 
FBXL4 mutations in mitochondrial disease are biallelic (Bonnen, Yarham et al. 2013, Gai, Ghezzi et al. 
2013), while the deletions encompassing the FBXL4 locus in leukemia are heterozygous and appear to 
leave the remaining copy of FBXL4 intact (Figures 1.8, 1.9) (Burkhardt, Moericke et al. 2008, Bonn, 
Rohde et al. 2013). Other than its predominant localization to mitochondria (Figure 1.3), the cellular roles 
of FBXL4 remain relatively unknown. Thus, to characterize the function of FBXL4 in mitochondrial 
encephalopathy and in acute leukemia, I addressed the following specific aims: 
 
1. Generate conditional Fbxl4 knockout mice to define the role of Fbxl4 in developmental homeostasis 
and to probe how Fbxl4 loss affects mitochondrial dynamics and contributes to mitochondrial disease in 
vivo and in vitro.  
 
2. Isolate the FBXL4 protein complex to delineate and categorize the FBXL4 protein interaction network.  
 
3. Analyze the role of FBXL4 inactivation in hematopoesis, T-cell development, and leukemogenesis 







Chapter 2. The Role of FBXL4 in Mitochondrial Encephalopathy 
2.A. Introduction 
Primary mitochondrial diseases encompass a sizeable and diverse group of conditions that affect 
multiple organ systems (Koopman, Willems et al. 2012, Schapira 2012, McInnes 2013). Mitochondrial 
disease can arise from mutations in nuclear or mitochondrial-encoded DNA (Tucker, Compton et al. 2010, 
Koopman, Willems et al. 2012), but notably, in more than 50% of cases, causative mutations are not 
identified (Kirby and Thorburn 2008). Moreover, even when underlying genetic events are known, the 
mechanisms of disease often remain elusive (Tucker, Compton et al. 2010, Koopman, Willems et al. 
2012). Overall, the prognosis of mitochondrial disease is grim, with a generally progressive clinical course 
that results in significant morbidity, decreased quality of life, and premature death (Uziel, Ghezzi et al. 
2011). Thus, there is an important need for relevant cellular and animal models of mitochondrial disease 
to help define the drivers of pathogenesis and to develop effective treatments for patients (Koopman, 
Willems et al. 2012). 
Recently, FBXL4 mutations have been implicated in a novel pediatric mitochondrial 
encephalopathy (Bonnen, Yarham et al. 2013, Gai, Ghezzi et al. 2013). Patients with FBXL4 mutations 
typically present months after birth with encephalopathy, hypotonia, lactic acidosis, and severe global 
developmental delay. At the cellular level, FBXL4 mutations are associated with impaired mitochondrial 
dynamics, including oxidative phosphorylation deficiency, depressed mitochondria membrane potential, 
mitochondrial DNA (mtDNA) depletion, and fragmentation of the mitochondrial network. The mutations in 
FBXL4 in mitochondrial encephalopathy are biallelic and are proposed to be inactivating (Figure 1.6, 
Table 1.2). Interestingly, in some cases, the severity of clinical presentation correlates with mutation type. 
For example, patients with mutations truncating the FBXL4 protein within the leucine-rich repeats 
exhibited a more severe clinical phenotype than a patient with a mutation affecting splicing of the last 
exon of the FBXL4 gene (Bonnen, Yarham et al. 2013, Gai, Ghezzi et al. 2013). 
The underlying mechanisms of FBXL4 loss in mitochondrial disease are unknown. To 
characterize the role of FBXL4 in mitochondrial encephalopathy, I generated conditional Fbxl4 knockout 
mice to study the consequences of Fbxl4 loss in vivo (2.B.i, 2.B.ii). I also isolated the FBXL4 protein 
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complex to define the FBXL4 protein interaction network and to link protein complex members to the 





2.B.i. Generation of Conditional Fbxl4 Knockout Mice 
The mouse Fbxl4 gene is located in mouse chromosome 4 and exhibits 88.5% nucleotide 
similarity to human FBXL4. The murine Fbxl4 locus is comprised of nine exons, but only exons three 
through nine are expressed (Figure 2.1A, Fbxl4 WT). Importantly, exons four and five encode the F-box 
domain, and exons six through nine encode the leucine-rich repeats. To generate an inducible knockout 
model of Fbxl4, I conditionally targeted exon five, which encodes the C-terminal portion of the F-box 
domain (Figure 2.1A, Fbxl4 WT). After electroporation of the conditional targeting construct into C57/BL6 
embryonic stem (ES) cells, successfully recombined ES cells will have a neomycin resistance cassette in 
intron 4 flanked by FRT recombination sites and lox P sites located 5’ and 3’ of Fblx4 exon five (Figure 
2.1A, Fbxl4 Neo-fl). Southern Blot analysis was used to identify ES clones with successful integration of 
the targeting construct at the Fbxl4 locus (Figure 2.1B). Following Southern Blot analysis, 3 independent 
conditionally targeted Fbxl4 ES cell lines were selected for injection into albino blastocysts. Notably, 
foster mice injected with these blastocysts gave birth to three male chimeras, which are identified by 






To obtain the targeted Fbxl4 allele in a pure C57/BL6 background, male chimeras (Figure 2.1C) 
were crossed to C57/BL6 albino females, and only offspring with completely black fur were genotyped for 
the presence of the Fbxl4 Neo-fl allele. Notably, the genotyping results indicated that all three male 
chimeras were capable of germline transmission of the targeted Fbxl4 allele. Next, Fbxl4Neo-fl/WT 
heterozygous mice were crossed to a C57/BL6 Flp recombinase deleter line to generate mice with a 
single conditional knockout Fbxl4 allele (Fbxl4fl) (Figure 2.2A, Fbxl4fl). I then crossed Fbxl4fl/WT mice to 
Cre deleter mice expressing Cre recombinase from the ubiquitous Rosa26 promoter to generate mice 
Figure 2.1. Conditional targeting strategy for Fbxl4. (A) Successful targeting of exon five 
of wildtype Fbxl4 (Fbxl4 WT) leads to the insertion of a Neomcyin resistance cassette 
flanked by FRT recombination sites and lox P sites positioned 5’ to the Neomycin gene and 
3’ of exon five (Fbxl4 Neo-fl). (B) Southern Blotting was performed using digestion at SphI 
sites (S*) and probe P (indicated in A) to yield a 10,469 bp band for the WT Fbxl4 allele and 
a 7,964 bp band for the successfully targeted Fbxl4 Neo-fl allele. Four ES cell lines (Fbxl4 
Neo-fl #1-4) showed successful integration, with C57/BL6 wildtype ES cells shown as a 
control. (C) Three male chimeras were generated from litters born after injection of targeted 
ES cells into albino blastocysts.  
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heterozygous for the Fbxl4 null allele (Fbxl4+/-). Exposure of the Fbxl4fl allele to Cre recombinase deletes 
exon five and creates a frameshift mutation truncating Fbxl4 within the F-box domain of the protein 
(Figure 2.2A, Fbxl4-). I ensured efficient Cre-mediated excision of the floxed Fbxl4 allele by PCR 
analysis of genomic DNA isolated from Fbxl4WT/- (Fbxl4+/-) mice, compared to Fbxl4WT/WT (Fbxl4+/+) mice 
(Figure 2.2B). Moreover, Western Blot analysis of Fbxl4+/+, Fbxl4+/-, and Fbxl4-/- mouse embryonic 
fibroblasts (MEFs) demonstrates that Cre-mediated recombination at the floxed Fbxl4 allele results in no 
detectable Fbxl4 protein in Fbxl4-/- MEFs and reduces Fbxl4 protein to 50% of wild-type levels in Fbxl4+/- 






2.B.ii. Characterizing the Role of Fbxl4 Inactivation in Mitochondrial Encephalopathy 
To examine the consequences of Fbxl4 loss in vivo, I generated constitutive Fbxl4 knockout mice 
and characterized the effects of germline Fbxl4 inactivation on developmental homeostasis, metabolism, 
gene expression, and mitochondrial function. I hypothesized that the phenotype of complete Fbxl4 
Figure 2.2. Cre recombinase efficiently excises the floxed Fbxl4 allele. (A) Exposure of 
the Fbxl4 Neo-fl allele to Flp recombinase removes the Neomycin gene via recombination at 
the FRT sites, generating the floxed Fbxl4 allele (Fbxl4 fl). Exposure of Fbxl4 fl to Cre 
recombinase results in recombination at the Lox P sites, generating a frameshift mutation 
within exon five to produce the Fbxl4-null allele (Fbxl4-). (B) The Fbxl4-null allele can be 
identified by PCR on genomic DNA using primers that produce a 406 bp product for the 
excised Fbxl4 allele (Fbxl4-) or an 1160 bp product for the wild-type Fbxl4 allele (Fbxl4 WT). 
Primers are indicated in A. (C) Western blot analysis of Fbxl4 protein levels in Fbxl4+/+ 
(n=2), Fbxl4-/- (n=3), and Fbxl4+/- (n=3) mouse embryonic fibroblast cell lines, with Tubulin 
shown as a loading control. The arrow indicates the band corresponding to Fbxl4. 
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inactivation would recapitulate central features of pediatric mitochondrial encephalopathy associated with 
FBXL4 mutations (Bonnen, Yarham et al. 2013, Gai, Ghezzi et al. 2013). Moreover, I postulated that 
Fbxl4 knockout mice would provide insights into the molecular and cellular functions of FBXL4 that could 
potentially be harnessed to design novel treatments for this devastating disease.   
 
2.B.ii.a. Germline Inactivation of Fbxl4 Results in Perinatal Lethality 
To study the role of FBXL4 in mitochondria encephalopathy, I crossed mice heterozygous for the 
Fbxl4-floxed allele (Fbxl4fl/WT) to germline Cre deleter mice, which express Cre recombinase from the 
ubiquitous Rosa26 promoter, to generate mice heterozygous for the Fbxl4 null allele (Fbxl4+/-) (Figure 
2.2A). I crossed the resulting Fbxl4+/- Rosa26Cretg/+ mice to wild-type C57/BL6 mice to remove the 
Rosa26Cre transgene. Mice heterozygous for one copy of the Fbxl4-null allele are viable and fertile. 
However, I hypothesized that mice homozygous for the Fbxl4 null allele (Fbxl4-/-) may exhibit impaired 
viability and developmental defects, similar to pediatric patients with homozygous FBXL4 mutations and 
associated mitochondria encephalopathy (Bonnen, Yarham et al. 2013, Gai, Ghezzi et al. 2013). To 
assess for the inheritance of the Fbxl4-null allele, I genotyped ninety offspring from Fbxl4+/- x Fbxl4+/- 
crosses. Strikingly, Fbxl4-/- mice overwhelmingly die before weaning age and thus the Fbxl4-null allele is 
not inherited according to the predicted 25% Fbxl4+/+, 50% Fbxl4+/-, and 25% Fbxl4-/- Mendelian 
proportions (Figure 2.3A). 
To identify when Fbxl4-null mice die, I performed timed matings and isolated embryos throughout 
gestation. Interestingly, Fbxl4-/- embryos are present in the predicted ratios at Embryonic Days 13.5-14.5 
(Figure 2.3B). Moreover, Fbxl4-null embryos isolated at Embryonic Days 13.5-14.5 or 18.5 are not 
grossly abnormal, compared to littermate controls (Figure 2.3C-D). Importantly, Fbxl4-null mice are 
carried to term, are delivered normally, and oxygenate (Figure 2.3E-F). However, Fbxl4-/- newborn mice 







Analysis of an extended cohort identified that 3% of Fbxl4-/- mice survive perinatally (Figure 
2.3A). Rare surviving Fbxl4-null mice exhibit a runted phenotype with impaired fertility and early death, 
compared to age- and gender-matched wild-type littermate controls (Figure 2.4A-B). Notably, the few 
Figure 2.3. Homozygous Fbxl4 inactivation results in perinatal lethality. (A) Table 
summarizing genotyping results of offspring (n=90) from Fbxl4+/- x Fbxl4+/- crosses 
analyzed at three to four weeks of age. (B) Table summarizing genotyping results of 
embryos (n=66) isolated at E13.5-14.5 from Fbxl4+/- x Fbxl4+/- crosses. (C) Representative 
Fbxl4+/+, Fbxl4+/-, and Fbxl4-/- embryos at E14.5. (D) Representative Fbxl4+/+, Fbxl4+/-, 
and Fbxl4-/- embryos at E18.5. (E) Table summarizing genotyping results of embryos from 
E18.5 and E20, as well as pups isolated within one hour of birth (P0) and pups isolated one 
day following birth (P1) from Fbxl4+/- x Fbxl4+/- crosses. (F) Representative Fbxl4+/+, 
Fbxl4+/-, and Fbxl4-/- pups within one hour of birth (P0). In C, D, and F, scale bars 
represent 5 mm. 
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I hypothesized that Fbxl4-null mice may exhibit defective brain development, given that pediatric 
patients with FBXL4 mutations exhibit microcephaly with cerebral atrophy and variable white matter, deep 
gray nuclei, and brainstem structure involvement (Bonnen, Yarham et al. 2013, Gai, Ghezzi et al. 2013). 
Notably, brains from perinatal Fbxl4-/- mice are smaller compared to brains from Fbxl4 wild-type 
littermates, with a significant decrease in brain length, width, and weight (Figure 2.5A-B). Moreover, 
Figure 2.4. Rare surviving Fbxl4-null mice are runted. (A) Representative six-week old 
Fbxl4-null male mouse (Fbxl4-/-), shown with an age-matched male wild-type control mouse 
(Fbxl4+/+). (B) Representative one-year old Fbxl4-null male mouse (Fbxl4-/-), shown with 
two age-matched male wild-type control mice (Fbxl4+/+). In A and B, scale bars represent 5 
cm. (C) Weights of Fbxl4 wild-type (Fbxl4+/+, n=7) and Fbxl4-null mice (Fbxl4-/-, n=4) at ten 
months to one year of age. 
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brains from perinatal Fbxl4-/- mice are also smaller than brains from mice heterozygous for one Fbxl4-null 
allele, with the decrease in width and weight reaching significance (Figure 2.5A-B). Brains from Fbxl4+/- 
or Fbxl4 wild-type mice do not differ in width or weight, and although Fbxl4+/- brains were slightly smaller 
than Fbxl4+/+ brains by length, taken together, these data suggest that inactivation of a single copy of 
Fbxl4 does not perturb brain development in vivo. (Figure 2.5A-B). Notably, the striatum and basal 
ganglia, regions affected in some patients with FBXL4-associated mitochondrial encephalopathy (Bonnen, 
Yarham et al. 2013, Gai, Ghezzi et al. 2013), exhibited normal architecture and cellularity in Fbxl4-/- 











To better characterize the mitochondria phenotype associated with Fbxl4 deletion in vivo, I 
isolated livers from Fbxl4+/+, Fbxl4+/-, and Fbxl4-/- perinatal mice. Notably, Fbxl4-/- liver cells exhibit a 
large variation in mitochondria membrane potential (ΔΨ), as measured by the mitochondria membrane 
potential-dependent fluorchrome TMRE, with a trend towards decreased membrane potential compared 
to Fbxl4+/+ and Fbxl4+/- livers (Figure 2.6A). In contrast, Fbxl4+/+ and Fbxl4+/- livers do not differ 
significantly in mitochondria membrane potential (Figure 2.6A). Interestingly, both Fbxl4+/- and Fbxl4-/- 
livers exhibit significantly decreased mitochondria mass, measured by MitoTracker Green staining, 
compared to Fbxl4+/+ livers (Figure 2.6B). The decrease in mitochondria mass in Fbxl4+/- livers is 
coupled with a statistically significant 1.6-fold increase in mtDNA content compared to Fbxl4+/+ or Fbxl4-
/- livers (Figure 2.6C), which may represent compensatory mitochondrial biogenesis to preserve 
mitochondrial function in the context of inactivation of one copy of Fbxl4. However, the mtDNA content of 
Fbxl4-/- livers does not differ significantly from Fbxl4+/+ livers (Figure 2.6C). Thus, Fbxl4-/- liver cells 
exhibit a trend towards decreased mitochondria membrane potential (Figure 2.6A) and a statistically 
significant drop in mitochondria mass (Figure 2.6B), but no change in mtDNA content (Figure 2.6C), 
compared to Fbxl4+/+ liver cells, which may indicate an inability to compensate via mitochondrial 
biogenesis for the deficits induced by Fbxl4 deletion. 
When a one-year-old Fbxl4-null mouse became sick and succumbed to disease complications, I 
analyzed mtDNA maintenance by quantitative PCR of genomic DNA isolated from liver, compared to 
three age- and gender-matched controls. Notably, I observed a significant decrease in mtDNA content 
with Fbxl4 inactivation, suggesting decreased mitochondria number and/or disordered maintenance of 
mtDNA in the setting of Fbxl4 loss (Figure 2.6D). This finding correlates with the mtDNA depletion 
observed in fibroblasts and skeletal muscle cells from patients with mitochondrial encephalopathy 
associated with FBXL4 mutations (Bonnen, Yarham et al. 2013, Gai, Ghezzi et al. 2013). 
 
Figure 2.5. Fbxl4-null mice have smaller brains than Fbxl4+/- or Fbxl4+/+ controls. 
Brain length and width (A), and brain weight (B), measured in perinatal Fbxl4+/+ (n=8), 
Fbxl4+/- (n=11), and Fbxl4-/- (n=16) mice. In A, bars represent mean + SD. (C) 
Representative images of basal ganglia (top panels, 4X magnification) and striatum (bottom 
panels, 10X magnification) of Fbxl4+/+, Fbxl4+/-, and Fbxl4-/- perinatal brains stained with 






2.B.ii.b. Fbxl4 Loss Drives Metabolic Perturbations 
Mitochondria are crucial metabolic hubs, tasked with generating energy through the currency of 
ATP, as well as coordinating key metabolic processes with cellular energy demands, including fatty acid 
Figure 2.6. Mitochondrial alterations associated with Fbxl4 inactivation. (A-B) Liver 
samples were isolated from Fbxl4+/+ (n=3), Fbxl4+/- (n=6), and Fbxl4-/- (n=3) perinatal 
mice. (A) Mitochondria membrane potential, measured by mean background-subtracted 
TMRE fluorescence, is shown as fold fluorescence intensity relative to Fbxl4 wild-type 
(Fbxl4+/+) livers. P values are not significant. (B) Mitochondria amount, measured by mean 
background-subtracted MitoTracker Green fluorescence, is show as fold fluorescence 
intensity relative to Fbxl4+/+ livers. (C) Quantification of mtDNA content in three perinatal 
liver samples per Fbxl4 genotype is shown as fold mtDNA copy number relative to Fbxl4+/+ 
livers. (D) Quantification of liver cell mtDNA amount in a one-year-old Fbxl4-/- mouse is 
shown as fold mtDNA copy number relative to three age-matched male Fbxl4+/+ controls 
(“Fbxl4+/+ 1” set to 1). In B, C, and D, bars represent mean + SD. 
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oxidation and gluconeogenesis (Koopman, Willems et al. 2012, McInnes 2013). Given the important 
contribution of mitochondria to metabolic homeostasis, metabolic disarray occurs frequently in 
mitochondrial disease, often in tissue- and energy demand-specific patterns (Debray, Lambert et al. 2008, 
Uziel, Ghezzi et al. 2011, McInnes 2013). To characterize in further detail the metabolic consequences of 
Fbxl4 loss, I performed metabolic profiling and starvation stress test experiments using Fbxl4-null mice 
and matched wild-type controls.  
 
2.B.ii.b.(1). Metabolic Profiling 
To gain insight into the metabolic effects of Fbxl4 inactivation in vivo, I performed metabolic 
profiling using GC/MS and LC/MS/MS platforms to quantify metabolite levels in perinatal liver, brain, and 
brown adipose tissue (Table 2.1). In this study, the metabolic profiling dataset comprised a total of 254 
named biochemical in adipose tissue, 243 in brain tissue, and 383 in liver tissue. Following log 
transformation and imputation with minimum observed values for each compound, Welch’s two-sample t-
test was used to identify biochemicals that differed significantly between experimental groups for all 
matrices (P<0.05). I hypothesized that Fbxl4-null mice might exhibit alterations consistent with impaired 
mitochondria function, including increased glycolysis and mobilization of alternate energy sources such 







Strikingly, multiple changes in protein and lipid handling were documented in Fbxl4-null tissues, 
while glycolysis remained unchanged. First, urea and the related metabolites proline and putrescine were 
significantly elevated in Fbxl4-null liver tissue (Figure 2.7A). I also observed elevated urea and altered 
levels of urea cycle intermediates in Fbxl4-null brain and adipose tissue (Figures 2.8A, 2.9A). Moreover, 
Table 2.1. Metabolic profiling experimental design. Brain, liver, and brown adipose 
tissue samples were isolated from Fbxl4+/+ (n=6) and Fbxl4-/- (n=6) perinatal mice and 
submitted for metabolic profiling analysis. 
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Fbxl4-null tissues had higher levels of mobilized amino acids compared to Fbxl4 wild-type tissues 
(Figures 2.7B, 2.8B, 2.9B). Notably, the gluconeogenic amino acids serine, asparagine, histidine, and 
glycine, the ketogenic amino acid lysine, and the dually gluconeogenic and ketogenic amino acid 
threonine were significantly elevated in various tissues lacking Fbxl4, compared to wild-type tissue 
(Figures 2.7B, 2.8B, 2.9B). Furthermore, alterations in branched chain amino acid (BCAA) handling were 
documented across Fbxl4-null tissues. In more detail, the levels of the BCAAs valine, isoleucine, and 
leucine were elevated across Fbxl4-/- tissues, narrowly missing the cut-off for statistical significance 
(Figures 2.7C, 2.8C, 2.9C). Notably, BCAA breakdown intermediates were significantly elevated, 
including isovalerylcarnitine and 3-methylglutarylcarntine in Fbxl4-/- liver, as well as isobutyrulcarnitine, 
isovalerylcarnitine, and hydroxyisovalerylcarntine in Fbxl4-/- brains (Figures 2.7C, 2.8C). Collectively, 
these findings suggest a global picture of increased protein turnover in the setting of Fbxl4 inactivation. 
Focusing more closely on lipid metabolism, the ketone body 3-hydroxybutyrate was significantly 
elevated in Fbxl4-null livers compared to wild-type livers (Figure 2.7D), with a trending elevation in 3-
hydroxybutyrate recorded in Fbxl4-null adipose tissue (Figure 2.9D). Moreover, 3-dehydrocarnitine, a 
degradation product of the biochemical chaperone carnitine that transports fatty acids into mitochondria, 
was significantly elevated in Fbxl4-/- adipose and brain and showed a trend in Fbxl4-/- liver (Figures 2.7E, 
2.8D, 2.9E). Further evidence of altered lipid handling was seen in the significant accumulation of 
essential and long chain fatty acids in Fbxl4-null brains, compared to wild-type brains (Figure 2.8E), as 
well as in the significant elevation of lipid membrane remodeling metabolites in Fbxl4-null liver and 




Figure 2.7. Fbxl4 loss results in altered protein and lipid metabolism in liver tissue.  
(A-F) Liver samples were isolated from Fbxl4 wild-type (Fbxl4+/+) and Fbxl4-null (Fbxl4-/-) 
mice and analyzed on GC/MS and LC/MS/MS platforms. (A) Urea, proline, and putrescine 
levels. P<0.05 in all cases. (B) Serine (P<0.05), threonine (P<0.001), asparagine (P<0.05), 
and lysine (P<0.05) levels. (C) Valine (P=0.06), isoleucine (P=0.05), leucine (P=0.09), 
isovalerylcarnitine (P<0.05), and 3-methylglutarylcarnitine (P<0.001) levels. (D) 3-
hydroxybutyrate (P<0.05) levels. (E) 3-dehydrocarnitine (P=0.05) levels. (F) Choline, 
phosphocholine, cytidine 5’-diphosphocholine, ethanolamine and phosphoethanolamine 






Figure 2.8. Metabolic changes associated with Fbxl4 deletion in brain tissue. (A-E) 
Brain samples were isolated from Fbxl4 wildtype (Fbxl4+/+) and Fbxl4-null (Fbxl4-/-) mice 
and analyzed as in Figure 2.7. (A) Urea (P=0.06), ornithine (P=0.05), citrulline (P<0.001), 
spermine (P<0.05) and spermidine (P<0.05) levels. (B) Serine (P<0.05) and histidine 
(P<0.05) levels. (C) Valine (P=0.10), isoleucine (P=0.06), leucine (P=0.05), 
isobutyrylcarnitine (P<0.05), isovalerylcarnitine (P<0.05), and hydroxyisovalerylcarnitine 
(P<0.05) levels. (D) 3-dehydrocarnitine (P<0.05) levels. (E) Table shows each fatty acid as 
the ratio of its level in Fbxl4-/- brain relative to its level in Fbxl4+/+ brain (Fbxl4-/- / WT) and 








Figure 2.9. Metabolic changes associated with Fbxl4 loss in adipose tissue. (A-F) 
Adipose samples were isolated from Fbxl4 wildtype (Fbxl4+/+) and Fbxl4-null (Fbxl4-/-) mice 
and analyzed as in Figure 2.7. (A) Urea (P<0.05), ornithine (P=0.05), and proline (P<0.05) 
levels. (B) Serine (P<0.0001), threonine (P<0.05), asparagine (P<0.05), glycine (P<0.05), 
and histidine (P<0.01) levels. (C) Valine (P=0.07), isoleucine (P=0.06), and leucine (P=0.08) 
levels. (D) 3-hydroxybutyrate (P=0.07) levels. (E) 3-dehydrocarnitine (P<0.05) levels. (F) 




2.B.ii.b.(2). Metabolic Changes Associated with Fasting 
Given the marked metabolic alterations observed perinatally with Fbxl4 loss, I postulated that rare 
surviving Fbxl4-null mice might exhibit disturbed metabolic homeostasis, particularly in response to stress. 
I fasted a cohort of Fbxl4-null mice (aged four months to one year) for eight hours and monitored blood 
glucose and urine ketone production, relative to age- and gender-matched control mice. Interestingly, two 
out of three female Fbxl4-null mice had trace levels of the ketone body acetocetic acid in urine at baseline 
and all three Fbxl4-null females quickly developed ketonuria that plateaued at 40 mg/dL during the course 
of the fast (Figure 2.10A). In contrast, female mice wild-type for Fbxl4, as well as male Fbxl4-/- mice and 
male Fbxl4+/+ controls, never developed ketonuria (Figures 2.10A, 2.11A). Blood glucose levels were 




Figure 2.10. Fasting female Fbxl4-null mice develop ketonuria. (A) Urine acetoacetic 
acid in Fbxl4-null females (Fbxl4-/- Females 1, 2 and 3) and in age-matched female controls 
wild-type for Fbxl4 (Fbxl4+/+ Controls, n=6) during an eight hour fast. (B) Blood glucose 
levels in the Fbxl4-null and control female mice described in A. In A and B, data points for 




Figure 2.11. Metabolic parameters in fasting male Fbxl4-null mice. (A) Urine 
acetoacetic acid in Fbxl4-null males (Fbxl4-/- Males 1, 2, and 3) and in age-matched male 
controls wild-type for Fbxl4 (Fbxl4+/+ Controls, n=4) during an eight hour fast. (B) Blood 
glucose levels in the Fbxl4-null and control male mice described in A. In A and B, data 
points for Controls indicate mean ± SD. 
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2.B.ii.c. Gene Expression Changes Associated with Fbxl4 Inactivation 
To interrogate the transcriptional programs associated with Fbxl4 inactivation, I performed 
microarray gene expression analysis of Fbxl4 wild-type and Fbxl4-/- MEFs and livers (Figures 2.12A, 
2.13A). First, to explore gene expression changes on the cellular level, I focused on the MEFs. The 
Fbxl4-/- MEFs showed a characteristic gene expression signature consisting of 17 upregulated and 20 
downregulated genes (>1.3-fold change, P<0.01) (Figure 2.12A). Gene-Set Enrichment Analysis (GSEA) 
of this signature against the C2 molecular signature database, a collection of 4,850 curated genesets 
assembled from online pathway databases, publications, and knowledge of domain experts (Gould, Getz 
et al. 2006), revealed a significant enrichment of genes implicated in mitochondria structure and function 






Following these results, and to gain insight into gene expression changes on a more global level 
following Fbxl4 inactivation, I turned to the microarray data generated from perinatal livers. The Fbxl4-/- 
livers exhibited a characteristic gene expression signature comprised of 35 upregulated and 48 
downregulated genes (>1.3-fold change, P<0.05) (Figure 2.13A). Notably, GSEA of this signature 
against the C2 molecular signature database revealed a significant enrichment of genes involved in 
mitochondria-related processes, including hypoxia, muscle contraction, and glucose and lipid metabolism, 
as well as liver related genes, in transcripts upregulated in Fbxl4-null livers (Figure 2.13B).  
 
Figure 2.12. Gene expression changes associated with Fbxl4 loss in MEFs. (A) Heat 
map diagram of top ranking differentially expressed genes by the Student t test in Fbxl4+/+  
(n=3) and Fbxl4-/- (n=3) MEFs. Genes in the heat map are shown in rows, and each 
individual sample is shown in one column. The scale bar shows color-coded differential 
expression, with red indicating higher levels of expression and blue indicating lower levels of 
expression. (B) GSEA enrichment plots of mitochondria-related gene sets associated with 









2.B.ii.d. Cellular Consequences of Fbxl4 Inactivation 
To examine the roles and mechanisms of Fbxl4 on the cellular level, I generated MEFs of various 
genetic backgrounds and performed several different assays. First, given that Fbxl4 inactivation is 
perinatal lethal, but mice heterozygous for the Fbxl4-null allele are viable and fertile, I hypothesized that 
inactivation of two copies of Fbxl4 might impair cell proliferation. To address this question, I created 
“inducible” MEFs with either one or two copies of the floxed Fbxl4 allele and one copy of a tamoxifen-
inducible Cre allele (Tm-Cre/+). In this system, tamoxifen exposure deletes the floxed Fbxl4 allele(s), while 
vehicle treatment leaves the floxed Fbxl4 locus intact. Interestingly, early passage MEFs inactivated for 
one or two copies of Fbxl4 do not show a significant difference in MTT absorbance relative to vehicle-
treated controls over a three-day time course (Figure 2.14A). Quantitative PCR on samples isolated at 
Day 3 indicated that Fbxl4 expression decreased to 50% and to 0% of control levels upon tamoxifen 
exposure in Fbxl4fl/WT and Fbxl4fl/fl cells, respectively (Figure 2.14B) Thus, cell proliferation is not affected 
by Fbxl4 gene dosage using an inducible system of Fbxl4 loss. 
 
Figure 2.13. Gene expression changes associated with Fbxl4 inactivation in perinatal 
livers. (A) Heat map diagram of top ranking differentially expressed genes by the Student t 
test in Fbxl4+/+ (n=3) and Fbxl4-/- (n=3) livers. Genes in the heat map are shown in 
columns, and each individual sample is shown in one row. The scale bar shows color-coded 
differential expression, with red indicating higher levels of expression and blue indicating 
lower levels of expression. (B) GSEA enrichment plots of indicated gene sets associated 






Given that mutations in FBXL4 are associated with mitochondrial disease, I postulated that 
FBXL4 loss might disrupt mitochondrial morphology. I visualized mitochondria in Fbxl4 knockout MEFs or 
Fbxl4 wild-type MEFs using MitoTracker Red staining and live-cell confocal microscopy. Notably, 
complete inactivation of Fbxl4 does not alter mitochondria size or shape, or cause fragmentation or 
shortening of the mitochondrial network, compared to cells with wild-type Fbxl4 (Figure 2.15). Therefore, 
Fbxl4 gene dosage does not affect mitochondrial morphology in MEFs.  
Figure 2.14. Fbxl4 loss does not affect proliferation of MEFs. (A) MTT absorbance 
relative to Day 0 for passage 4 MEFs during tamoxifen or vehicle treatment for three days. 
Data points show mean ± SD. (B) Quantitative PCR showing Fbxl4 expression relative to 
Gapdh and normalized to “Fbxl4fl/WT (VEH)”, for Day 3 cells treated with vehicle (VEH) or 






To characterize the mitochondrial role of FBXL4 in more detail, I used MEFs homozygous, 
heterozygous, and wildtype for the Fbxl4-null allele to test the hypothesis that Fbxl4-null MEFs would 
exhibit defective mitochondrial function. Strikingly, MEFs lacking both copies of Fbxl4 exhibit a significant 
decrease in mitochondria membrane potential (ΔΨ) to about 50% of that in Fbxl4 wild-type or Fbxl4 
heterozygous MEFs, as measured by a membrane-potential dependent fluorchrome, TMRE (Figure 
2.16A). However, Fbxl4 loss did not impact mitochondria mass, quantified by MitoTracker Green 
fluorescence, or mtDNA content, measured by quantitative PCR on genomic DNA (Figure 2.16B-C). 
Interestingly, when I measured respiratory chain complex protein levels by immunoblotting, Fbxl4-null 
Figure 2.15. Fbxl4 loss does not alter mitochondrial morphology in MEFs. 
Representative confocal images of Mitotracker Red staining in live MEFs for two 
independent Fbxl4 wild-type (Fbxl4+/+, top panels) and Fbxl4-null (Fbxl4-/-, bottom panels) 
cell lines. Scale bars represent 50 microns. 
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cells exhibited a marked decrease in electron transport chain protein levels across all five OXPHOS 
complexes, compared to Fbxl4+/- or Fbxl4+/+ cells (Figure 2.16D). Notably, bulk mitochondria levels, as 
measured by the membrane protein TOMM20, were relatively constant across MEFs of different Fbxl4 
gene dosages, with a slight decrease noted in Fbxl4-null MEFs (Figure 2.16D). Therefore, complete 
inactivation of Fbxl4 affects the stability of the OXPHOS protein system and depresses mitochondria 
membrane potential, without significantly altering mitochondria number. 
Mitophagy is a quality control mechanism employed by cells to eliminate damaged mitochondria 
(Youle and van der Bliek 2012). Given the notable OXPHOS protein complex destabilization in the setting 
of Fbxl4 inactivation, I postulated that excessive mitophagy of damaged mitochondria might be 
pathogenic in this case, which has been shown for other diseases with impaired mitochondrial 
maintenance, such as Parkinson’s disease and Huntington’s disease (Cui, Tang et al. 2010, Guo, 
Disatnik et al. 2013). I treated MEFs for twenty-four hours with the small molecule mitophagy inhibitor 
MDIVI-1 (Cassidy-Stone, Chipuk et al. 2008), or with vehicle as a control, but mitophagy inhibition did not 
restore membrane potential in Fbxl4-null MEFs and actually MDIVI-1 treatment resulted in a trend 








2.B.iii. Isolation of the FBXL4 Protein Interaction Network 
Since the cellular roles and mechanisms of FBXL4 are largely unknown, I endeavored to define 
the FBXL4 protein interaction network using proteomics approaches. As an F-box protein, FBXL4 is 
predicted to target protein substrates for ubiquitin-mediated proteolysis as a component of the SKP1-
CUL1-Fbox (SCF) complex (Bai, Sen et al. 1996, Cenciarelli, Chiaur et al. 1999, Skaar, Pagan et al. 
Figure 2.16. Fbxl4 inactivation impairs mitochondrial dynamics in MEFs. (A-E) For 
each Fbxl4 genotype, three independent MEF lines were analyzed. Bars represent mean + 
SD. (A) Mitochondria membrane potential, measured by mean background-subtracted 
TMRE fluorescence, is shown as fold fluorescence intensity relative to Fbxl4 wild-type 
(Fbxl4+/+) MEFs. (B) Mitochondria content in MEFs, measured by mean background-
subtracted MitoTracker Green fluorescence, is shown as fold fluorescence intensity relative 
to Fbxl4+/+ MEFs. (C) Quantification of mtDNA content in MEFs is shown as fold mtDNA 
copy number relative to Fbxl4+/+ MEFs. (D) Western blot analysis of MEF cell lines. 
TUBULIN and GAPDH are shown as loading controls. (E) MEFs were treated with 10 uM 
MDIVI-1 or DMSO vehicle for twenty-four hours, followed by measurement of mitochondria 
membrane potential as in A. 
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2013). The F-box domain of FBXL4 is predicted to interact with SKP1 of the SCF complex, while the 
leucine-rich repeat domains of FBXL4 are predicted to serve as protein-protein interaction scaffolds (Jin, 
Cardozo et al. 2004). To date, only one candidate FBXL4 substrate has been proposed, a histone lysine 
demethylase (Van Rechem, Black et al. 2011), but this finding is incongruent with the predominant 
mitochondrial localization of FBXL4. I hypothesized that loss of function of FBXL4 in mitochondrial 
disease may lead to the aberrant accumulation of protein substrates normally targeted for proteasomal 
degradation. An improved understanding of the FBXL4 protein interaction network, particularly in the 
context of the mitochondrial roles of FBXL4, will shed insight into the pathological implications of FBXL4 
inactivation in mitochondrial encephalopathy and may yield new treatments for patients.  
 
2.B.iii.a. Tandem Affinity Purification of the FBXL4 Complex 
Biochemical assays show that FBXL4 predominantly localizes to mitochondria (Figure 1.3). 
Moreover, bioinformatics approaches such as the MitoProtII algorithm (Claros and Vincens 1996) predict 
that amino acids 1-26 of FBXL4 constitute a cleaved mitochondrial localization sequence (MLS) (Figure 
2.17A) that results in export of FBXL4 to mitochondria with a 94.27% probability. Thus, given the critical 
role FBXL4 appears to play in the maintenance of mitochondrial homeostasis, I wanted to identify the 
spectrum of FBXL4-interacting proteins related to mitochondria function. To achieve this aim, I generated 
a form of FBXL4 that lacks the F-box domain but retains the mitochondrial localization sequence (MLS) 
and the putative protein-protein interaction domains of the leucine-rich repeats (FBXL4ΔFbox) (Figure 
2.17A). I hypothesized that this approach would transiently enrich cells for FBXL4-interacting proteins by 
preventing proteins bound to the FBXL4 leucine-rich repeats from being targeted for ubiquitin-mediated 
proteolysis. Immunofluorescence with an antibody directed against the C-terminal FLAG tag of 
FBXL4ΔFbox or wild-type FBXL4 shows that FBXL4ΔFbox localizes with mitochondria, similar to wild-
type FBXL4 (Figure 2.17B). Moreover, cell fractionation analyses reveal that the majority of FBXL4ΔFbox 
protein is targeted to mitochondria (Figure 2.17C). Therefore, FBXL4ΔFbox recapitulates the 
mitochondrial localization of wild-type of FBXL4. 
After ensuring that FBXL4ΔFbox localizes predominantly to mitochondria (Figure 2.17B-C), I 
performed tandem affinity purification with 109 HEK-293T cells transiently transfected with HA-FLAG-
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tagged FBXL4ΔFbox or with empty vector as a negative control. Briefly, cleared lysates were incubated 
with anti-FLAG beads, eluated with FLAG peptide, then incubated with anti-HA beads, and finally eluated 
with HA peptide. To assess the efficacy of the tandem affinity purification, I resolved aliquots of the HA 
eluates on a polyacrylamide gel by electrophoresis (Figure 2.17D). Notably, silver staining indicates 
recovery of a diverse set of proteins in the FBXL4ΔFbox condition that are absent from the negative 
control condition, including efficient recovery of the FBXL4ΔFbox protein bait by tandem affinity 
purification (Figure 2.17D). 
Mass spectrometry analysis was performed on HA eluates isolated from cells expressing 
FBXL4ΔFbox or empty vector as a negative control. Peptides corresponding to multiple mitochondrial 
proteins were identified in FBXL4 ΔFbox immunoprecipitates, including solute carriers like the 
mitochondrial ADP/ATP carrier SLC25A4, electron transport chain components such as the complex III 
member UQCRC2 and the ATP synthase subunit ATP5A1, and regulators of mitochondrial dynamics 
such as the apoptosis-inducing factor AIFM1 and the heat shock response protein DNAJA2  (Figure 





Figure 2.17. Tandem affinity purification of the FBXL4 complex. (A) FBXL4(ΔFbox) was 
generated by cloning the mitochondrial localization sequence (MLS) of FBXL4 (amino acids 
1-25) upstream of the leucine-rich repeats (L) (amino acids 336-621), removing the F-Box 
domain (FBOX). (B) Immunofluorescence of HEK-293T cells transfected with empty vector 
and dsRed2-Mito (top panels), FLAG-tagged FBXL4 and dsRed2-Mito (middle panels), or 
FLAG-tagged FBXL4(ΔFbox) and dsRed2-Mito (bottom panels). Mitochondria are visualized 
by dsRed2-Mito in the red channel, and FLAG is visualized in the green channel (anti-FLAG 
primary antibody (rabbit) and anti-rabbit AlexaFluor 488 secondary antibody). Scale bars 
represent 10.4 microns. (C) Western blot analysis of FBXL4 and FBXL4(ΔFbox) levels in 
cytosol or mitochondria fractions by detection with an anti-HA antibody. TUBULIN and COX 
IV are shown as loading controls for the cytosol and mitochondria, respectively. (D) Silver 
stain of HA eluates (20% of total volume) following tandem affinity purification of HA-FLAG-
tagged FBXL4(ΔFbox) (FBXL4) or empty vector (Control). Proteins corresponding to 
peptides recovered in the mass spectrometry analysis of FBXL4(ΔFBOX) are shown in blue 







2.B.iii.b. Validation of FBXL4-Interacting Proteins 
To investigate whether binding between FBXL4 and candidate interacting proteins is specific, I 
performed co-immunoprecipitation experiments using HA-FLAG-tagged FBXL4ΔFbox and MYC-tagged 
candidates. I prioritized candidates for validation by choosing proteins with high peptide representation in 
the mass spectrometry data and/or a critical mitochondrial function. Interestingly, I found that FBXL4 
interacts with a diverse set of mitochondrial factors (Figures 2.19A-F). ATP5A1 (Figure 2.19A) is an 
alpha subunit of the catalytic core of mitochondrial ATP synthase, and mutations in ATP5A1 lead to a 
fatal neonatal mitochondrial encephalopathy characterized by destabilization of ATP synthase 
(Jonckheere, Renkema et al. 2013). AGK (Figure 2.19B), which participates in lipid and glycerol lipid 
metabolism in the mitochondrial membrane, is mutated in Sengers syndrome, a mitochondrial disease 
characterized by congenital cataracts, hypertrophic cardiomyopathy, skeletal myopathy, and lactic 
Figure 2.18. Functional categories of FBXL4 complex members. Proteins indicated with 
an asterisk are mutated in human disease via the OMIM database. 
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acidosis, as well as in isolated congenital cataracts (Aldahmesh, Khan et al. 2012, Calvo, Compton et al. 
2012, Mayr, Haack et al. 2012). SLC25A4 (Figure 2.19C) forms a gated pore in the inner mitochondrial 
membrane that transports the adenine nucleotides ADP and ATP between the matrix and cytosol 
(Clemencon, Babot et al. 2013). Mutations that disrupt SLC25A4 activity have been described in 
autosomal dominant progressive external opthalmoplegia with mtDNA deletions and in familial 
cardiomyopathy and myopathy (Mayr, Zimmermann et al. 2011, Park, Kim et al. 2011, Clemencon, Babot 
et al. 2013, Strauss, DuBiner et al. 2013). DNAJA2 (Figure 2.19D), as well as the closely related protein 
DNAJA1, which was also identified in the FBXL4 protein complex (Appendix B), are co-chaperones for 
the Hsp70/Hsc70 family of heat shock proteins and are important in mitochondrial protein import (Terada 
and Mori 2000, Bhangoo, Tzankov et al. 2007). SLC25A11 (Figure 2.19E) transports 2-oxoglutarate 
across the inner mitochondrial membrane in an electroneutral exchange for malate and other dicarboxylic 
acids (Bisaccia, Indiveri et al. 1985, Monne, Miniero et al. 2013). SLC25A11 contributes to several key 
mitochondrial procesess, including the malate/asparate shuttle, the oxoglutarate-isocitrate (citrate) shuttle, 
the pyruvate/isocitrate cycling pathway, gluconeogenesis from lactate, and nitrogen metabolism (Monne, 
Miniero et al. 2013). SLC25A13 (Figure 2.19F) exchanges aspartate for glutamate and a proton across 
the inner mitochondrial membrane in a calcium-dependent manner (Palmieri, Pardo et al. 2001). 
SLC25A13 is mutated in adult-onset citrullinemia (citrullinemia type II) and in neonatal intrahepatic 
cholestasis (Kobayashi, Sinasac et al. 1999, Saheki and Kobayashi 2002). Collectively, these results 
underscore that FBXL4 interacts with a diverse set of crucial mitochondrial factors that must function 







Following on the results that FBXL4 interacts with multiple mitochondrial proteins (Figure 2.19), I 
tested if any FBXL4 complex members may be substrates specifically targeted for degradation by FBXL4. 
To achieve this aim, I first assessed for substrate accumulation in the setting of FBXL4 loss of function by 
using Fbxl4-null MEFs, where proteins typically targeted for degradation by Fbxl4 may accumulate in the 
absence of Fbxl4. Notably, I observed an overall decrease in mitochondrial-associated candidate 
substrate proteins in Fbxl4-null MEFs, including the ATP/ADP transporter SLC25A4, the apoptosis-
inducing factor AIFM1, and the electron transport chain complex members UQCRC2 and ATP5A1 
(Figure 2.20A). Interestingly, these results echo my previous findings of decreased stability of the 
electron transport chain in Fbxl4-null MEFs (Figure 2.16D) and may be indicative of a global loss of 
mitochondrial protein stability in Fbxl4-null MEFs.  
As an alternative approach to screen for substrate accumulation, I took advantage of the 
FBXL4ΔFbox mutant, a truncated form of FBXL4 that lacks the F-box domain and thus loses the ability to 
interact with the SCF complex and target bound substrates for ubiquitin-mediated proteolysis. 
Overexpression of the FBXL4ΔFbox mutant is predicted to sequester and stabilize candidate substrates, 
Figure 2.19. Validation of candidate FBXL4-interacting proteins. (A-E) MYC-tagged 
candidate interactors were immunopurified from HEK-293T cells using anti-MYC beads. 
Samples were analyzed by immunoblotting with anti-HA antibody to visualize HA-FLAG-
tagged FBXL4(ΔFbox) and anti-MYC antibody to visualize MYC-tagged ATP5A1 in A, AGK 
in B, SLC25A4 in C, DNAJA2 in D, SLC25A11 in E and SLC25A13 in F. 
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similar to an approach using a dominant-negative CUL1 that cannot bind to the rest of the SCF complex 
but still interacts with its requisite F-box protein and any corresponding substrates (Jin, Ang et al. 2005). 
Interestingly, relatively low amounts of FBXL4ΔFbox stabilized endogenous SLC25A4 (Figure 2.20B). 
However, decreased SLC25A4 protein levels were observed with increasing amounts of FBXL4ΔFbox 
(Figure 2.20B), which may represent global mitochondria destabilization due to FBXL4ΔFbox 
overexpression. Remarkably, none of the other candidate proteins tested, including AIFM1, UQCRC2, 
and ATP5A1, were stabilized by expressing increasing amounts of FBXL4ΔFbox (Figure 2.20B).  
Given that SLC25A4 and FBXL4 interact (Figure 2.19C), and SLC25A4 is stabilized by 
FBXL4ΔFbox (Figure 2.20B), I sought to better establish the role of FBXL4 in targeting SLC25A4 for 
proteasomal degradation. First, I identified an intermediate level of FBXL4ΔFbox expression that 
stabilizes tagged SLC25A4 without resulting in cell toxicity (Figure 2.20C). Next, I sought to determine if 
FBXL4 ubiquitinates SLC25A4. I postulated that ubiquitinated SLC25A4 would accumulate with 
expression of wild-type FBXL4 and proteasomal inhibition by MG132, while SLC25A4 ubiquitination 
would decrease with expression of the FBXL4ΔFbox mutant under the same experimental conditions. To 
formally test this hypothesis, I performed ubiquitin pull down assays using cells expressing HIS-tagged 
ubiquitin, MYC-tagged SLC25A4, and HA-tagged FBXL4 or FBXL4ΔFbox. However, I was unable to 
detect bands representing ubiquitinated SLC25A4 in basal conditions or upon expression of the different 
FBXL4 constructs (Figure 2.20D). Thus, it appears that FBXL4 does not play a role in ubiquitinating 









Figure 2.20. SLC25A4 stability but not ubiquitination is mediated by FBXL4. (A) 
Lysates from Fbxl4+/+, Fbxl4-/-, and Fbxl4+/- MEFs were probed with anti-SLC25A4, anti-
AIMF1, anti-ATP5A1, and anti-UQCRC2 antibodies. TUBULIN and GAPDH are shown as 
loading controls. (B) HEK-293T cells were transfected with the indicated amounts of HA-
FLAG-tagged FBXL4(∆Fbox) or with empty vector to a final amount of 6 micrograms of DNA 
per transfection. Immunoblotting was performed with anti-SLC25A4, anti-AIMF1, anti-
ATP5A1, and anti-UQCRC2 antibodies. FBXL4(∆Fbox) was visualized with anti-FLAG 
antibody. GAPDH is shown as a loading control. (C) HEK-293T cells were transfected with 
MYC-tagged SLC25A4 (3 ug) and empty pcDNA3 vector (3 ug) in lane 1, MYC-tagged 
SLC25A4 (3 ug) and HA-tagged FBXL4(∆Fbox) (3 ug) in lane 2, or HA-tagged 
FBXL4(∆Fbox) (3 ug) and empty pcDNA3 vector (3 ug) in lane 3. Anti-HA and anti-MYC 
antibodies were used to visualized FBXL4(∆Fbox) and SLC25A4, respectively. TUBULIN is 
shown as a loading control. (D) HEK-293T cells were transfected with HIS-tagged ubiquitin, 
HA-tagged FBXL4, HA-tagged FBXL4(ΔFbox), and MYC-tagged SLC25A4 as indicated. 
Following 4 hours of treatment with 10 uM MG132, cells were lysed and HIS-tagged 
ubiquitin was immunopurified with nickel resin. Anti-HA antibody was used to visualize the 
FBXL4 constructs and anti-MYC antibody was used to visualize SLC25A4 in the IPs (top) 
and inputs (bottom). 
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Notably, cycloheximide assays reveal that FBXL4 is an unstable protein, with a half life of less 
than two hours for both full length FBXL4 and the FBXL4(∆Fbox) mutant (Figure 2.21A). Moreover, 
ubiquitin pull-down assays using HIS-tagged ubiquitin reveal that FBXL4 is itself targeted for ubiquitin-
mediated degradation, with the FBXL4(∆Fbox) mutant exhibiting significantly more ubiquitination than 
wild-type FBXL4 (Figure 2.21B). Importantly, the instability of FBXL4 protein may have critical 








Deletion of Fbxl4 in vivo recapitulates central features of human mitochondrial encephalopathy 
Figure 2.21. FBXL4 protein is unstable. (A) HEK-293T cells were transfected with HA-
tagged FBXL4 or HA-tagged FBXL4(ΔFbox). Cells were treated with 20 ug/mL 
cycloheximide (CHX) for the indicated times, and total cell lysates were analyzed by 
immunoblotting with anti-HA antibody to visualize the FBXL4 constructs and anti-TUBULIN 
antibody for a loading control. (B) HEK-293T cells were transfected with HIS-tagged 
Ubiquitin, HA-tagged FBXL4, or HA-tagged FBXL4(ΔFbox) as indicated. Following four 
hours of treatment with 10 uM MG132, cells were lysed and HIS-tagged ubiquitin was 
immunopurified with nickel resin. Anti-HA antibody was used to visualize the FBXL4 
constructs in the IPs (top) and inputs (bottom). The brackets on the right mark a ladder of 




Using Fbxl4 knockout mice, I have shown that constitutive deletion of Fbxl4 recapitulates crucial 
features of the pediatric mitochondrial encephalopathy associated with FBXL4 mutations (Bonnen, 
Yarham et al. 2013, Gai, Ghezzi et al. 2013), including failure to thrive, early lethality, microcephaly, and 
impaired OXPHOS functioning and mitochondrial DNA maintenance. Moreover, my findings provide novel 
insights into the roles of FBXL4 in mitochondrial encephalopathy pathogenesis, including characterization 
of the metabolic alterations associated with Fbxl4 deletion at baseline and upon starvation.  
Building on my results, I could design several studies using the rare surviving Fbxl4-null mice to 
further characterize the disease phenotype and define the contribution of altered FBXL4 function to the 
mechanisms of disease. For example, I could perform a treadmill exercise stress test (Yatsuga and 
Suomalainen 2012), where I hypothesize that Fbxl4-null mice may exhibit exercise intolerance (Menezes, 
Riley et al. 2014) and fatigue earlier than age- and gender-matched Fbxl4 wild-type controls. At the same 
time, I could measure blood lactate levels before and after the treadmill exercise test to evaluate my 
hypothesis that Fbxl4-/- mice may have increased baseline lactate and higher levels of lactate following 
stress, compared to Fbxl4+/+ mice with intact OXPHOS capacity. Moreover, I could perform brain MRIs 
on perinatal and/or rare surviving Fbxl4-/- mice, with matched Fbxl4 wild-type mice as controls, to look for 
additional evidence of brain atrophy and microcephaly and to document any white and gray matter 
lesions similar to the neurological findings in human patients with FBXL4 mutations (Bonnen, Yarham et 
al. 2013, Gai, Ghezzi et al. 2013). Finally, it will be important to perform a comprehensive post-mortem 
analysis of the rare surviving adult Fbxl4-null mice, with the relevant Fbxl4 wild-type mice used as 
controls. I predict that adult Fbxl4-/- mice will exhibit altered OXPHOS function and mtDNA depletion, 
similar to or even more severe than the findings that I have previously documented in Fbxl4-/- MEFs, 
Fbxl4-/- perinatal liver cells, and in a single Fbxl4-/- mouse that succumbed to disease complications at 
one year of age. In this post-mortem analysis, on the cellular level, I could assess mitochondria-rich 
tissues such as liver, brain, brown adipose, and skeletal muscle for OXPHOS integrity by immunoblotting, 
mitochondria membrane potential using TMRE uptake, mitochondria DNA content using quantitative PCR, 
and ATP production and oxygen consumption using a Seahorse bioanalyzer. Moreover, I could perform 
histological analyses, including Hematoxylin and Eoisin staining to identify brain lesions, as well as SDH 
and COX staining to quantify OXPHOS function in skeletal muscle, brain, and liver tissue. 
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 Metabolomics analysis of Fbxl4-null perinatal tissues has provided important insights into the 
metabolic alterations associated with Fbxl4 loss of function in mitochondrial encephalopathy. Notably, 
metabolic profiling reveals multiple changes in protein and lipid handling in Fbxl4-/- liver, brain, and brown 
adipose. For example, elevated 3-hydroxybutyrate levels in Fbxl4-/- liver are suggestive of increased 
ketogenesis, which has been shown to function as a compensatory mechanism for decreased OXPHOS 
capacity in mitochondrial disease by providing a glucose-alternative energy source for skeletal muscle, 
brain, and heart (Celotto, Chiu et al. 2011). Moreover, the increased levels of urea and urea cycle 
intermediates, coupled with elevated amino acids, suggests a global picture of protein turnover with Fbxl4 
inactivation. In addition, the alterations in lipid handling in Fbxl4-/- tissues, including elevated lipid 
membrane remodeling intermediates and increased breakdown of carnitine, likely indicate increased 
lipolysis. Taken together, these results suggest mobilization of alternate energy sources in the form of 
amino acids and lipids in the context of misinterpreting the OXPHOS defect and decreased ATP 
synthesis as starvation (Nunnari and Suomalainen 2012). Interestingly, the elevated levels of essential 
and long chain fatty acids in Fbxl4-/- brains may represent increased lipolysis for energy production, or 
the accumulation of these lipids may represent aberrant deposition in the setting of impaired 
mitochondrial beta-oxidation (Bartlett and Eaton 2004). Notably, further study is required to determine if 
brain lipid accumulation is contributing to the neurological pathology characteristic of human patients with 
FBXL4 mutations. 
Following on these results, it would be interesting to extend the metabolic profiling data set to 
include the rare surviving Fbxl4-null mice, compared to age- and gender-matched controls, to explore 
potential metabolic compensations that occur in the context of surviving without functional Fbxl4. 
Moreover, to probe the dynamics of the metabolic alterations associated with Fbxl4 inactivation, I could 
collect tissues for metabolic profiling from various time points starting immediately after birth and 
extending until the Fbxl4-null mice are about to die (hours to days after birth). In this data set, in addition 
to Fbxl4-/- and Fbxl4+/+ tissues, I could also include Fbxl4+/- tissues, as Fbxl4+/- mice survive without 
one copy of Fbxl4 and thus may employ metabolic compensations that could potentially be exploited as 
novel treatments for patients with FBXL4 loss of function mutations. 
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Given the profound metabolic alterations observed in perinatal Fbxl4-null mice, I hypothesized 
that rare surviving Fbxl4-null mice may be more sensitive to stress, compared to Fbxl4 wild-type mice. In 
fact, several patients with FBXL4 mutations died in infancy due to metabolic decompensation in the 
context of a stressor such as illness (Gai, Ghezzi et al. 2013). To test this hypothesis, I subjected 
Fbxl4+/+ and Fbxl4-/- mice to a relatively short fast of eight hours duration. Importantly, 67% of the Fbxl4-
/- females exhibited urine ketones at baseline, and 100% of Fbxl4-/- females rapidly developed ketonuria 
for the duration of the fast. In contrast, Fbxl4+/+ or Fbxl4-/- males and Fbxl4+/+ female controls did not 
develop ketonuria. Typically, fasting ketosis develops in adults over a period of days, increasing 
progressively after postprandial nutrients and then tissue glycogen is gradually depleted (Fukao, 
Lopaschuk et al. 2004). However, in mitochondrial disease, ketogenesis is a common finding at baseline 
and/or with limited fasting and is believed to arise from the shuttling of fatty acid substrates into ketone 
body production to yield energy in the context of OXPHOS dysfunction (Gropman 2001, Parikh, Saneto et 
al. 2009). It is interesting that only Fbxl4-/- females developed ketonuria during the short fast. Initial 
reports have documented mitochondrial encephalopathy associated with FBXL4 mutations in ten male 
and two female patients (Bonnen, Yarham et al. 2013, Gai, Ghezzi et al. 2013). It is possible that females 
are less represented in this cohort because they are less affected by this disease, or fewer females may 
be documented because females have a more clinically severe course and die before presentation and 
genetic testing. Notably, gender-based differences in mitochondrial disease presentation have been 
previously documented in some models (Ahola-Erkkila, Carroll et al. 2010) but the underlying 
mechanisms require additional study. 
Following on these results, it is pertinent to study how Fbxl4-/- mice tolerate prolonged food 
deprivation by performing a longer fast. I predict that a longer fast may elicit ketonuria in Fbxl4-/- males 
and increase the severity of ketonuria in Fbxl4-/- females. Moreover, although blood glucose levels were 
not altered by a relatively short fast in Fblx4-/- and control mice, it is possible that a prolonged fast may 
result in hypoglycemia in Fbxl4-/- mice more quickly than in Fbxl4+/+ mice. In fact, hypoglycemia with 
both short (four hours) and long (fifteen to thirty hours) fasts has been previously documented in patients 
with defects in mitochondrial respiration, possibly through the reduction of cofactors resulting from 
impaired oxidative phosphorylation (Mochel, Slama et al. 2005). 
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Further analysis of the metabolic alterations associated with Fbxl4 inactivation is warranted. For 
example, increased glycolytic flux and/or elevated blood lactate are common findings in mitochondrial 
disease that suggest a switch from oxidative respiration to glycolysis in an attempt to compensate for the 
ATP deficit due to mitochondrial dysfunction (McInnes 2013). Although metabolomics did not detect 
altered levels of glycolysis pathway intermediates in Fbxl4-/- tissues, I could measure glycolytic flux in 
vivo by injecting Fbxl4+/+ and Fbxl4-/- perinatal mice with 13C-labeled glucose. Then, after a given period 
of time, I could isolate tissues and use multinuclear high-resolution magnetic resonance (NMR) 
spectroscopy or mass spectrometry techniques to assess metabolite abundance, the relative contribution 
of 13C to different metabolites, and the position(s) of 13C within each metabolite of interest. These data 
can then be used in established mathematical models to calculate metabolic flux (Zwingmann, Leibfritz et 
al. 2004, DeBerardinis and Thompson 2012). In these experiments, I hypothesize that Fbxl4-/- tissues 
may show increased flux through glycolysis compared to matched Fbxl4+/+ controls. In addition, elevated 
blood lactate was detected frequently in patients presenting with mitochondrial encephalopathy 
associated with FBXL4 mutations (Bonnen, Yarham et al. 2013, Gai, Ghezzi et al. 2013). Notably, lactate 
levels were within normal limits in Fbxl4-/- tissues perinatally and in the blood of rare surviving Fbxl4-/- 
mice (data not shown), but it is likely that a stressor such as a treadmill exercise test, a prolonged 
starvation, or an infection would elicit elevated lactate levels in Fbxl4-/- mice and is worth pursuing in 
future experiments. Finally, although much of the metabolomics data likely reflects changes on the 
organismal level, it would be interesting to formally test metabolic alterations on a cellular level when 
possible. To address this question, I could acutely delete Fbxl4 in the inducible MEFs with tamoxifen, or 
leave Fbxl4 intact with vehicle treatment, and then perform metabolic profiling to see if amino acid and 
lipid changes in Fbxl4-/- mice are recapitulated on the cellular level. Moreover, I could look for evidence of 
increased glycolytic flux in Fbxl4-/- versus Fbxl4+/+ MEFs by simultaneously detecting oxygen 
consumption rate, to quantify mitochondrial respiration, and extracellular acidification rate, an indicator of 
glycolysis, using a Seahorse analyzer (Wu, Neilson et al. 2007). 
Microarray analysis on Fbxl4-null livers and MEFs revealed distinct gene expression signatures 
associated with Fbxl4 loss of function in those tissues. Overall, the magnitude of the gene expression 
changes associated with Fbxl4 deletion were not that large, typically on the order of 1.3- to 1.6-fold, which 
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might be expected given that FBXL4 is predicted to predominantly function at the protein level. Moreover, 
I refrained from crossing the Fbxl4-/- liver and MEFs signatures to assess overlap and to generate a 
common signature because each signature was quite distinct, most likely because MEFs and liver are 
very different cell systems. Notably, C2 analysis of the Fbxl4-/- MEF gene expression signature revealed 
enrichment for genes associated with mitochondria function, a finding that fits with the important role of 
FBXL4 in mitochondria homeostasis. On the other hand, C2 analysis of the Fbxl4-/- liver gene expression 
signature revealed enrichment for a diverse set of genes with a common dependence on and/or role in 
mitochondrial function, including the hypoxia response, which can be stimulated by low oxygen conditions 
or by mitochondria-generated reactive oxygen species (ROS) (Nunnari and Suomalainen 2012), genes 
involved in muscle contraction, an ATP-dependent process (Batters, Veigel et al. 2014), and genes 
contributing to glucose and lipid metabolism, which are important metabolic pathway closely tied to 
mitochondria function (McInnes 2013). To expand on these results, I could perform in situ hybridization 
with a Fbxl4 probe on perinatal mouse embryos to see where Fbxl4 is most highly expressed and then 
isolate these tissues for gene expression analysis from Fbxl4+/+ and Fbxl4-/- perinatal embryos, to 
further characterize the gene expression changes characteristic of Fbxl4 deletion.  
To more closely assess the cellular roles of FBXL4, I generated MEFs with different dosages of 
the Fbxl4 gene. Given that Fbxl4 inactivation is perinatal lethal and results in profound metabolic 
alterations in perinatal mice, I had hypothesized that Fbxl4 deletion may impair MEF growth. However, 
using an inducible system to counteract the intrinsic growth properties of individual MEF cell lines, I found 
no difference in proliferation upon deletion of one or two copies of Fbxl4. It has previously been shown 
that mouse survival and MEF survival are not necessarily linked, as in the case of Mfn1 Mfn2 double-
knockout mice, where inactivation of these two crucial mitochondrial fusion genes results in perinatal 
lethality in mice but Mfn1 Mfn2 double-knockout MEFs survive in culture (Chen, Chomyn et al. 2005). To 
follow up on my results, I could assess MEF proliferation in the setting of a chronic stressor, such as 
serum starvation or exposure to low doses of reactive oxygen species. In these experiments, I postulate 
that Fbxl4-/- MEFs may be more sensitive to stress and thus exhibit less proliferation over time, 
compared to Fbxl4+/+ or Fbxl4+/- MEFs cultured under the same conditions.  
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Interestingly, Fbxl4-/- MEFs exhibited normal mitochondrial morphology, in contrast to the 
potentially more fragmented mitochondrial network observed in fibroblasts cultured from patients with 
FBXL4 mutations (Bonnen, Yarham et al. 2013, Gai, Ghezzi et al. 2013). Following on these results, 
electron microscopy might be a more sensitive approach to characterize the mitochondrial morphology in 
Fbxl4-/- MEFs. In addition, it may be more pertinent to explore mitochondrial morphology using confocal 
and electron microscopy of mitochondria-rich tissues including skeletal muscle, brain, and liver isolated 
from Fbxl4-/- mice, either perinatally or from rare surviving Fbxl4-/- mice. 
I also used MEFs to tease out the mitochondrial mechanisms of FBXL4 by performing several 
assays of mitochondrial function. Notably, Fbxl4-/- MEFs exhibit a 50% decrease in mitochondria 
membrane potential coupled with a global decrease in OXPHOS protein levels, while mitochondria 
amount did not change. Cells isolated from human patients with FBXL4 mutations also exhibit decreased 
mitochondria membrane potential and depressed OXPHOS function, including decreased OXPHOS 
complex protein levels (Bonnen, Yarham et al. 2013, Gai, Ghezzi et al. 2013). The consequences of 
these findings are discussed below. At the same time, additional approaches to assess mitochondrial 
function following Fbxl4 deletion in MEFs are warranted and include analysis of OXPHOS function using 
the Seahorse system, as well as assays to measure electron transport complex biochemical activity, 
succinate dehydrogenase (SDH) and cytochrome oxidase (COX) staining, calcium signaling, reactive 
oxygen species production, and redox state, to name a few (Koopman, Willems et al. 2012, Nunnari and 
Suomalainen 2012). Importantly, it is crucial to obtain primary material from perinatal Fbxl4-/- mice, as 
well as from rare surviving Fbxl4-/- mice, to assess mitochondrial function in the context of Fbxl4 deletion 
using these same assays but on isolated primary tissues. 
An important question raised by these analyses is how to apply insights from Fbxl4-/- mice to 
design rational treatments for patients with mitochondrial encephalopathy associated with FBXL4 
mutations. Initially, I had hypothesized that excessive mitophagy of damaged mitochondria may be 
pathogenic in the context of Fbxl4 deletion, similar to what has been shown previously in other diseases 
with impaired maintenance of mitochondria, including Parkinson’s disease and Huntington’s disease (Cui, 
Tang et al. 2010, Guo, Disatnik et al. 2013). Interestingly, inhibiting mitophagy drove a trend towards an 
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even lower membrane potential across all Fbxl4 MEF genotypes, suggesting that intact mitophagy is 
important for mitochondrial homeostasis. 
My research indicates that strategies to increase mitochondrial biogenesis are potentially fruitful 
therapies for patients with FBXL4 mutations. Notably, OXPHOS dysfunction was observed in Fbxl4-/- 
MEFs, Fbxl4-/- perinatal livers, and in patients with FBXL4 mutations, and it has been shown previously 
that chronic OXPHOS dysfunction blocks mitochondria biogenesis (Nunnari and Suomalainen 2012). I 
failed to observe evidence of a compensatory increase in mitochondria number in Fbxl4-/- MEFs or in 
perintal livers that might help combat mitochondrial dysfunction in this context. Moreover, data from 
patients with FBXL4 mutations and a rare surviving Fbxl4-null mouse revealed profound mtDNA depletion 
and greatly reduced COX staining, strongly suggesting a picture of mitochondria depletion. Although 
multiple pathways contribute to mitochondrial biogenesis, PPAR-y co-activator 1-alpha (PGC-1α) is a 
master regulator of this process and acts by interacting with or increasing the activity of transcription 
factors that then directly or indirectly induce genes related to mitochondrial proliferation, oxidative 
catabolism, and respiration (Viscomi, Bottani et al. 2011, Boland, Chourasia et al. 2013). Recently, 
several studies in various mouse models of mitochondrial disease have indicated that induction of the 
PGC1-α pathway can slow disease progression through increased mitochondrial biogenesis (Wenz, Diaz 
et al. 2008, Viscomi, Bottani et al. 2011, Yatsuga and Suomalainen 2012). For example, activation of the 
PPAR/PGC-1α pathway by expression of PGC1-α in skeletal muscle or treatment with the PPAR 
panagonist bezafibrate led to mitochondrial proliferation, improved residual respiratory capacity, and 
enhanced OXPHOS capacity per muscle mass in a mouse model of mitochondrial myopathy caused by 
cytochrome c oxidase deficiency (Wenz, Diaz et al. 2008). Moreover, a high-fat low-carbohydrate 
ketogenic diet, which has also been shown to induce mitochondrial biogenesis (Bough, Wetherington et al. 
2006), led to increased mitochondrial mass and OXPHOS activity and resulted in delayed disease 
progression in a mouse model of a late-onset mitochondrial myopathy (Ahola-Erkkila, Carroll et al. 2010). 
As a first pass experiment, I could test if bezafibrate or ketone body treatment restores mitochondria 
membrane potential and OXPHOS protein stability in Fbxl4-/- MEFs, compared to vehicle treatment. At 
the same time, I could look for evidence of increased mitochondrial biogenesis in treated cells by 
measuring mitochondria DNA copy number and respiratory chain transcript and protein amounts 
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(Yatsuga and Suomalainen 2012), and assess mitochondria amount and morphology with electron 
microscopy (Ahola-Erkkila, Carroll et al. 2010). I could also try to rescue the perinatal lethality of Fbxl4 
inactivation by injecting perinatal mice with bezafibrate or with ketone bodies to test if increased 
mitochondrial biogenesis in vivo can delay disease progression and/or death in Fbxl4-/- mice. 
Interesting, my findings in Fbxl4+/- cells and tissues suggest that Fbxl4 heterozygosity activates 
compensatory mechanisms that could potentially be harnessed for treating patients with FBXL4-
associated mitochondrial encephalopathy. For example, Fbxl4+/- MEFs exhibited higher levels of 
OXPHOS proteins compared to Fbxl4+/+ MEFs, while overall mitochondria numbers did not change. 
Moreover, in the setting of a statistically significant drop in mitochondria content, Fbxl4+/- perinatal livers 
exhibited preserved mitochondria membrane potential, which may be partially explained by the 50% 
increase in mitochondria DNA content. To explore in further detail the mechanisms of compensation in 
Fbxl4+/- mice, I could preform gene expression profiling on Fbxl4+/- MEFs and perinatal tissues, 
compared to Fbxl4+/+ and Fbxl4-/- controls, to look for activation of genes and pathways involved in 
mitochondrial biogenesis and other compensatory mechanisms to combat the mitochondrial dysfunction 
associated with Fbxl4 inactivation. I could then use these gene expression signatures to generate 
connectivity maps (Lamb, Crawford et al. 2006) that may shed insight into novel pharmacological 
treatments for the Fbxl4-/- condition that co-opts the same pathways employed in the Fbxl4+/- setting as 
compensatory mechanisms for the loss of one copy of Fbxl4. 
 
 
Isolation and characterization of the FBXL4 protein interaction network 
Isolation of the FBXL4 complex by tandem affinity purification reveals that FBXL4 interacts with 
many interesting proteins, including multiple mitochondrial proteins involved in crucial processes such as 
oxidative phosphorylation, solute transport, and maintenance of mitochondrial dynamics. Interestingly, 
many of the proteins that I confirmed interact with FBXL4 are also mutated in human diseases, including 
a fatal neonatal mitochondrial encephalopathy characterized by destabilization of ATP synthase 
(Jonckheere, Renkema et al. 2013), Sengers syndrome (Aldahmesh, Khan et al. 2012, Calvo, Compton 
et al. 2012, Mayr, Haack et al. 2012), autosomal dominant progressive external opthalmoplegia and 
familial cardiomyopathy and myopathy (Mayr, Zimmermann et al. 2011, Park, Kim et al. 2011, Clemencon, 
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Babot et al. 2013, Strauss, DuBiner et al. 2013), and adult-onset citrullinemia (citrullinemia type II) and 
neonatal intrahepatic cholestasis (Kobayashi, Sinasac et al. 1999, Saheki and Kobayashi 2002). Thus, 
given the essential cellular roles of these proteins, it is possible that their dysregulation in the context of 
FBXL4 inactivation may contribute to disease pathogenesis in mitochondrial encephalopathy associated 
with FBXL4 mutations. It would be interesting to assess for accumulation of candidate substrates in 
tissues from Fbxl4-/- mice and/or from patients with FBXL4 mutations, compared to tissues expressing 
wild-type FBXL4. Accumulated proteins in this context may provide clues as to which pathways are 
deregulated in patients with FBXL4 mutations and guide the development of novel treatments. Moreover, 
given that the point mutations in FBXL4 in mitochondrial encephalopathy cluster within the leucine-rich 
repeats, which are the putative protein-binding domains of FBXL4, I hypothesize that these mutations 
may alter the ability of FBXL4 to bind and target candidate substrates for proteasomal degradation. To 
assess this aim, I could stably express several different FBXL4 point mutants in HEK-293T cells, as well 
as wild-type FBXL4 as a negative control and FBXL4(ΔFbox) as a positive control, and then perform 
SILAC labeling (Ong 2012). Following quantitative mass spectrometry analysis, I could assess for 
accumulation of proteins in the context of the FBXL4 point mutations that may represent candidate 
substrates normally targeted by FBXL4 for proteasomal degradation. At the same time, the point 
mutations in the leucine rich repeats may confer FBXL4 with novel protein-protein interactions, and thus I 
could use cell lines stably expressing FBXL4 point mutants or wild-type FBXL4 as a control, perform 
SILAC labeling, and then isolate the FBXL4 complexes using tandem affinity purification and mass 
spectrometry analysis in order to obtain quantitative data regarding the binding profiles of the different 
FBXL4 mutants compared to wild-type FBXL4. 
The experimental approach that I used to isolate the FBXL4 protein complex, transient 
transfection followed by tandem affinity purification and mass spectrometry analysis, has been used 
previously to effectively isolate protein complexes for multiple other F-box proteins (Busino, Millman et al. 
2012, Kuchay, Duan et al. 2013). As an alternative approach to avoid over-expression, I generated stable 
cell lines expressing HA-FLAG-tagged FBXL4 or empty vector as a control and then performed a brief 
treatment with a low dose of MG132 (four hours, 10 uM) to transiently inhibit the proteasome and enrich 
cells for candidate FBXL4 substrates, but the MG132 treatment proved to be too toxic for the cells. I also 
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tried a SILAC approach using Fbxl4-/- and Fbxl4+/+ MEFs, where I hypothesized that Fbxl4 substrates 
may accumulate in Fbxl4-/- MEFs but not in Fbxl4+/+ MEFs, where Fbxl4 function is intact. In these 
experiments, I grew MEFs in media containing labeled lysine and arginine and then isolated mitochondria 
to focus on candidate substrates related to the mitochondrial roles of Fbxl4. However, the primary MEFs 
started to senesce and thus failed to achieve sufficient incorporation of the labeled amino acids into 
proteins. I could try this experiment using HEK-293T cells stably expressing a hairpin against FBXL4 or 
against GFP as a control and then repeat the SILAC approach, as these cells should achieve sufficient 
doubling for SILAC incorporation. I hypothesize that knockdown of FBXL4 may lead to accumulation of 
candidate proteins normally targeted for degradation by FBXL4, and these proteins could be explored 
further to connect the cellular mechanisms of FBXL4 to the pathophysiology of mitochondrial 
encephalopathy associated with FBXL4 mutations. 
 Additional experiments beyond co-immunoprecipitation analyses are warranted to further describe 
the interaction between FBXL4 and each candidate substrate. For example, to show evidence of an 
endogenous interaction, I could immunoprecipitate FBXL4 using an anti-FBXL4 antibody and immunoblot 
with antibodies against each substrate. If a candidate substrate interacts with FBXL4, I predict that I will 
recover the substrate when I immunoprecipitate FBXL4 but not when I immunoprecipitate using IgG 
control. I could also use a tagged FBXL4 construct lacking leucine-rich repeats, which I predict will no 
longer immunoprecipitate substrates because I will have disrupted FBXL4’s putative substrate binding 
domain. For evidence of a direct FBXL4-substrate interaction, I could perform in vitro binding assays with 
a GST-FBXL4 fusion protein expressed in E. coli and candidate substrates generated by in vitro 
transcription-translation. After mixing GST-FBXL4 with each substrate, if FBXL4 directly interacts with the 
substrate, I expect to recover the substrate following GST pulldown on immobilized glutathione beads and 
immunoblotting with a substrate-specific antibody. As a control, GST alone will be mixed with each 
substrate, and GST should not pull down the substrates if the substrates are specifically interacting with 
FBXL4. 
Notably, although I screened multiple candidate substrates for accumulation in the context of 
FBXL4 loss of function, only SLC25A4 consistently showed stabilization. However, my stabilization 
studies were confounded by what appeared to be global mitochondrial instability associated with Fbxl4 
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inactivation in Fbxl4-/- MEFs or with expressing increasing amounts of FBXL4(ΔFbox) in HEK-293T cells. 
Moreover, I was unable to observe FBXL4-mediated ubiquitination of SLC25A4. It is possible that FBXL4 
does not mediate ubiquitination of SLC25A4, which I will discuss in more detail below. On the other hand, 
my failure to observe any ubiquitination of SLC25A4, even at baseline, may have occurred because I 
could only express low levels of SLC25A4 for these analyses, as over expression of SLC25A4 induces 
apoptosis (Bauer, Schubert et al. 1999), and thus SLC25A4 ubiquitination may have been below the level 
of detection of this assay. As an alternative approach, I could treat cells with FBXL4 or control siRNA and 
then immunoprecipitate HIS-tagged ubiquitin and immunoblot for MYC-tagged SLC25A4 (or immunoblot 
for endogenous SLC25A4, if cells do not tolerate SLC25A4 overexpression). In these studies, I expect 
decreased ubiquitination of SLC25A4 in the presence of the FBXL4 siRNA versus control siRNA. Finally, I 
could apply in vitro ubiquitination approaches (Carrano, Eytan et al. 1999, Chiang, Chen et al. 2008) 
using recombinant SCF components (SKP1, CUL1, RBX1) to indicate that FBXL4 directly ubiquitinates 
SLC25A4 via an SCF-dependent process. 
 Since FBXL4 is predicted to recognize substrates at degrons with various post-translational 
modifications (Skaar, Pagan et al. 2013), if I find that FBXL4 mediates ubiquitination of SLC25A4, an 
important next step would be to determine the substrate recognition moieties employed by FBXL4. To 
address this, I could examine SLC25A4 for candidate degrons using protein databases and examples 
from other F-box protein-substrate interactions. Then, I could disrupt each putative degron using site-
directed mutagenesis. If I have managed to abrogate the FBXL4-substrate interaction via mutation of a 
crucial degron, I expect to observe stabilization of SLC25A4 through immunoblotting. Since I expect 
accumulation on the protein level, I can perform quantitative real-time PCR with primers specific for 
SLC25A4 to show that there are not significant changes on the SLC25A4 mRNA level. It will also be 
important to show that disruption of the critical degron(s) within SLC25A4 impedes FBXL4-substrate 
binding in an in vitro GST-pulldown assay. Finally, I can clone the putative degron into GFP and check 
that when I express FBXL4 in cells transfected with the GFP-degron construct, the half-life of GFP is now 
shortened, which can be measured by flow cytometry for GFP fluorescence over time, or by 
immunoblotting lysates obtained over time for GFP protein levels (Reis, Levasseur et al. 2006). 
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Strikingly, my results indicate that FBXL4 may not function as a canonical F-box protein at 
mitochondria, particularly given my inability to link candidate substrate accumulation with ubiquitination. 
Previously, a single protein substrate has been proposed for FBXL4, the histone lysine demethylase 
JMJD2A/KDM4A (Van Rechem, Black et al. 2011). Van Rechem et al. (2011) show that JMJD2A is 
ubiquitinated by a CUL1-dependent process, that JMJD2A protein accumulates upon inactivation of 
FBXL4, and that FBXL4 interacts with JMJD2A (Van Rechem, Black et al. 2011). However, the authors 
provide no direct evidence that FBXL4 associates with the SCF complex or that FBXL4 contributes to 
JMJD2A ubiquitination, and the experimental approaches used to indicate that FBXL4 and JMJD2A 
interact cannot exclude non-specific binding (Van Rechem, Black et al. 2011). Moreover, JMJD2A is 
located in the nucleus (Berry and Janknecht 2013), while I and others (Bonnen, Yarham et al. 2013, Gai, 
Ghezzi et al. 2013) have shown that FBXL4 predominantly localizes to mitochondria. Although roles for 
the SCF complex have been described at the outer mitochondrial membrane, including FBXW7-mediated 
degradation of the pro-survival factor MCL1 (Inuzuka, Shaik et al. 2011, Wertz, Kusam et al. 2011), and 
other ubiquitination machinery such as the ubiquitin ligases MARCH-V and MULAN and the 
deubiquitinating enzyme Usp16/USP30 is are embedded in the outer mitochondrial membrane (Livnat-
Levanon and Glickman 2011), there are currently no reports of SCF complex activity within mitochondria. 
Notably, the precise mitochondrial localization of FBXL4 is predicted to be within the intermembrane 
space (Gai, Ghezzi et al. 2013), although it is possible that the localization of FBXL4 within mitochondria 
is dynamic. Moreover, although the FBXL4 complex contained peptides corresponding to SKP1, I have 
not formally shown that FBXL4 associates with an SCF complex comprised of CUL1, RBX1, and SKP1. 
Thus, it is important to explore non-canonical roles for FBXL4 at mitochondria. For example, the yeast F-
box protein Mfb1 contributes to mitochondrial dynamics, as mitochondria in Mfb1 knockout cells are 
capable of fusion but form aberrant aggregates of interconnected tubules (Durr, Escobar-Henriques et al. 
2006, Kondo-Okamoto, Ohkuni et al. 2006). Notably, this mitochondrial role of Mfb1 appears to be SCF-
independent, as there are no known substrates for Mfb1 and no core components of the mitochondrial 
fusion or fission pathways are stabilized in the setting of Mfb1 inactivation (Durr, Escobar-Henriques et al. 
2006, Kondo-Okamoto, Ohkuni et al. 2006). Moreover, very recent work indicates that the mammalian F-
box protein FBXO7 contributes to mitochondrial maintenance, in part by functioning as a scaffold for the 
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mitophagy mediators PINK and PARKIN (Burchell, Nelson et al. 2013). Notably, FBXO7 is mutated in 
early-onset autosomal-recessive Parkinson’s Disease, and expression of Parkinson’s Disease-causing 
FBXO7 mutants interferes with mitophagy induction (Burchell, Nelson et al. 2013). While FBXO7 has 
previously been implicated in SCF-dependent degradation of the substrates HURP, cIAP1 and TRAF2 
(Nelson, Randle et al. 2013), the roles of FBXO7 in mitophagy do not appear to involve canonical F-box 
functioning (Burchell, Nelson et al. 2013). Therefore, it is becoming increasingly clear that F-box proteins 
are able to contribute to mitochondrial homeostasis outside of SCF-mediated ubiquitination, and further 
study of the potential SCF-dependent and SCF-independent roles of FBXL4 at mitochondria are 
warranted.  
Importantly, FBXL4 is an unstable protein that appears to be targeted for ubiquitin-mediated 
proteolysis. Interestingly, multiple yeast F-box proteins, including Grr1p, Cdc4p, and Met30p, are 
degraded in a ubiquitin- and proteasome-dependent manner via what the authors argue is an 
“autocatalytic” mechanism, where F-box proteins direct their own ubiquitination and subsequent 
degradation (Galan and Peter 1999). However, there is not much known about ubiquitin-mediated 
turnover of mammalian F-box proteins (Kipreos and Pagano 2000). Therefore, it would be interesting to 
determine the mechanisms of FBXL4 turnover in cells. While there are multiple protein complexes 
involved in ubiquitin-mediated proteolysis, as a first pass approach, I would transfect cells with tagged 
FBXL4 in combination with tagged truncated versions of each cullin that retain the ability to bind to 
substrate adaptor molecules but are unable to create a function CRL complex and thus function as 
dominant negatives (Jin, Ang et al. 2005). I hypothesize that FBXL4 protein will accumulate when co-
expressed with the dominant negative version of the cullin(s) that are normally responsible for FBXL4 
degradation. Next, I could apply many of the same techniques that I have previously described, including 
studies to assess if FBXL4 directly interacts with the particular cullin, if this cullin mediates ubiquitination 
of FBXL4, and which substrate adaptor molecules mediate the interaction of FBXL4 with this CRL 
complex. Notably, given that the cellular levels of FBXL4 appear to be tightly controlled, an improved 
understanding of the mediators of FBXL4 stability will likely have key consequences for understanding the 
roles and mechanisms of FBXL4. 
 
! 82 
Chapter 3. The Role of FBXL4 in T-cell Acute Lymphoblastic Leukemia 
3.A. Introduction 
T-cell Acute Lymphoblastic Leukemia (T-ALL) is an aggressive malignancy of immature 
lymphoblasts expressing immunophentoypic T-cell markers (Ferrando 2009). Following the development 
of intensified chemotherapy protocols in T-ALL, 5-year relapse-free survival rates have approached 75% 
for pediatric T-ALL and 50% for adult T-ALL (Pui, Relling et al. 2004). However, 25% of children and 50% 
of adults do relapse and ultimately succumb to their disease, thus T-ALL remains an important clinical 
problem (Pui, Robison et al. 2008). 
Dissection of the underlying molecular events in T-ALL using chromosomal and molecular genetic 
analyses has led to the identification of primary genetic alterations in virtually all cases. However, a 
thorough understanding of these genetic aberrations and their impact on clinical course is lacking. 
Moreover, there is a critical need to apply the catalogue of genetic alterations in T-ALL to the 
development of novel targeted therapies with decreased toxicity for patients (Pui, Mullighan et al. 2012). 
 
3.B. Results 
3.B.i. FBXL4 is a Novel Candidate Tumor Suppressor in T-ALL 
Deletions of the long arm of chromosome 6 (6q-) occur frequently in T-ALL and are associated 
with an intermediate or poor prognosis (Sinclair, Sorour et al. 2004, Taborelli, Tibiletti et al. 2006, 
Strefford, Worley et al. 2007). These deletions are typically large and heterogeneous, yet the 
consequences of inactivating the commonly deleted genes remain relatively unknown (Burkhardt, 
Moericke et al. 2008). We discovered that the FBXL4 gene is recurrently and focally deleted in pediatric 
T-ALL as part of 6q- (Figure 1.8). Moreover, very recently, microsatellite analysis in T-cell Lymphoblastic 
Lymphoma (T-LBL) described a commonly deleted region of chromosome 6 encompassing FBXL4 and 
just one other gene, a neural transcription factor named POU3F2 predominantly expressed in neurons 
(Figure 1.9) (Bonn, Rohde et al. 2013). T-ALL and T-LBL are typically considered to be different clinical 
manifestations of the same disease, with the designation between leukemia and lymphoma based on the 
bone marrow blast count being more than 25% or less than 25%, respectively (Vardiman, Thiele et al. 
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2009). Thus, further study of FBXL4 as a novel candidate tumor suppressor in T-cell lineage leukemia is 
warranted.  
Analysis of our aCGH data reveals that chromosome 6 deletions encompassing the FBXL4 locus 
are always heterozygous (Table 3.1). To characterize the spectrum of genetic alterations in 6q- pediatric 
T-ALLs in more detail, I assessed for mutations in NOTCH1, the most frequent oncogenic alteration in T-
ALL (Weng, Ferrando et al. 2004). In this patient series, about half of the patients exhibited an activating 
mutation in NOTCH1 (Table 3.1). In more detail, Sample 3 has a point mutation in the NOTCH1 
heterodimerization (HD) domain that replaces leucine with proline at amino acid position 1593, as well as 
an insertion (ins) in the PEST domain at nucleotide position 7539 (Table 3.1). On the other hand, Sample 
4 has a translocation affecting the NOTCH1 locus on chromosome 9 (Table 3.1), resulting in NOTCH1 
truncation with translocation most likely into the TCRα-TCRδ locus in chromosome 14 (Tosello and 
Ferrando 2013). Another prominent genetic alteration in T-ALL is deletion of the CDKN2A/2B locus in 
chromosome band 9p21, containing the p16/INKF4A and p14/ARF tumor suppressor genes, which 
occurs in more than 70% of T-ALLs (Hebert, Cayuela et al. 1994, Ferrando, Neuberg et al. 2002). In this 
6q- series, three out of five patient samples (Samples 2, 3 and 5) have homozygous deletions 





Our array CGH analysis reveals that deletions encompassing the FBXL4 locus in T-ALL are 
exclusively heterozygous, affecting only one allele of FBXL4  (Table 3.1). Interestingly, we sequenced 
100 T-ALL patient samples (6q- and 6q wildtype) but did not discover any mutations in coding exons or 
splice sites. Moreover, I failed to detect epigenetic silencing of the non-deleted FBXL4 allele in 6q- T-ALL 
patient samples compared to 6q wildtype T-ALL patient samples using quantitative real-time PCR. Thus, I 
Table 3.1. Genetic lesions associated with 6q- in pediatric T-ALL. For each pediatric T-
ALL sample, the deletion encompassing FBXL4 on chromosome 6 is described in more 
detail. Mutations in NOTCH1 and/or deletions at the CDKN2A/2B locus on chromosome 9 
are also indicated. The NOTCH1 mutation status of Sample 5 was unknown. 
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hypothesized that FBXL4 functions as a heterozygous tumor suppressor, where deletion of one copy is 
sufficient to contribute to disease pathogenesis, similar to what has been observed in myelodysplastic 
syndrome for genes deleted as part of 5q- (Look 2005, Ebert 2009). 
To explore the potential role of FBXL4 in the hematopoietic system, I looked at Fbxl4 expression 
using quantitative real-time PCR on cDNA from mouse thymocytes at different stages of T-cell 
development. This analysis showed that Fbxl4 is differentially expressed during T-cell development, with 
low levels of expression in intermediate single positive (ISP) cells and transcriptional regulation as cells 
mature into double positive and single positive populations (Figure 3.1). Fbxl4 was most highly 
expressed in mature single positive CD4+ and CD8+ T-cells (Figure 3.1). 
 
 
Given that FBXL4 is recurrently deleted in T-ALL as part of 6q-, and FBXL4 is differentially 
expressed during the highly coordinated process of T-cell development, I hypothesized that FBXL4 may 
be a novel tumor suppressor in T-ALL. Moreover, I postulated that FBXL4 inactivation may lead to the 
oncogenic accumulation of protein substrates normally targeted for proteasomal degradation by FBXL4. 
Thus, I set out to study the role of FBXL4 in hematopoesis and in leukemogenesis, using the approaches 
outlined in the following sections.  
Figure 3.1. Fbxl4 is differentially expressed during T-cell development. Fbxl4 
expression is shown relative to Gapdh expression and normalized to double positive (DP) 
cells. DN1 (Double Negative 1), DN2 (Double Negative 2), DN3 (Double Negative 3), DN4 
(Double Negative 4), ISP (Isolated Single Positive), DP, CD4+ single positive and CD8+  




3.B.ii. The Role of Fbxl4 in Hematopoesis 
To characterize the roles and mechanisms of FBXL4 in hematopoesis, I used conditional Fbxl4 
knockout mice (Figure 2.1, 2.2) and tissue-specific Cre recombinase technology. To analyze the 
consequences of Fbxl4 inactivation during T-cell development, I used a Cre recombinase driven by the 
mouse Lck promoter. To study the consequences of Fbxl4 inactivation in hematopoietic stem cells 
(HSCs), which give rise to all blood cell lineages, I used a Cre recombinase driven by the mouse Vav 
promoter.  
 
3.B.ii.a. Function of Fbxl4 in T-Cell Development 
To study the role of Fbxl4 in T-cell development, I used a Cre allele driven by the mouse Lck 
promoter, which is active at the DN2 stage of T-cell development and thus excises Fbxl4 in uncommitted 
T-cell progenitors. I generated mice with two copies of the floxed Fbxl4 allele and one Lck-cre allele 
(Fbxl4fl/fl Lck-Cre/+), resulting in Fbxl4-/- thymocytes. As a control, I generated wild-type mice with one 
Lck-Cre allele to control for any effects Lck-Cre in the setting of Fbxl4+/+ thymocytes. At four to five 
weeks of age, I isolated thymuses from four mice per group and found no difference in thymus size, 
thymus weight, or thymus cellularity when Fbxl4 is inactivated during early T-cell development, compared 
to control mice (Figure 3.2A-C). Using quantitative real time PCR on cDNA prepared from thymocytes, I 





T-cell development is a coordinated process, as early T-cell precursors migrate through distinct 
thymic microenvironments as they differentiate from double negative (DN), to double positive (DP), to 
single positive (SP) stages (Figure 1.7) (Rothenberg, Moore et al. 2008). Flow cytometry analysis on 
viable thymocytes isolated from Fbxl4+/+ and Fbxl4-/- thymuses revealed no differences in T-cell 
development between the two groups (Figure 3.3). In more detail, I first examined the relatively more 
Figure 3.2. Lck Cre-mediated deletion of Fbxl4 does not affect thymus size or thymus 
cellularity. (A) Thymuses isolated from Fbxl4WT/WT Lck-Cre/+ (Fbxl4+/+, #5-8) and Fbxl4fl/fl 
Lck-Cre/+ (Fbxl4-/-, #1-4) mice. Scale bar represents 5 mm. (B) Weight of Fbxl4+/+ and 
Fbxl4-/- thymuses. P = n.s. (C) Hematoxylin & Eosin staining of representative Fbxl4+/+ and 
Fbxl4-/- thymuses at 40X magnification. (D) Fbxl4 expression in available samples is show 
by quantitative RT-PCR, relative to Gapdh and normalized to Fbxl4+/+ 7. Bars represent 
mean + SD. 
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mature T-cell populations using fluorescence-conjugated anti-CD4 and anti-CD8 antibodies. There were 
no significant differences in the proportions of double positive (CD4+ CD8+), double negative (CD4- CD8-
), or mature single positive (CD4+ CD8- or CD8+ CD4-) cells in the setting of Fbxl4 inactivation, 
compared to intact Fbxl4 (Figure 3.3). To analyze early T-cell progenitors, I stratified double negative 
cells (CD4- CD8-) using fluorescence-conjugated anti-CD44 and anti-CD25 antibodies. This analysis 
showed no difference in the proportion of double negative 1 (DN1, CD44+ CD25-), double negative 2 
(DN2, CD44+ CD25+), double negative 3 (DN3, CD44- CD25+) and double negative 4 (DN4, CD44- 
CD25-) populations with complete Fbxl4 loss, compared to Fbxl4 wildtype controls (Figure 3.3). Thus, 
although Fbxl4 is differentially expressed during T-cell development (Figure 3.1), inactivation of Fbxl4 




3.B.ii.b. Contribution of Fbxl4 to Hematopoesis 
After finding that Fbxl4 is dispensable in T-cell development, I next explored the role of Fbxl4 in 
hematopoesis. To excise Fbxl4 in hematopoietic stem cells (HSCs), which give rise to all blood cell 
lineages, I generated mice with two copies of the floxed Fbxl4 allele and one copy of the Vav-Cre allele 
(Fbxl4fl/fl Vav-Cre/+). Cre recombinase driven by the mouse Vav promoter is active in HSCs, generating 
Figure 3.3. Deletion of Fbxl4 does not perturb T-cell development (A) FACS analysis of 
T-cell populations in Fbxl4WT/WT Lck-Cre/+ (Fbxl4+/+, #5-8) and Fbxl4fl/fl Lck-Cre/+ (Fbxl4-/-, 
#1-4) mice. Populations labeled “CD4/CD8” were identified using anti-CD4 and anti-CD8 
fluorescence-conjugated antibodies. Double negative (“DN”, CD8- CD4-) cells were further 
stratified using anti-CD25 and anti-CD44 fluorescence-conjugated antibodies. 
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Fbxl4-/- cells across all hematopoietic lineages. As a control, I generated wild-type mice heterozygous for 
the Vav-Cre allele (Fbxl4WT/WT Vav-Cre/+) to control for the presence of the Vav-Cre allele while 
maintaining Fbxl4+/+ cells across hematopoietic lineages. At twelve weeks of age, I isolated the spleen, 
bone marrow, thymus, and peripheral blood from Fbxl4fl/fl Vav-Cre/+ (n=6) and Fbxl4WT/WT Vav-Cre/+ (n=6) 
mice. Notably, no significant differences existed in spleen size or bone marrow cellularity between groups 
(Figure 3.4A-B). Vav-Cre-mediated excision of Fbxl4 was complete in hematopoietic tissues (Figure 
3.4C). I then performed flow cytometry analysis with fluorescence-conjugated antibodies to analyze 
hematopoietic stem cells, myeloid progenitors, and the development of myeloid cells, erythroid cells, B-





Figure 3.4. Deletion of Fbxl4 in HSCs does not affect spleen size or bone marrow 
cellularity. (A) Spleen size in Fbxl4+/+ (Fbxl4WT/WT Vav-Cre/+, #7-12) and Fbxl4-/- (Fbxl4fl/fl 
Vav-Cre/+, #1-6) mice. Scale bar represents 5 mm. (B) Bone marrow cellularity in cells per 
femur (times 107) in Fbxl4+/+ and Fbxl4-/- mice. P = n.s. (C) PCR using primers to amplify 
the wildtype (1100 bp) and excised (400 bp) Fbxl4 alleles on DNA isolated from bone 







To analyze the hematopoietic stem cell compartment, I first excluded lineage-committed cells by 
gating out cells expressing Gr1 or CD11b (myeloid cells), Ter119 (erythroid cells), B220 (B-cells), or CD4 
or CD8 (T-cells). From this lineage negative population, I selected for the Sca1+ cKit+ LSK population, 
which represent total HSCs (Figure 3.6). Notably, there was no significant difference in LSK population 
size in Fbxl4-/- bone marrow, compared to Fbxl4+/+ bone marrow (Figure 3.6). I further stratified the LSK 
population by CD150 and CD48 expression to quantify long-term HSCs (LT-HSCs, CD150+ CD48-), 
short-term HSCs (ST-HSCs, CD150+ CD48+), and multipotent progenitor cells (MPP, CD150- CD48+/-) 
(Figure 3.6). Once again, there was no significant difference in the size of the LT-HSC, ST-HSC, or MPP 
compartments in Fbxl4-/- bone marrow compared to Fbxl4+/+ bone marrow (Figure 3.6). Thus, Fbxl4 is 
dispensable for homeostasis in the HSC compartment in vivo. 
Figure 3.5. Analysis of hematopoesis by flow cytometry. Summary of hematopoietic 
compartments studied and tissues analyzed by flow cytometry with fluorescence-conjugated 







 To characterize myeloid progenitor cells, I first excluded lineage-committed cells expressing Gr1, 
CD11b, B220, CD4, and/or CD8. Within the lineage negative population, the cKit+ Sca1- cells represent 
the total common myeloid progenitor (CMP) population, which was not significantly different in size in 
Fbxl4-/- bone marrow compared to Fbxl4+/+ bone marrow (Figure 3.7A). The common myeloid 
progenitor population in A was further stratified by CD150 and CD41 expression to analzye the CD150+ 
CD41+ megakaryocyte progenitor population (MkP), which did not differ significantly in size in Fbxl4-/- 
Figure 3.6. Fbxl4 inactivation does not perturb the composition of the HSC 
compartment. Representative FACS plots of HSC staining in bone marrow isolated from 
Fbxl4+/+ (#7, 8, 9) and Fbxl4-/- (#1, 2, 4) mice. Within the “Gated Lineage-” FACS plots,  
the cKit+ Sca1+ LSK population is indicated by a box. This LSK population is further 
stratified by CD150 and CD48 staining in the “gated LSK” FACS plots.  
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bone marrow versus Fbxl4+/+ bone marrow (Figure 3.7B). Next, I gated on the CD41- population from B 
to visualize granulocyte/monocyte progenitors (GMP), shown as the FCγRII/III+ CD150- population 
(Figure 3.7C). The size of the GMP population was not significantly different in Fbxl4-/- bone marrow 
compared to Fbxl4+/+ bone marrow (Figure 3.7C). Finally, I gated on the FCγRII/III- cells in C and 
stratified the cells by CD105 and CD150 expression to visualize the pre-GM population (CD105- CD150-), 
which are primitive granulocyte/monocyte progenitors, as well as the pre-Meg-E population (CD105- 
CD150+), which give rise to megakaryocytes or erythrocytes, and finally the erythrocyte precursor 
populations called pre-CFU-E (CD105+ CD150+) and CFU-E (CD105+ CD150-) (Figure 3.7D) (Pronk 
and Bryder 2011). The pre-GM, pre-Meg-E, pre-CFU-E, and CFU-E populations did not differ in size in 
Fbxl4-/- bone marrow compared to Fbxl4+/+ bone marrow (Figure 3.7D). Therefore, Fbxl4 is dispensable 






 To study myeloid and erythroid cell development in the setting of Fbxl4 inactivation, I 
characterized the composition of these populations in the bone marrow, spleen, and peripheral blood in 
Fbxl4-/- mice and Fbxl4+/+ mice. Overall, there were no significant differences in any of the populations 
across the matrices analyzed, thus Fbxl4 is dispensable for the development of erythroid and myeloid 
cells in vivo. Notably, through this analysis, I detected a unique myeloid population specific to Fbxl4-/- 
bone marrow (Figure 3.8). In more detail, developing myeloid cells in the bone marrow, which include 
developing granulocytes and monocytes, express CD11b and may or may not express Gr1. Notably, the 
CD11b+ Gr1+ and CD11b+ Gr1- populations did not differ in size in Fbxl4-/- or Fbxl4+/+ bone marrow. 
However, in Fbxl4-/- bone marrow, a population of cells characterized by Gr1 expression and low CD11b 
expression comprised approximately 6% of the total cells and was not detectable in wild-type bone 
marrow (Figure 3.8A-B). Interestingly, the CD11b-low Gr1+ population was not detected in the periphery 
in Fbxl4-/- mice via analysis of spleen and blood cells and thus appears to be a bone marrow-specific 
phenomenon.  
Figure 3.7. Fbxl4 is dispensable in the development of early myeloid progenitor cells. 
Representative FACS plots of myeloid progenitor staining in bone marrow isolated from 
Fbxl4+/+ (#7, 8, 9) and Fbxl4-/- (#1, 2, 3) mice. (A) Gated Lineage- cells are stratified by 
cKit and Sca1 expression to quantify the cKit+ Sca1+ common myeloid progenitor 
population (CMP), indicated by a box. (B) Gated cKit+ cells from A are analyzed for CD150 
and CD41 expression to detect the CD150+ CD41+ megakaryocyte progenitor (MkP) 
population, indicated by the rightmost box. (C) Gated CD41- cells from B are separated by 
FCγII/III and CD150 expression to visualize the FCγII/III+ CD150- granulocyte and 
monocyte progenitor population (GMP), indicated by the top box. (D) Gated FCγII/III- cells 
from C are stratified by CD105 and CD150 expression to visualize the pre-GM (CD105- 
CD150-), pre-Meg-E (CD105- CD150+), pre-CFU-E (CD105+ CD150+), and CFU-E 






 Conditional inactivation of Fbxl4 with Vav-Cre was also used to study the role of Fbxl4 in 
lymphopoesis. In general, B-cell development in the bone marrow, spleen, and peripheral blood was not 
significantly different in Fbxl4-/- mice compared to Fbxl4+/+ mice. Moreover, inactivation of Fbxl4 in HSCs 
by Vav-Cre failed to perturb T-cell development. T-cell populations visualized by CD4 and CD8 
expression in the thymus and in the periphery in Fbxl4-/- mice did not differ significantly from those 
Figure 3.8. Inactivation of Fbxl4 leads to a unique myeloid cell population in Fbxl4-/- 
bone marrow. (A) Representative FACS plots of myeloid population staining in bone marrow 
isolated from Fbxl4+/+ (#7, 8, 10) and Fbxl4-/- (#1, 2, 4) mice. The CD11b-low Gr1+ 
population is indicated by a box. (B) Quantification of the CD11b-low Gr1+ population in 
Fbxl4+/+ (n=6) and Fbxl4-/- (n=6) bone marrow samples. Bars represent mean + SD. 
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populations in mice wild-type for Fbxl4 (Figure 3.9). These results fit with the finding that Fbxl4 is 





3.B.iii. The Role of Fbxl4 in Leukemogenesis 
Given that FBXL4 is recurrently deleted in T-ALL (Figure 1.8) and in the closely related T-LBL 
(Figure 1.9), I hypothesized that FBXL4 may be a novel tumor suppressor in T-cell leukemia. To address 
Figure 3.9. T-cell development is not perturbed when Fbxl4 is inactivated in HSCs. 
Representative FACS plots of T-cell populations by CD4 and CD8 expression in thymuses 
(A) and spleens (B) isolated from Fbxl4+/+ (#7, 8, 9) and Fbxl4-/- (#1, 2, 3) mice. 
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this hypothesis, I designed experiments to assess the leukemogenic potential of FBXL4 in de novo tumor 
generation (3.B.iii.a). I also used bone marrow transplant models to investigate a role for FBXL4 as a 
tumor suppressor in NOTCH1-induced T-ALL (3.B.iii.b, 3.B.iii.c). Finally, I studied the consequences of 
acutely deleting FBXL4 in established T-ALLs (3.B.iii.d). 
 
3.B.iii.a. Analysis of Leukemia Predisposition in the Setting of Fbxl4 Inactivation 
To characterize the role of Fbxl4 inactivation in leukemogenesis, I assessed leukemia 
development in the context of Vav-Cre, to delete Fbxl4 in all hematopoietic compartments, and Lck-Cre, 
to inactivate Fbxl4 in early T-cell progenitors. I generated cohorts of transgenic and wild-type littermate 
controls from Fbxl4fl/WT and Fbxl4fl/fl lines (Table 3.2). The Fbxl4fl/WT mice recapitulate the heterozygous 
inactivation of FBXL4 frequently observed in 6q-deleted leukemia, while Fbxl4fl/fl mice model the effects of 
homozygous Fbxl4 loss. The primary endpoints of these analyses were disease-free survival (time to 
develop leukemia and/or tumor masses) and overall survival. The secondary endpoints were the cellular 






During twelve months of follow up, no mice developed leukemia in any of the groups (Figure 
3.10). As the first mice across the cohorts approached one year of age, I analyzed peripheral blood for 
evidence of leukemia (Table 3.3). However, the parameters of the complete blood count were within 
normal limits, with the exception of a nonspecific mildly elevated white blood cell count across 
experimental and control groups, likely due to an ongoing infection in the mouse facility (Table 3.3). 
Moreover, mice processed at twelve months of age failed to show internal signs of leukemia including 
splenic or thymic enlargement (Figure 3.11A-B). Excision of Fbxl4 by Lck-Cre or Vav-Cre was complete, 
as indicated previously (Figures 3.2D and 3.4C, respectively). 
Table 3.2. Summary of mice included in long term leukemogenesis cohorts. Mice were 




Figure 3.10. Leukemia does not develop following inactivation of Fbxl4 in 
hematopoietic progenitors. Mice in the Lck-Cre (left panels) and Vav-Cre (right panels) 
cohorts were followed for one year from birth for leukemia development. A mouse in the 




Table 3.3. Fbxl4 deficiency does not lead to leukemia. Mean and standard deviation for 
counts of White Blood Cells (WBC), Hematocrit (HCT), and Platelets (PLT) from peripheral 
blood analysis (automated) at approximately one year of age. Normal ranges: WBC 1.8-






Figure 3.11. Fbxl4 inactivation in HSCs or in T-cell progenitors does not result in 
leukemia. Weights of spleens and thymuses isolated from the Lck-Cre (A) or the Vav-Cre 
(B) cohorts after approximately one year of follow up. No differences in weight achieved 
statistical significance. Data are shown for all mice from which primary material was 
available. 
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3.B.iii.b. Kinetics of Primary T-ALLs with and without Fbxl4 
As NOTCH1 pathway activation is the most prominent oncogenic mechanism in T-ALL (Aster, 
Blacklow et al. 2011, Van Vlierberghe and Ferrando 2012), I explored a possible cooperation between 
loss of FBXL4 and NOTCH1 activation in T-ALL latency. To formally address the interaction between 
oncogenic NOTCH1 and Fbxl4 loss in T-cell transformation, I analyzed the effects of genetic inactivation 
of Fbxl4 in a retroviral-transduction bone marrow transplantation model of NOTCH1-induced T-ALL (Pear, 
Aster et al. 1996). I hypothesized that deletion of one copy of FBXL4, which models heterozygous 6q 
deletions encompassing the FBXL4 locus, may accelerate NOTCH1-induced leukemia development. In 
this experiment, I infected Lineage negative (Lin-) hematopoietic progenitor cells from mice heterozygous 
for the Fbxl4-null allele and wild-type littermate controls with bicistronic GFP retroviruses driving 
expression of ΔE-NOTCH1, a truncated and constitutively active form of a human NOTCH1 oncogene 
(Palomero, Barnes et al. 2006), and transplanted them into irradiated isogenic recipients. Forced 
expression of activated NOTCH1 in this model typically results in a wave of extrathymic T-cell 
lymphopoiesis three weeks after transplantation with the transient release of immature CD4+ CD8+ 
double positive cells into peripheral blood, which is followed by full leukemia transformation five to ten 
weeks later (Pear, Aster et al. 1996). 
Recipient mice were followed over time for signs and symptoms of leukemia, particularly by the 
number of GFP-positive and CD4+ CD8+ double-positive cells in peripheral blood, and the resulting 
tumors were analyzed for molecular phenotype with flow cytometry using fluorescence-conjugated 
antibodies to T-cell markers. Notably, there was no significant difference in overt leukemia development 
and leukemia-associated mortality for mice that developed T-ALLs lacking one copy of Fbxl4 compared to 
mice that developed T-ALLs wildtype for Fbxl4 (Figure 3.12A). T-ALLs that developed in Fbxl4+/- bone 
marrow retained expression of the wild-type Fbxl4 allele (Figure 3.12B). On the molecular level, Fbxl4+/+ 
and Fbxl4+/- tumors did not differ in immunophenotype and were typically CD4+ CD8+ double positive or 
CD4+ CD8+ double positive with a distinct CD8+ population (Figure 3.12C). These findings are 
compatible with the characteristically immature T-cell phenotype observed with NOTCH1-induced tumors 









Figure 3.12. Inactivation of one copy of Fbxl4 does not alter survival in NOTCH1-
induced T-ALL. (A) Kaplan-Meier survival curve in mice transplanted with Fbxl4+/- or 
Fbxl4+/+ bone marrow transduced with ΔE-NOTCH1. (B) PCR using primers to amplify the 
wildtype (1100 bp) and excised (400 bp) Fbxl4 alleles on DNA isolated from Fbxl4+/+ (#1-3) 
and Fbxl4+/- (#4-6) T-ALLs. (C) FACS plots showing representative tumor 
immunophenotypes by CD4 and CD8 expression. 
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3.B.iii.c. Kinetics of T-ALLs Secondarily Deleted for Fbxl4 
To explore the effects of secondarily deleting one or two copies of Fbxl4 in established T-ALLs, I 
took advantage of a tamoxifen-inducible Cre recombinase knocked into the ubiquitous Rosa26 promoter 
(Tm-Cre). In this system, tamoxifen administration deletes the floxed Fbxl4 allele, while vehicle treatment 
leaves the floxed Fbxl4 allele intact. First, I generated primary tumors induced by NOTCH1 in Fbxl4fl/fl Tm-
Cre/+, Fbxl4fl/WT Tm-Cre/+, or Fbxl4WT/WT Tm-Cre/+ bone marrow. As previously mentioned, the ΔE-
NOTCH1 allele is an oncogenic form of the NOTCH1 receptor lacking the negative regulatory effects of 
the extracellular domain (Palomero, Barnes et al. 2006). In contrast, the HD-DP NOTCH1 allele is a more 
weakly oncogenic mutant form of the NOTCH1 receptor with a point mutation in the heterodimerization 
domain, as well as a deletion in the PEST domain that impairs degradation of the activated receptor 
(Weng, Ferrando et al. 2004). Both ΔE-NOTCH1 and HD-DP NOTCH1 drive constitutive activation of the 
NOTCH1 receptor, but in mouse models of T-ALL, primary ΔE-NOTCH1-induced tumors are typically 
100% penetrant, while primary HD-DP NOTCH1-induced tumors are generally 25-80% penetrant (Aster, 
Xu et al. 2000, Chiang, Xu et al. 2008). 
Following transplantation of syngenic recipients with NOTCH1-induced Lin- bone marrow, I 
monitored tumor progression by GFP percentage, as the NOTCH1-encoding vectors also contain a 
bicistronic IRES-GFP sequence. I recovered multiple T-ALLs generated with ΔE-NOTCH1 and with HD-
DP NOTCH1 in Fbxl4fl/fl Tm-Cre/+, Fbxl4fl/WT Tm-Cre/+, or Fbxl4WT/WT Tm-Cre/+ bone marrow. On the 
molecular level, these T-ALLs exhibited immunophenotypes characteristic of NOTCH1-induced T-ALL, 
with most tumors categorized as CD4+ CD8+ double positive or CD4+ CD8+ double positive with a 
significant CD8+ component (Figure 3.13A-D) and thus compatible with an immature T-cell phenotype 






To perform secondary bone marrow transplants, I injected sub-lethally irradiated syngenic wild 
type mice with 106 primary leukemia cells (Figure 3.13), waited for engraftment, and then treated 
recipient mice with a single dose of tamoxifen to delete the floxed Fbxl4 allele, or with vehicle as a control. 
I monitored recipient mice daily for signs and symptoms of leukemia, guided by the endpoints of disease-
free survival (time to develop leukemia) and overall survival. I also performed cellular and molecular 
characterization on collected tumors.  
Since 6q deletions are typically heterozygous, I first investigated the consequences of secondarily 
deleting a single copy of Fbxl4 in NOTCH1-induced T-ALL. I hypothesized that deletion of one copy of 
Fbxl4 may accelerate death if Fbxl4 loss cooperates with NOTCH1 activation in these tumors. However, 
Figure 3.13. Immunophenotypes of primary ΔE-NOTCH1 and HD-DP NOTCH1 T-ALLs. 
FACS plots gated on GFP positive cells show CD4 and CD8 expression for primary tumors 
used in secondary bone marrow transplants. (A) ΔE-NOTCH1 Fbxl4fl/fl T-ALL in thymus. (B) 
HD-DP NOTCH1 Fbxl4fl/fl T-ALL in peripheral blood. (C) ΔE-NOTCH1 Fbxl4fl/WT T-ALL in 
thymus. (D) HD-DP NOTCH1 Fbxl4fl/WT T-ALL in peripheral blood.  
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deletion of one copy of Fbxl4 did not alter the kinetics of survival in ΔE-NOTCH1-induced T-ALLs, as 
there was no significant difference in survival for recipients treated with tamoxifen (Fbxl4+/- tumor, 
median survival 48.5 days) compared to recipients treated with vehicle (Fbxl4+/+ tumor, median survival 
48.0 days) (Figure 3.14A). Since ΔE-NOTCH1 tumors are characteristically aggressive and thus small 
differences in survival may be obscured in this setting, I designed a secondary bone marrow transplant 
using a T-ALL induced by HD-DP NOTCH1, which is more weakly oncogenic allele of activated NOTCH1, 
in contrast to the very strongly oncogenic ΔE-NOTCH1 allele (Chiang, Xu et al. 2008). In T-ALLs induced 
by HD-DP NOTCH1, there was no significant difference in survival with deletion of one copy of Fbxl4 by 
tamoxifen treatment (Fbxl4+/-, median survival 58.5 days) compared to vehicle treatment (Fbxl4+/+, 
median survival 42.5 days) (Figure 3.14C). Cre-mediated excision of Fbxl4 was verified in tumors 
recovered from tamoxifen-treated recipients (Figure 3.14B,D). Therefore, deleting one copy of Fbxl4 






Figure 3.14. Heterozygous inactivation of Fbxl4 does not affect the kinetics of 
NOTCH1-induced T-ALL. (A,C) Kaplan-Meier survival curves in mice treated with 
tamoxifen or vehicle after allograft transplantation of Fbxl4fl/WT Tm-Cre/+ ΔE-NOTCH1-
induced (A) or Fbxl4fl/WT Tm-Cre/+ HD-DP NOTCH1-induced (C) T-ALL tumor cells. Arrow 
indicates drug treatment. (B,D) PCR using primers to amplify the wildtype (1,100 bp) and 
excised (400 bp) Fbxl4 alleles on DNA isolated from Fbxl4+/+ (Vehicle-treated) and Fbxl4+/- 
(Tamoxifen-treated) T-ALLs.  
! 107 
 
Following on these results, I next modeled the consequences of homozygous Fbxl4 inactivation 
by secondarily deleting both copies of Fbxl4 in NOTCH1-induced T-ALL. Given that complete Fbxl4 
inactivation results in a fatal mitochondrial encephalopathy in humans (Bonnen, Yarham et al. 2013, Gai, 
Ghezzi et al. 2013) and in mice (Chapter 2), coupled with the fact that Fbxl4 inactivation in leukemia is 
exclusively heterozygous, I hypothesized that inactivation of both copies of Fbxl4 in leukemia may be 
detrimental to tumor progression. Interestingly, I observed a significant delay in leukemia-associated 
mortality for mice that developed T-ALLs upon deletion of both copies of Fbxl4 using two independent 
NOTCH1-induced tumors (Figure 3.15A,C). In more detail, in a secondary bone marrow transplant using 
a ΔE-NOTCH1 tumor, the median survival for vehicle-treated recipients (Fbxl4+/+) was 27.0 days, while 
the median survival for tamoxifen treated recipients (Fbxl4-/-) was extended to 32.0 days (Figure 3.15A). 
Moreover, in a secondary bone marrow transplant with an HD-DP NOTCH1 tumor, the median survival for 
vehicle-treated recipients (Fbxl4+/+) was 33.0 days, while the median survival for tamoxifen-treated 
recipients (Fbxl4-/-) was prolonged to 52.0 days (Figure 3.15C). Evidence of efficient Fbxl4 excision in 
tamoxifen-treated tumors underscores that the prolonged survival is not driven by tumor cells escaping 
Fbxl4 inactivation (Figure 3.15B,D). Thus, in a secondary bone marrow transplant model of NOTCH1-






To control for the potential effects of tamoxifen administration on survival, I performed a 
secondary bone marrow transplant using a ΔE-NOTCH1 T-ALL generated in bone marrow with one copy 
of the Tm-Cre allele but otherwise wild-type. Importantly, tamoxifen treatment did not significantly alter 
survival, compared to vehicle treatment, with a median survival of 21.5 and 23.0 days in the Vehicle and 
Tamoxifen groups, respectively (Figure 3.16). Thus, the phenotypes observed in the secondary bone 
marrow transplants with different dosages of the Fbxl4 gene (Figure 3.16) appear to arise from the 
individual tumors and genetic backgrounds tested and are not an artifact of tamoxifen treatment.  
 
Figure 3.15. Homozygous deletion of Fbxl4 delays NOTCH1-induced T-ALL. (A,C) 
Kaplan-Meier survival curves in mice treated with tamoxifen or vehicle after allograft 
transplantation of Fbxl4fl/fl Tm-Cre/+ ΔE-NOTCH1-induced (A) or Fbxl4fl/fl Tm-Cre/+ HD-DP 
NOTCH1-induced (C) T-ALL tumor cells. Arrow indicates drug treatment. (B,D) Fbxl4 
expression is shown relative to Gapdh expression and normalized to Fbxl4+/+ 1 for Vehicle-






In summary, I used primary and secondary bone marrow transplant models to dissect a potential 
cooperation between FBXL4 loss and oncogenic NOTCH1 in T-ALL (Table 3.4). Inactivation of one copy 
of Fbxl4 during T-ALL tumor initiation or after engraftment of established T-ALLs did not alter the kinetics 
of T-ALL, indicated by no significant difference in survival between groups (Table 3.4). Notably, deletion 
of both copies of Fbxl4 after T-ALL engraftment delayed tumor progression in two independent tumors 
(Table 3.4). The delay in tumor onset could not be explained by a potential chemotherapeutic effect of 
tamoxifen, as mice transplanted with a NOTCH1-induced T-ALL generated in a Fbxl4 wild-type 
background and then treated with tamoxifen or vehicle showed no significant difference in survival (Table 
3.4). On the molecular level, no change in tumor immunophenotype occurred upon deletion of one or two 
copies of Fbxl4, compared to T-ALLs wild-type for Fbxl4.  
Thus, complete inactivation of Fbxl4 appears to be detrimental in T-ALL. This finding is especially 
interesting given that FBXL4 deletions in human T-ALL appears to be exclusively heterozygous, 
suggesting that loss of one copy of FBXL4 is beneficial but loss of two copies is disadvantageous to 
tumors.  
Figure 3.16. Tamoxifen does not alter the kinetics of T-ALL. Kaplan-Meier survival curve 
in mice treated with tamoxifen or vehicle after allograft transplantation of Fbxl4WT/WT Tm-
Cre/+ ΔE-NOTCH1-induced T-ALL tumor cells. Arrow indicates drug treatment. 
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Interestingly, GSEA of the gene expression signature of Fbxl4-null livers (Figure 2.13A) against 
the C2 molecular signature database revealed a significant enrichment of genes downregulated in 
cancer-associated signatures in transcripts upregulated in Fbxl4-null livers (Figure 3.17). Thus, on the 
level of gene expression, complete loss of Fbxl4 is anti-correlated with cancer, which fits with the survival 
benefit following Fblx4 deletion in established T-ALL (Table 3.4). 
Table 3.4. Summary of primary and secondary bone marrow transplants testing the 
role of Fbxl4 in NOTCH1-induced T-ALL. Survival outcomes are based on P values 




3.B.iii.d. Consequences of Acute Loss of Fbxl4 in T-ALL 
I have previously shown that secondary deletion of Fbxl4 prolongs survival in T-ALL (3.B.iii.c), 
but the dynamics and cellular mechanisms underlying this effect are unknown. Thus, I designed in vitro 
Figure 3.17. The Fbxl4-/- gene expression signature is anti-correlated with cancer. 




approaches to address the acute effects of Fbxl4 inactivation in T-ALL. I hypothesized that loss of Fbxl4 
may impair proliferation, slow cell cycle progression, and/or increase apoptosis in T-ALL cells. Moreover, 
as I have previously shown that Fbxl4 is a crucial regulator of mitochondrial dynamics, I hypothesized that 
some of the cellular effects of Fbxl4 inactivation may be mediated through mitochondrial dysfunction.  
To address the cellular and molecular effects of acute Fbxl4 loss in T-ALL, I designed an in vitro 
system using cell lines generated from primary HD-DP NOTCH1 Fbxl4fl/fl Tm-Cre/+ or HD-DP NOTCH1 
Fbxl4fl/WT Tm-Cre/+ tumors. I maintained freshly harvested mouse T-ALL cells as co-cultures with OP9 
stroma until the tumors cells became cell lines capable of OP9-independent growth (Schmitt and Zuniga-
Pflucker 2002). I will focus on HD-DP NOTCH1 Fbxl4fl/fl Tm-Cre/+ T-ALLs, as no HD-DP NOTCH1 
Fbxl4fl/WT Tm-Cre/+ T-ALLs became capable of OP9-independent growth after five months in culture. 
To examine the acute effects of Fbxl4 loss on the cellular level, I treated two independent HD-DP 
NOTCH1 Fbxl4fl/fl Tm-Cre/+ T-ALLs with tamoxifen or vehicle in vitro, resulting in Fbxl4-/- and Fbxl4+/+ T-
ALLs, respectively, differing only in Fbxl4 gene dosage. Following tamoxifen or vehicle treatment, I 
assessed proliferation by MTT absorbance, cell cycle by propidium iodide staining, and apoptosis with 
Annexin-V/7-AAD staining over the ensuing five days. Given that complete Fbxl4 inactivation prolonged 
survival in bone marrow transplant models of T-ALL (Figure 3.15A,C), I hypothesized that homozygous 
Fbxl4 loss may decrease proliferation, stall the cell cycle, and/or increase apoptosis of T-ALL tumor cells. 
Importantly, I observed a statistically significant decrease in MTT reactivity in two independent Fbxl4-/- 
tumors at Days 3 and 5, compared to Fbxl4 wild-type tumors (Figure 3.18A-B). Notably, the effects of 
Fbxl4 loss on cell cycle were mild and inconsistent across tumors (Figure 3.19A-B) and thus fail to 
account for the greatly decreased MTT reactivity observed at Day 5 (Figure 3.18A-B). For example, upon 
Fbxl4 deletion in tumor 1266, there was an increased percentage of cells in G2/M phase at Day 3, but at 
Day 5 there was a decrease in the percentage of cells in G1 and increase in the percentage of cell in S 
phase with no significant change in G2/M phase, relative to Fbxl4+/+ tumor cells (Figure 3.19A). In 
contrast, upon Fbxl4 deletion in tumor 1269, the percentage of cells in G1 and S phases at Day 3 and 
Day 5 increased, relative to Fbxl4+/+ tumor cells (Figure 3.19B). Thus, acute Fbxl4 inactivation in T-ALL 
does not have a consistent cell cycle phenotype. Interestingly, Fbxl4-/- tumors developed significantly 
more early apoptotic and dead cells than Fbxl4+/+ tumors, with the most striking effects observed at Day 
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5 (Figure 3.20A-B). Therefore, acute homozygous deletion of Fbxl4 in T-ALL results in decreased MTT 
reactivity, which is typically an indicator of cell proliferation, as well as increased apoptosis and cell death, 
compared to matched T-ALLs that retain Fbxl4 expression. Fbxl4 excision in tamoxifen-treated cells was 






Figure 3.18. Decreased MTT reactivity in T-ALLs acutely deleted for Fbxl4. MTT 
absorbance is shown as the fold change relative to Day 0 of tamoxifen or vehicle treatment 





Figure 3.19. Cell cycle analysis in tumors acutely deleted for Fbxl4. The percentage of 
cells in G1, S, and G2/M phases is shown following tamoxifen or vehicle treatment of HD-






Given that FBXL4 plays a crucial role in mitochondrial homeostasis, I hypothesized that acute 
Fbxl4 inactivation in T-ALL may impinge on mitochondrial functioning. To test this hypothesis, I set up an 
acute treatment in vitro to explore the impact of Fbxl4 loss on several parameters of mitochondria function. 
Figure 3.20. Increased early apoptosis and death in T-ALLs acutely deleted for Fbxl4. 
The percentage of live, early apoptotic, and dead cells is shown following tamoxifen or 
vehicle treatment of HD-DP NOTCH1 Fbxl4fl/fl Tm-Cre/+ Tumor 1266 (A) and 1269 (B). Bars 
represent mean ± SD. 
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Five days after treating three independent HDDP NOTCH1 Fbxl4fl/fl Tm-Cre/+ tumors with tamoxifen to 
excise Fbxl4 (Fbxl4-/-) or with vehicle as a control (Fbxl4+/+), the mitochondria membrane potential 
decreased in all three Fbxl4-/- tumors relative to controls (Figure 3.21A). The magnitude of this effect is 
tumor-specific, as the baseline mitochondria membrane potential varied across tumors (86.4% PE 
positive in 1266 versus 42.9% in 1269), and the relative decrease in mitochondria membrane potential 
also varied for each tumor (86.4% to 66.3% for 1266 versus 42.9% to 8.64% for 1269) (Figure 3.21A). 
Interestingly, analysis of mitochondria DNA copy number five days after tamoxifen or vehicle treatment 
revealed a significant 2- to 3-fold increase in mitochondria DNA in two Fbxl4-/- tumors, relative to vehicle-
treated controls (Figure 3.21B). However, the mitochondria DNA copy number did not differ for tumor 
1266 regardless of Fbxl4 status (Figure 3.21B). Interestingly, tumor 1266 also had the highest baseline 
mitochondria membrane potential and the smallest relative decrease in mitochondria membrane potential 
with Fbxl4 loss, suggesting that this tumor is less sensitive to Fbxl4 inactivation compared to the other 
tumors analyzed. Finally, I ensured efficient Fbxl4 deletion with tamoxifen treatment using Day 5 tumor 


















Figure 3.21. Altered mitochondria following acute deletion of Fbxl4 in T-ALL. (A) 
FACS plots showing mitochondria membrane potential by TMRE accumulation (PE) in GFP 
positive (FITC) T-ALL cells after five days of tamoxifen or vehicle treatment. Gates were 
generated using unstained control cells. (B) Mitochondria DNA copy number is normalized 
to the vehicle-treated control (Fbxl4+/+) for each tumor. Bars show mean ± SD. (C) PCR 
using primers to amplify the wildtype (1,100 bp) or excised (400 bp) Fbxl4 allele on tumor 
cell DNA isolated after five days of tamoxifen or vehicle treatment. 
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3.C. Discussion 
Fbxl4 in dispensable for hematopoesis and T-cell development   
FBXL4 is differentially regulated during T-cell development, thus I hypothesized that FBXL4 may 
contribute to the process of T-cell maturation and differentiation. In particular, Fbxl4 expression levels are 
lowest during the proliferative burst accompanying β-selection and rise to their highest levels during 
commitment to CD4+ or CD8+ T-cell fate, which may indicate regulation in concert with T-cell 
development (Sicinska, Aifantis et al. 2003, Aster, Pear et al. 2008). However, I found that Fbxl4 is 
dispensable for T-cell development using two independent systems to conditionally delete Fbxl4 in early 
T-cell progenitors (Lck-Cre) or in HSCs (Vav-Cre). It is possible that redundancy or compensation 
mechanisms exist in progenitor cells lacking Fbxl4 expression, thus masking the phenotype of Fbxl4 
deletion in developing T-cells. Notably, although the ratios of immature and mature T-cell populations did 
not differ with intact or deleted Fbxl4, it would be interesting to test the functionality of Fbxl4-/- T-cells. For 
example, I could assess for proliferation following in vitro stimulation of unprimed T-cells obtained from 
Fbxl4fl/fl Lck-Cre/+ (Fbxl4-/-) and Fbxl4WT/WT Lck-Cre/+ (Fbxl4+/+) mice. Or, I could first perform in vivo T-
cell priming and then measure proliferation following in vitro stimulation of T-cells isolated from Fbxl4-/- 
and Fbxl4+/+ mice. In these experiments, proliferation is a read out of T-cell activation, and thus 
decreased proliferation in response to stimulation in Fbxl4-/- T-cells, compared to Fbxl4+/+ T-cells, 
suggests impaired T-cell reactivity and warrants further examination (Kruisbeek, Shevach et al. 2004). 
FBXL4 is dispensable in hematopoietic stem cells, as conditional inactivation of Fbxl4 in HSCs 
failed to disrupt the ratios of progenitor and mature cells formed across blood lineages and hematopoietic 
tissues. There may be redundancy and/or compensation mechanisms at play with Fbxl4 loss, which 
would be difficult to tease out without a more thorough understanding of the role of FBXL4 in HSCs. 
However, it is possible that a phenotype for Fbxl4-/- HSCs may be elicited with a stressor, such as a bone 
marrow repopulation assay. This experiment could be performed by transplanting Fbxl4-/- or Fbxl4+/+ 
bone marrow cells isolated from Fbxl4fl/fl Vav-Cre/+ or Fbxl4WT/WT Vav-Cre/+ mice, respectively, into lethally 
irradiated recipients and then examining the consequences of Fbxl4 deletion on bone marrow 
reconstitution and leukemia development using flow cytometry analysis of progenitor and terminally 
differentiated hematopoietic cells. The repopulation experiment could also be performed by transplanting 
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Fbxl4fl/fl Tm-Cre/+ bone marrow cells into lethally irradiated recipients, waiting three weeks for engraftment, 
and then treating with tamoxifen to excise Fbxl4 or with vehicle as a control and assessing for 
reconstitution and leukemia development. Moreover, to formally test HSC function in the context of Fbxl4 
deficiency, I could perform competitive repopulation assays using Fbxl4+/+ CD45.2 or Fbxl4-/- CD45.2 
bone marrow cells mixed at varying ratios with competitor C57/BL6 CD45.1 bone marrow cells and 
transplanted into lethally irradiated recipients. In these experiments, I could use flow cytometry analysis to 
assess CD45.1/CD45.2 chimerism and relative contribution to different hematopoietic compartments over 
time to determine if Fbxl4-/- cells exhibit a competitive disadvantage or advantage, compared to Fbxl4+/+ 
cells (Hofmann, Stover et al. 2009). Finally, to test if Fbxl4 might be important for response to stress in 
the hematopoietic system, I could treat cohorts of Fbxl4fl/fl Vav-Cre/+ (Fbxl4-/-) and Fbxl4WT/WT Vav-Cre/+ 
(Fbxl4+/+) mice with 5-FU and monitor complete blood counts and survival over time to assess if Fbxl4-/- 
mice are more or less susceptible to hematopoietic stress than wild-type controls (Cheng, Rodrigues et al. 
2000). 
Interestingly, I identified a population of myeloid cells expressing Gr1 but with low CD11b 
expression in Fbxl4-/- bone marrow. In the mouse bone marrow, cells expressing Gr1 and CD11b are 
thought to represent myeloid precursors, which can go on to become monocytes/macrophages or 
granulocytes (Yang, Ai et al. 2011). Notably, monocytes/macrophages can be identified by expression of 
CD11b (Mac1) and Ly71 (F4/80), while bone marrow granulocytes and peripheral neutrophils can be 
identified by expression of Gr1 (Ly6G). I hypothesize that the Gr1+ CD11b-low population may be 
developing granulocytes that downregulated CD11b expression. To further analyze this cell population, I 
could stain the Gr1+ CD11b-low population with a panel of antibodies to more fully characterize the 
phenotype of these cells, including Ly71 (F4/80) to determine if these cells have macrophage 
characteristics, combined with microscopy-based morphological analysis, including assessment of the 
presence of cytoplasmic granules, a key feature of granulocytes (Jiang and Schwarz 2010). 
 
The roles and mechanisms of Fbxl4 in T-ALL 
Since FBXL4 is recurrently deleted in T-ALL, I hypothesized that FBXL4 may function as a tumor 
suppressor in this disease. However, inactivation of Fbxl4 in T-cell precursors and in HSCs failed to lead 
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to leukemia over one year of follow up. Given that T-ALL is a genetically heterogeneous disease in which 
numerous chromosomal and genetic alterations cooperate to promote the aberrant proliferation and 
survival of leukemic lymphoblasts (Paganin and Ferrando 2011), it is possible that Fbxl4 loss cooperates 
with other genetic alterations in leukemogenesis. For example, the F-box protein FBXW7 is recurrently 
mutated in many cancers, including T-ALL (Akhoondi, Sun et al. 2007), but monoallelic deletion of Fbxw7 
in the hematopoietic system by Mxi-Cre fails to induce leukemia (Mao, Perez-Losada et al. 2004). Notably, 
following irradiation, tumors developed in 30% of the Fbxw7+/- mice (Mao, Perez-Losada et al. 2004). 
Thus, it would be interesting to test the consequences of irradiation on cohorts of Fbxl4fl/fl Vav-Cre/+, 
Fbxl4fl/WT Vav-Cre/+ and Fbxl4WT/WT Vav-Cre/+ mice, where I hypothesize that tumors may develop with an 
increased frequency in Fbxl4fl/WT Vav-Cre/+ mice, compared to Fbxl4fl/fl Vav-Cre/+or Fbxl4WT/WT Vav-Cre/+ 
mice, following the stress of irradiation. On the other hand, in the same Fbxw7 study, Fbxw7+/- mice with 
a concomitant deletion of p53 developed tumors more quickly than p53+/- mice wild-type for Fbxw7 (Mao, 
Perez-Losada et al. 2004). Therefore, it would be interesting to assess the kinetics of tumor development 
in Fbxl4fl/WT Vav-Cre/+ p53+/- mice compared to Fbxl4WT/WT Vav-Cre/+ p53+/- mice, where I postulate that 
deletion of one copy of Fbxl4 may accelerate p53-driven tumors. 
Notably, since the deletions encompassing the FBXL4 locus in human T-ALL are often large and 
contain many genes (Burkhardt, Moericke et al. 2008), the loss of multiple genes in this region may 
cooperate to induce leukemia. To formally test this hypothesis, I could perform pooled shRNA screens 
using hairpins targeted against the genes commonly deleted in 6q-, similar to approaches used in 
studying 6q deletions in B-cell lymphoma (Oricchio, Nanjangud et al. 2011, Scuoppo, Miething et al. 
2012). To perform these experiments, I could infect Lin- progenitor cells with pools of pre-validated GFP-
expressing short hairpins directed against the genes commonly deleted in 6q- leukemia, transplant 
cohorts of lethally irradiated recipients with the transduced cells, and assess for the development of GFP-
positive leukemia over time. As a positive control, I could transplant a cohort of mice with Lin- cells 
transduced with a hairpin against p53 (Stoddart, Fernald et al. 2014). As a negative control, 
transplantation of Lin- cells transduced with a GFP-tagged scrambled hairpin should not result in GFP+ 
leukemia development. Following leukemia development in the experimental mice, for a given shRNA 
pool, I could determine the contribution of the different hairpins to tumorigenesis by PCR amplification of 
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the unique barcode sequence attached to each hairpin. In this way, I could tease out the contribution of 
Fbxl4 and the various genes deleted on 6q, alone and in different combinations with each other, to T-ALL 
leukemogenesis.  
Since aberrant activation of the NOTCH1 pathway is the most prominent oncogenic mechanism 
in T-ALL (Weng, Ferrando et al. 2004), I assessed for a genetic interaction between Fbxl4 deletion and 
NOTCH1 activation. Notably, deletion of one copy of Fbxl4, which mimics the context of 6q-, did not 
accelerate leukemia development in NOTCH1-induced primary or secondary T-ALLs. In these 
experiments, I tested strongly and weakly activated forms of NOTCH1 (Chiang, Xu et al. 2008), including 
ΔE-NOTCH1 (Palomero, Barnes et al. 2006) and HD-DP NOTCH1 (Weng, Ferrando et al. 2004), 
respectively, but it is possible that even the weakly activated HD-DP NOTCH1 allele may have obscured 
the effects of Fbxl4 deletion on the kinetics of leukemia development. To address this issue, I also 
assessed Fbxl4 leukemogenesis by ageing cohorts of mice with conditional deletion of Fbxl4 in the 
hematopoietic system using Lck-Cre or Vav-Cre, as I have previously discussed. Notably, although these 
experimental approaches indicate that Fbxl4 inactivation is not sufficient to induce leukemia, they do not 
conclusively rule out a tumor suppressor function for Fbxl4 and further studies are warranted.  
It remains possible that NOTCH1 activation is not the most pertinent cooperating oncogenic 
mechanism to study with FBXL4 loss. In our array CGH study, only two out of five patients with 6q 
deletions encompassing FBXL4 had known NOTCH1 mutations, and the full complement of genetic 
alterations in these five samples remains unknown. Moreover, in the T-LBL patient series, NOTCH1 
mutations were rarely observed in 6q- patients, leading the authors to argue that NOTCH1 mutations and 
6q deletions are mutually exclusive (Bonn, Rohde et al. 2013). Thus, although the overall number of 6q-
deleted patients in these studies is low, it seems pertinent to explore the consequences of deleting Fbxl4 
in T-ALLs induced by alternative oncogenic mechanisms. To design this experiment, I would first perform 
whole exome sequencing on 6q- and 6q+ T-ALLs to determine which additional genetic alterations occur 
more frequently in Fbxl4-deleted leukemias. Next, I would infect Fbxl4+/- or Fbxl4+/+ Lin- bone marrow 
progenitor cells with viruses expressing each of the top candidate genetic alterations and transplant the 
cells into lethally irradiated recipients to determine if Fbxl4 loss accelerates tumor development compared 
to the same genetic alteration in Fbxl4+/+ bone marrow. 
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Strikingly, inactivation of both copies of Fbxl4 in NOTCH1-induced T-ALL delayed tumor 
progression in two independent T-ALLs. Following these results, I used quantitative PCR to measure 
Fbxl4 expression levels in tamoxifen- and vehicle-treated tumors, and I verified that the observed delay in 
leukemia development could not be explained by genetic escapers re-expressing Fbxl4. Notably, 
deletions encompassing FBXL4 appear to be exclusively heterozygous in T-ALL, and thus there may be 
some disadvantage to complete loss of FBXL4 function in tumors. On the cellular level, I found that acute 
homozygous deletion of Fbxl4 leads to decreased proliferation, increased apoptosis and cell death, and 
impaired mitochondria function in T-ALL cells. These findings could help explain the delayed progression 
of Fbxl4-/- T-ALLs in bone marrow transplant models. Notably, the MTT assay used to measure cell 
proliferation is also a read out of mitochondria function, as the process of conversion of the tetrazolium 
salt MTT into formazan crystals is an NAD(P)H-dependent process (van Meerloo, Kaspers et al. 2011). 
Moreover, apoptosis is intricately linked with mitochondrial homeostasis and health (Nunnari and 
Suomalainen 2012). It would be interesting to perform comprehensive “mitochondrial profiling” (Boland, 
Chourasia et al. 2013) on T-ALLs acutely deleted for Fbxl4, compared to wild-type T-ALLs, including 
analysis of OXPHOS function, mitochondrial mass and turnover, calcium signaling, and ROS production, 
as well as metabolic profiling to complement the metabolic analyses previously performed on Fbxl4-/- and 
Fbxl4+/+ perinatal tissues. These experiments would likely yield important insights into the consequences 
of Fbxl4 deletion-meditated mitochondrial dysfunction in T-ALL pathogenesis. It would also be interesting 
to perform Western blot analysis on Fbxl4+/+ and Fbxl4-/- tumors to screen for the accumulation of 
candidate FBXL4 substrates in the context of Fbxl4 deletion to further characterize the mechanistic 
contributions of Fbxl4 deletion to the pathogenesis of T-ALL.  
To more closely address the in vivo roles and mechanisms of homozygous Fbxl4 deletion in T-
ALL, I could set up an in vivo “acute treatment”. In this experiment, I could treat mice harboring 
established isogenic Fbxl4fl/fl Tm-Cre/+ NOTCH1 HD-DP T-ALLs with tamoxifen to delete Fbxl4 or with 
vehicle as a control and analyze the mice forty-eight hours later. At this time point, I would measure tumor 
burden by organ infiltration of GFP+ T-ALLs cells, as well as analyze cell cycle by PI and BRDU staining 
and apoptosis by AnnexinV/7-AAD staining. I hypothesize that Fbxl4 deletion may result in decreased 
tumor burden, impaired cell cycle progression, and/or increased apoptosis and cell death, compared to 
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Fbxl4 wild-type tumors. I could also use a Leukemia Initiating Cell experiment (LIC) to study the effects of 
homozygous Fbxl4 deletion in T-ALL. In this experiment, I would transplant equivalent numbers of GFP+ 
leukemia cells sorted from Fbxl4+/+ or Fbxl4-/- NOTCH1 HD-DP T-ALLs into secondary recipients at a 
range of doses from 101-106 cells per recipient (King, Trimarchi et al. 2013). In this context, I hypothesize 
that the frequency of leukemia would be higher when Fbxl4 is intact compared to when Fbxl4 is deleted, 
particularly at lower leukemia cell doses, where differences in LIC capacity may become more apparent. 
Moreover, I hypothesize that the LIC frequency, calculated by limiting dilution analysis (Buchstaller, 
McKeever et al. 2012), would be higher in Fbxl4 wild-type versus Fbxl4 deleted T-ALL.  
Interestingly, the effects of Fbxl4 loss appear to be tumor specific. For example, I observed 
varying degrees of mitochondria membrane potential decrease upon acute Fbxl4 deletion in different T-
ALL in vitro. Notably, the two T-ALLs with the biggest loss in mitochondria membrane potential in vitro 
also exhibited a statistically significant 2- to 3-fold increase in mitochondria DNA copy number, which may 
represent a compensatory increase in mitochondrial biogenesis to combat the deleterious effects of 
decreased mitochondria membrane potential (Nunnari and Suomalainen 2012). Given the role Fbxl4 
plays in mitochondrial homeostasis, the variable dependence on Fbxl4 function in T-ALL may be due to a 
threshold effect, where defective mitochondria accumulate to toxic levels (Koopman, Willems et al. 2012). 
Additionally, the inter-tumor dependence on Fbxl4 function may be due to the presence of additional 
oncogenic mechanisms that are synthetic lethal with Fbxl4 loss of function. 
 There are several examples of hemizygous tumor suppressors that exhibit detrimental effects 
following inactivation of both copies. For example, Dicer1, which encodes a factor important in microRNA 
processing, is heterozygously deleted, but never homozygously deleted, in an array of human cancers 
(Kumar, Pester et al. 2009). In mouse models of lung cancer and of sarcoma, attempts to delete both 
copies of Dicer led to prolonged survival compared to mice that developed tumors in a Dicer+/- 
background (Kumar, Pester et al. 2009). In another example, Sfpi1, encoding the ETS family transcription 
factor PU.1, is recurrently inactivated in human leukemia (Burda, Laslo et al. 2010), but complete Sfpi1 
inactivation impairs lymphoid and myeloid development and results in embryonic or perinatal lethality in 
mice (Scott, Simon et al. 1994, McKercher, Torbett et al. 1996). Interestingly, mice with a hypomorphic 
PU.1 allele that decreases PU.1 expression/activity to about 20% of normal levels develop acute 
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myelogenous leukemia (AML) at a high frequency, yet mice with homozygous or heterozygous deletions 
of SfpI1 do not develop AML, suggesting that some retained function of PU.1 is required for AML 
development (Rosenbauer, Wagner et al. 2004). Notably, GSEA analysis of the gene expression 
signature of Fbxl4-/- livers against the C2 molecular signature database reveals significant enrichment of 
genes downregulated in cancer-associated signatures. This finding correlates with the in vivo and in vitro 
data supporting an anti-cancer effect in Fbxl4-/- T-ALLs. Interestingly, this anti-tumor effect may be 
specific to NOTCH1-induced T-ALLs, or it may be a more general mechanism. It would be interesting to 
test the consequences of homozygous Fbxl4 deletion in combination with oncogenes other than NOTCH1 
using bone marrow transplant models of hematological malignancy. For example, I could test Fbxl4 
deletion with the MLL-AF9 oncogene in AML (Krivtsov, Twomey et al. 2006), with the BCR-ABL oncogene 
in myeloproliferative disease (Huntly, Shigematsu et al. 2004), or with oncogenic K-ras (K-ras G12D) 
expressed from its endogenous promoter in hematopoietic cells in myeloproliferative disease (Chan, 
Kutok et al. 2004), to assess if loss of Fbxl4 function has a general anti-tumor effect resulting in 
decreased tumor progression following Fbxl4 deletion, compared to Fbxl4 wild-type tumors. 
Importantly, the ability to harness the mechanisms by which homozygous Fbxl4 deletion 
negatively affects T-ALL may yield novel anti-cancer therapeutics. For example, although these 
mechanisms are not yet fully understood, an in vitro screen of pre-existing compounds using a read out of 
decreased mitochondria membrane potential coupled with increased apoptosis in T-ALL cells may yield 
new clinically applicable compounds that recapitulate the cellular effects of homozygous Fbxl4 deletion. 
As an alternative approach, 6q- leukemias may be more sensitive to certain treatments that would 
synergize with deletion of one copy of Fbxl4. To investigate this hypothesis, I could grow Fbxl4fl/WT HD-DP 
NOTCH1 tumors in vitro and collect samples over time following treatment with tamoxifen to delete Fbxl4 
or with vehicle to leave Fbxl4 intact. Next, I could perform gene expression profiling and generate 
connectivity maps (Lamb, Crawford et al. 2006) to find drugs that yield statistically significant negative 
connectivity with Fbxl4+/- T-ALL gene signatures and thus may represent novel therapies for 6q- 
leukemias. As a complimentary approach, I could perform Western Blot analysis on these same samples 
to look for accumulation of candidate Fbxl4 substrates in Fbxl4-deleted cells. In the Fbxl4+/- cells, 
accumulation of certain proteins may be oncogenic or may represent a compensatory response to 
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deletion of one copy of Fbxl4, but in either case, small molecule inhibition of a candidate protein may 
specifically kill Fbxl4+/- leukemia cells and thus result in a novel treatment for 6q- patients. Finally, I could 
perform an in vitro shRNA screen in 6q- leukemias and assess for shRNA depletion over time to find 
genes that when knocked-down synergize with deletion of one copy of Fbxl4 and then design drugs that 
mimic the effect of knocking down this gene of interest that would be used to specifically kill 6q-deleted T-
ALLs. 
At the start of these experiments, I intended to link the accumulation of proteins normally targeted 
for proteasomal degradation by FBXL4 to the pathogenesis of FBXL4 loss in leukemia, hypothesizing that 
these substrates may be oncogenic. However, isolating the FBXL4 complex from T-ALL cells proved to 
be experimentally unfeasible due to low levels of FBXL4 expression in this system. Ultimately, I isolated a 
robust FBXL4 complex from HEK-293T cells, which can still provide valuable insights into the cellular 
roles and mechanisms of FBXL4 in T-ALL. As an alternative approach to tandem affinity purification of the 
FBXL4 complex, I could preform SILAC labeling (Ong 2012) on Fbxl4-/- T-ALLs and Fbxl4+/+ T-ALLs 
grown in vitro and following quantitative mass spectrometry analysis, look for accumulation of proteins in 
the Fbxl4-/- context that may represent candidate substrates normally targeted by Fbxl4 for proteasomal 
degradation. However, it must be noted that using tandem affinity purification approaches, I have only 
been able to identify one candidate FBXL4 substrate to date, SLC25A4, and this protein does not appear 
to be ubiquitinated by FBXL4. Thus, it is possible that FBXL4 functions as a non-canonical F-box protein. 
Notably, the yeast F-box proteins Mdm30 and Mfb1 exhibit non-redundant, F-box-independent roles, as 
they are required for proper mitochondrial distribution and morphology during mitotic growth (Willems, 
Schwab et al. 2004). Moreover, SCF-independent roles have been described for 12% of mammalian F-
box proteins to date (Nelson, Randle et al. 2013). For example, the mammalian F-box protein FBXO7, 
which is mutated in Parkinson’s Disease, appears to contribute to mitophagy via SCF-independent and 
dependent mechanisms (Nelson, Randle et al. 2013). Therefore, further study is required to understand 
the mitochondrial roles and mechanisms of FBXL4 and what these functions mean for T-ALL 





In summary, FBXL4 is mutated in pediatric mitochondrial encephalopathy, and I have show that 
FBXL4 plays important roles in developmental homeostasis, metabolism, and mitochondria function. I 
have also isolated the FBXL4 protein complex and shown that FBXL4 interacts with important regulators 
of mitochondrial dynamics, including solute transporters and components of the electron transport chain. 
On the other hand, FBXL4 is recurrently deleted in T-cell leukemia as part of heterozygous deletions 
affecting the long arm of chromosome 6 (6q-). My results indicate that Fbxl4 is dispensable for 
hematopoesis and T-cell development. Moreover, de novo leukemias do not develop following conditional 
deletion of one or two copies of Fbxl4 in HSCs or T-cell progenitors. Notably, FBXL4 may still function as 
a heterozygous tumor suppressor in T-ALL in cooperation with other genetic alterations. Interestingly, 
deletion of both copies of FBXL4 in T-ALL has a profound anti-tumor effect that is partially explained by 
increased cell death and apoptosis and impaired mitochondrial function in Fbxl4-/- T-ALL cells.  
A thorough understanding of the cellular roles and mechanisms of FBXL4 will help drive the 
development of rational therapies in mitochondrial encephalopathy, a currently incurable disease 
associated with significant morbidity and mortality. Moreover, it is possible that the mechanisms 
underlying the anti-tumor effects of Fbxl4 deletion in T-ALL may be exploited to yield novel treatments for 
cancer patients, especially in the context of treating 6q- patients, whose tumors may be more sensitive to 
certain treatments compared to 6q wild-type patients. Thus, further study of FBXL4 function will hopefully 






Materials and Methods 
Array Comparative Genomics Hybridization (aCGH) 
aCGH of human T-ALLs was performed with SurePrint G3 Human CGH 1 x 1M Oligo Microarrays 
(Agilent Technologies) using standard procedures. The aCGH data was analyzed with the Genomic 
Workbench 5.0.14 software (Agilent Technologies). 
 
Bone Marrow Transplants 
To generate primary NOTCH1-induced T-ALL tumors in mice, bone marrow from 6-8-week-old 
C57BL6 or Fbxl4+/- mice was harvested and lineage depleted using the Mouse Lineage Cell Depletion Kit 
(Milteny). Lin- progenitor cells were subjected to 2 rounds of infection with MigR1-ΔE-NOTCH1(Palomero, 
Barnes et al. 2006) or MigR1-NOTCH1 L1601P ΔPEST (HD-DP)(Weng, Ferrando et al. 2004) retroviral 
particles. Fifty thousand Lin-Sca1+–infected cells were transplanted into irradiated C57BL6 recipients via 
intravenous injection. Transplanted animals were monitored for leukemia development by flow cytometry 
analysis of green fluorescent protein (GFP) and CD4/CD8 expression in peripheral blood. 
Secondary bone marrow transplants were initially performed by injecting intravenously 1 x 106 
leukemic spleen cells into each recipient, waiting 48 hours for engraftment, and then injecting secondary 
recipients intra-peritoneally with tamoxifen (Sigma Aldrich, 5 mg per mouse in corn oil) or vehicle (equal 
volume of corn oil). However, this dose of tamoxifen resulted in an unacceptable level of toxicity, so the 
protocol was adjusted to allow 72 hours for engraftment and the tamoxifen dose was lowered to 3 mg per 
mouse in corn oil, which greatly reduced toxicity. Transplanted animals were monitored for leukemia 
development by flow cytometry analysis of GFP and CD4/CD8 expression in peripheral blood. 
 
Cell Cycle and Apoptosis Measurements 
For cell cycle analysis, cells were incubated in a hypotonic propidium iodide (Sigma Aldrich) 
solution overnight at 4°C in the dark and then subjected to FACS analysis using the PE channel. For 
apoptosis analysis, cells were incubated with APC-conjugated Annexin-V (BD Biosciences) and 7-AAD 
(BD Biosciences) in Annexin V Binding Buffer (BD Biosciences) for 15 minutes at 4°C in the dark and 
diluted with Annexin V binding buffer before FACS analysis. 
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Cell Culture and Drug Treatments 
Mouse embryonic fibroblasts (MEFs) were generated according to standard methods. MEFs were 
grown in DMEM (Corning) supplemented with 10% FBS (Sigma Aldrich) and 1% Penicillin/Streptomycin 
(Corning) at 37°C, 5% CO2. HEK293T cells were grow in DMEM supplemented with 10% FBS and 1% 
penicillin/streptomycin at 37°C, 5% CO2. For MDIVI-1 treatment, 1 x 105 MEFs were seeded in 6-well 
plates, allowed to adhere, and then incubated with 10 uM MDIVI-1 (Sigma Aldrich) or DMSO vehicle for 
24 hours at 37°C, 5% CO2, before proceeding with FACS-based analysis of membrane potential. For 
cycloheximide treatment, HEK-293T cells were treated with 20 ug/mL cycloheximide (Sigma Aldrich) or 
DMSO vehicle for the indicated times at 37°C, 5% CO2 before processing for Western Blot analysis. 
 
Cell Fractionation 
 Mitochondrial and cytoplasmic extracts were prepared using a mitochondria isolation kit 
(Qproteome, Qiagen) according to the manufacturer’s recommendations. 
 
Cell viability and proliferation studies 
Cell growth was determined by measurement of the metabolic reduction of the tetrazolium salt 
MTT using the Cell Proliferation Kit I (Roche) following the manufacturer's instructions. All experiments 
were done in triplicates.  
 
Clinical Samples 
 Leukemic DNA and cryopreserved lymphoblast samples were provided by collaborating 
institutions in the US (Eastern Cooperative Oncology Group and Pediatric Oncology Group). All samples 
were collected in clinical trials with informed consent and under the supervision of local institutional 
review boards and analyzed under the supervision of the Columbia University Medical Center Institutional 





Complete Blood Count 
 Complete Blood Count (CBC) analysis was performed on mouse peripheral blood using a 
Hemavet 950 (Drew Scientific). 
 
Expression Plasmids 
The FBXL4 construct consists of the FBXL4 cDNA (nucleotide positions 392-2257, reference 
sequence NM_012160.4) and a 3’-end HA-FLAG-HA-FLAG epitope coding sequence, cloned into the 
pMSCV-PURO vector (Clontech). The FBXL4 construct lacking the F-box domain (FBXL4ΔFbox) consists 
of the FBXL4 mitochondria localization sequence (MLS) (nucleotide positions 392-490) placed directly 
upstream of nucleotides 1397-2257 (NM_012160.4) and an HA-FLAG epitope coding sequence in the 3’-
end, cloned into pcDNA3.1(+) (Invitrogen).  
The ATP5A1 (pLOC-ATP5A1-MYC) and SLC25A11 constructs (pLOC-SLC25A11-MYC) contain 
C-terminal MYC epitope tags and were obtained from Dr. Jose Silva. The AGK (pCMV6-Entry-AGK-MYC-
ddk, #RC201891, OriGene) and SLC25A13 (pCMV6-Entry-SLC25A13-MYC-ddk, #RC201038, OriGene) 
constructs have C-terminal MYC and FLAG epitope tags. The DNAJA2 construct consists of the DNAJA2 
cDNA (nucleotide positions 143-1381, reference sequence NM_005880.3) and an N-terminal MYC 
epitope coding sequence, cloned into pCDNA3.1(-) (Invitrogen). The SLC25A4 construct consists of the 
SLC25A4 cDNA (nucleotide positions 111-1007, reference sequence NM_001151.3) and an N-terminal 
MYC epitope coding sequence, cloned into pCDNA3.1(-) (Invitrogen). 
 
FACS-Based Assessment of Mitochondria Membrane Potential and Mitochondria Content 
Mitochondria membrane potential was analyzed by loading 2 x 105 cells per sample with 20 nM 
TetraMethylRhodamine, Ethyl ester (TMRE) (Abcam) in HBSS (Life Technologies) at 37°C, 5% CO2 for 
45 minutes. The cells were either stained with TMRE directly or pre-incubated with 100 nM carbonyl 
cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) for 10 minutes at 37°C, 5% CO2 prior to TMRE 
staining. Mitochondria content was analyzed by loading 2 x 105 cells per sample with 50 nM MitoTracker 
Green FM (MTG) (Invitrogen) in HBSS at 37°C, 5% CO2 for 30 minutes. For both TMRE and MTG, 
unloaded control samples were run in parallel. Fluorescence activated cell sorting (FACS) was performed 
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with a FACS Canto II flow cytometer (BD Biosciences) equipped with a 488 nm laser with 490/516 nm 
excitation/emission for MTG and 549/75 nm excitation/emission for TMRE. A total of 20,000 events were 
recorded per sample. Mitochondria membrane potential was calculated from background-subtracted and 
FCCP-subtracted geometric means of TMRE. Mitochondria content was calculated from background-
subtracted geometric means of MTG. 
 
FACS-based analysis of T-cell Development, Hematopoesis, and Tumor Immunophenotypes  
Single-cell suspensions of total bone marrow cells, thymocytes, or spleen cells from the indicated 
mice were prepared by passing the indicated cells through a 40µm filter. Sample data was collected using 
a BD FACSCanto II and a BD LSRFortessa cell analyzer (BD Bioscience). Data was analyzed using the 
FlowJo flow cytometry analysis software (TreeStar Inc.) 
For analysis of T-cell development using Lck-Cre mice, the following antibodies from BD 
Biosciences were used: Pac Blue-CD3, APC-CD4, PE-CD8a, PerCP Cy5.5-CD44, and FITC-CD25.  
For analysis of HSCs, myeloid progenitors, B/T cells, and myeloid cells using Vav-Cre mice, 
antibody staining and FACS analysis were performed in collaboration with the laboratory of Dr. Iannis 
Aifantis at NYU. For the HSC stain, the Lineage cocktail consisted of APC Cy7-Gr1, -Cd11b, -Ter119, -
B220, -CD4, and -CD8. Additionally, APC-cKit, PE Cy7-Sca1, PE-CD150, Pac Blue-CD48, and Alexa 
700-FcyRII/III antibodies were used. For analysis of myeloid progenitors, the Lineage cocktail consisted 
of APC Cy7-Gr1, -Cd11b, -B220, -CD4, and –CD8. Additionally, FITC-cKit, PE-Sca1, APC-CD150, Pac 
Blue-CD105, PE Cy7-CD41, and Alexa 700-FcyRII/III antibodies were used. For analysis of B/T cells, 
APC-IgM, PE Cy7-B220, APC Cy7-CD4, Pac Blue-CD8, FITC-cKit, PE-CD25, and PE Cy5.5-CD44 
antibodies were used. For analysis of myeloid cells, APC-Gr1, APC Cy7-Cd11b, Pac Blue-F4/80, FITC-
CD71, PE Cy7-CD41, and PE Cy5.5-Ter119 antibodies were used. 
 For analysis of tumor immunophenotypes, antibodies obtained from BD Biosciences were used in 
the following combinations, along with DAPI (Life Technologies). The “T-cell 1” stain consisted of APC-
CD4, PE-CD8a, and PerCp Cy5.5-CD3. The “T-cell 2” stain consisted of APC-CD4, PE_CD8, PerCP 
Cy5.5-CD44, and APC Cy7-CD25. The “myeloid” stain consisted of PE-GR1 and APC-Cd11b. 
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Histology and Biochemistry 
Mouse embryos and thymuses were isolated using standard procedures and then processed for 
histologic analysis following 48 hours of fixation in 10% neutral buffered formalin. Perinatal brains were 
isolated from full term mouse pups, fixed in 4% paraformaldehyde for 48 hours, and stored in 30% 
sucrose before analysis and processing for histological studies. Hematoxylin and Eosin staining was 
performed by the Columbia Histology Core Facility according to standard procedures and slides were 
analyzed on a Nikon Eclipse E600e microscope with NIS Elements F 3.20 Software. 
 
Immunofluorescence 
HEK293T cells were transfected to express a mitochondria marker (pDsRed2-mito, Clontech) and 
empty vector or FBXL4 (FBXL4 with an C-terminal HA-FLAG-HA-FLAG epitope tag cloned into pmscv-
puro, or an FBXL4 mutant lacking the Fbox (FBXL4ΔFbox) with a C-terminal HA-FLAG tag, cloned into 
pcDNA3). FBXL4 immunofluorescence was performed using anti-FLAG antibody (1:50, Cell Signaling), 
followed by anti-rabbit AlexaFluor 488 (1:500, Invitrogen) staining and confocal microscopy on a Nikon 
A1RMP microscope with a Nikon 100x / 1.45 objective.  
 
In Vitro Manipulation of Mouse T-ALLs 
Murine T-ALL spleen cells were grown on OP9 stroma as previously described.(Schmitt and 
Zuniga-Pflucker 2002) Co-cultures were maintained in MEM alpha GlutaMAX (Life Technologies) 
supplemented 10% FBS (Sigma Aldrich), 1% Penicillin/Streptomycin (Corning), 0.1% Beta-
mercaptoethanol (Sigma Alrdrich), and 10 ng/uL of mouse IL7 (Peprotech) at 37°C, 5% CO2. Once T-ALL 
cells became capable of OP9-independent growth, the media was no longer supplemented with mouse 
IL7. 
 
Long Term Monitoring of Leukemia Development in Fbxl4 Transgenic Mice  
Cohorts of transgenic and wild type littermate controls from Fbxl4fl/fl (n=19), Fbxl4fl/WT (n=10), and 
Fbxl4WT/WT (n=19) lines were monitored daily for signs and symptoms of disease for 12 months. The 
primary endpoints of these analyses were disease-free survival (time to develop leukemia and/or tumor 
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masses) and overall survival. Differences in survival between control animals and the experimental group 
were represented using Kaplan–Meier curves and statistical significance was determined using Fisher’s 
exact test. At approximately 1 year of age, mice were sacrificed and examined for signs and symptoms of 
leukemia. At the same time, spleens and thymuses were excised, weighed, and then fixed for 48 hours in 
10% formalin for histological analysis.  
 
Metabolic Parameter Analysis In Vivo 
Mice were fasted for the indicated times with continuous access to water. Glucose levels were 
determined using the FreeStyle Lite Blood Glucose Monitoring System (Abbott) on whole blood isolated 
from distal tails. Urine ketones were measured using Ketostix Reagent Strips for Urinalysis (Bayer).  
 
Metabolic Profiling 
Liver, brain, and brown adipose samples from perinatal mice were analyzed by GC/MS and 
LC/MS/MS. Briefly; tissue samples were collected from full term perinatal mouse pups and snap frozen 
directly after harvesting. Samples were extracted and prepared for analysis using standard solvent 
extraction methods. The extracted samples were split into equal parts for analysis on the GC/MS and 
LC/MS/MS platforms in Metabolon facilities.  
The metabolic profiling dataset comprises a total of 254 named biochemical in adipose tissue, 
243 in brain tissue, and 383 in liver tissue.  Following log transformation and imputation with minimum 
observed values for each compound, Welch’s two-sample t-test was used to identify biochemicals that 
differed significantly between experimental groups for all matrices (p<0.05). An estimate of the false 
discovery rate (q-value) was calculated to take into account the multiple comparisons that normally occur 
in metabolomic-based studies.  For example, when analyzing 200 compounds, we would expect to see 
about 10 compounds meeting the p ≤ 0.05 cut-off by random chance. 
 
Microarray Analysis 
RNA isolation from Fbxl4+/+ and Fbxl4-/- MEFs and perinatal livers was performed in triplicate 
using the RNeasy Micro kit (Qiagen) according to the manufacturer’s protocol. Next, 10 ng of RNA from 
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each sample was amplified using Illumina TotalPrep RNA Amplification Kit (Illumina) and hybridized to 
MouseWG-6 v2.0 Expression BeadChip (Illumina)! microarray chips according to the manufacturer’s 
protocol. Expression values were normalized with GeneChip Robust Multiarray Averaging using the open-
source Bioconductor project (www.bioconductor.org) within the statistical computing environment R 
(http://cran.r-project.org). Differentially expressed genes were selected by the Student t test (P < .001) 
and fold change greater than 1.5. Gene Set Enrichment Analyses (GSEAs) were carried out in MATLAB, 
including the C2 molecular signature database gene sets.(Gould, Getz et al. 2006) 
 
Mitochondria DNA Copy Number Assessment 
Genomic DNA was extracted from confluent cells or liver tissue using the DNeasy Blood & Tissue 
Kit (Qiagen) according to the manufacturer’s instructions. Quantitative real-time PCR experiments were 
performed with an Applied Biosystems 7500 Real Time PCR Machine (Life Technologies), Fast Start 
Universal SYBR Green Master Rox (Roche), and primers to amplify Nd1 (forward primer 5’- 
CCTTCGACCTGACAGAAGGA-3’ and reverse primer 5’-GATGCTCGGATCCATAGGAA-3’) and Beta 
Actin (forward primer 5’-AGGTGACAGCATTGCTTCTG-3’ and reverse primer 5’-
GCTGCCTCAACACCTCAAC-3’). Actin was used as the nuclear gene normalizer for the calculation of 
mitochondria DNA to nuclear DNA ratio. All assays were conducted in triplicate and the results are shown 
as the average and standard deviation.   
 
Mitochondrial Morphology 
 Mitochondrial morphology was assessed by seeding 5 x 104 or 1 x 105 MEFs in glass bottom 
tissue culture dishes (MatTex). Fifteen hours later, cells were treated with 50 nM MitoTracker Red FM 
(MTR) (Invitrogen) in HBSS without phenol red (Life Technologies) at 37°C, 5% CO2 for 30 minutes. Cells 
were washed three times with PBS and imaged in HBSS without phenol red. Confocal microscopy was 





Mouse Strains and Genotyping 
To generate Fbxl4 conditional knockout mice, we introduced LoxP sites at mouse genomic 
(GRCm38/mm10) positions 22,390,197 and 22,391,137 flanking Exon 5 of the mouse Fbxl4 gene 
together with a neomycin selection cassette flanked by Frt sites by homologous recombination in 
C57BL/6 embryonic stem cells. We generated chimeras in C57BL/6 albino blastocysts using three 
independent targeted embryonic stem cell clones identified by PCR analysis and verified by Southern 
blot.  We verified germline transmission in the offspring of highly chimeric male mice crossed with 
C57BL/6 albino females. Presence of the Fbxl4 neo-fl allele was confirmed by PCR amplification using 
primers within the neomycin cassette (forward primer 5’-CGCTGTTCTCCTCTTCCTCA-3’ and reverse 
primer 5’-GCTCTTCGTCCAGATCATCC-3’) and primers to amplify the distal lox P site (forward primer 5’-
CAGAGGGTTCATCTCTGTATCAG-3’ and reverse primer 5’-AGCACCTGTTTGTATCCTAAGAA-3’). To 
remove the neomycin selection cassette we crossed mice harboring the targeting construct with a Flp 
germline deleter line (B6.Cg-Tg(ACTFLPe)9205Dym/J), the Jackson Laboratory). The Flp allele was 
amplified with primers within Flp recominbase (forward primer 5’-CACTGATATTGTAAGTAGTTTGC-3’ 
and reverse primer 5’-CTAGTGCGAAGTAGTGATCAGG-3’). The Fbxl4 fl allele was amplified by two 
separate PCR reactions, one using primers flanking the proximal lox P site (forward primer 5’-
TTTAGAAAGCTCCAACTGGAAA-3’, reverse primer 5’-GCACAAAGATATACGCACTGG-3’) and one 
using primers flanking the distal lox P site. 
To generate mice carrying a Fbxl4 deletion, we first crossed mice harboring this resulting 
conditional Fbxl4 targeted allele with ROSA26Cretg/ROSA26Cretg mice (obtained from Dr. Thomas 
Ludwig), which express Cre recombinase from the ubiquitous Rosa26 locus. The presence of the excised 
Fbxl4 allele (Fbxl4-) was identified by PCR amplification with primers that amplify an 1,100 base pair 
product of the Fbxl4 wild-type allele or a 406 base pair product of the deleted allele  (Fbxl4-) (forward 
primer 5’-AACATGCTATCCCACAGTTGC-3’ and reverse primer 5’-TTTCCATTTCTGACAATCACA-3’). 
The resulting mice were then crossed with wild type C57BL/6 animals to breed out the ROSA26Cretg 
allele.  
To conditionally delete Fbxl4 in early T-cell development, Fbxl4fl mice were crossed to mice 
harboring a Cre allele driven by the Lck promoter (The Jackson Laboratory). To conditionally excise Fbxl4 
! 135 
in hematopoietic stem cells, Fbxl4fl mice were crossed to mice with a Cre allele under control of the Vav 
promoter (The Jackson Laboratory). To generate conditional inducible Fbxl4 knockout mice, animals 
harboring the conditional Fbxl4fl targeted allele were bred with ROSA26TMCretg/+ mice, which express a 
tamoxifen-inducible form of the Cre recombinase from the ubiquitous Rosa26 locus.(Guo, McMinn et al. 
2007) 
All animals were maintained in specific pathogen-free facilities at the Irving Cancer Research 
Center at Columbia University Medical Campus. Animal procedures were approved by the Columbia 
University IACUC. 
 
Mouse T-ALL Monitoring and Processing 
Mice transplanted to develop primary or secondary NOTCH1-induced T-ALLs were monitored by 
submandibular phlebotomy to obtain peripheral blood for FACS analysis of circulating GFP-positive 
immature t-cell progenitors (list under the “FACS” section). Upon developing signs and symptoms of 
leukemia, or at the end of the follow up period, mice were sacrificed by euthanasia with CO2 and cervical 
dislocation. Tissue pieces were either snap-frozen for later use or processed for histological analysis by 
48 hours of formalin fixation and subsequent paraffin embedding. Additionally, single cell suspensions 
were prepared from leukemic spleen, thymus, and bone marrow samples using standard procedures. 
Different aliquots of single cells were analyzed by Flow Cytometry using T-cell markers (listed under the 
“FACS” section), snap frozen for later use, and frozen in 90% FBS, 10% DMSO.  
 
Nucleic Acid Isolation 
Genomic DNA (gDNA) was isolated using DNeasy Blood & Tissue Kit (Qiagen) according to the 
manufacturer’s instructions. RNA was prepared with RNeasy Micro Kit (Qiagen) by following the 
manufacturer’s protocol. The SuperScript First-Strand Synthesis System for RT-PCR was used to prepare 
cDNA from RNA (2 ug total input) according to the manufacturer’s instructions (Life Technologies). gDNA, 




Quantitative Real Time PCR (quantitative RT-PCR) 
qRT-PCR was performed using Fast Start Universal SYBR Green Master Rox (Roche), an 
Applied Biosystems 7500 Real Time PCR Machine (Life Technologies) using primers to amplify the 
mouse Fbxl4 gene (forward primer 5’-ACCATCCTGGAGCAGTCATC-3’ and reverse primer 5’-
GTATGGCTGAGGTTGAGGT-3’) or the mouse Gapdh gene (forward primer 5’-
TGGCAAAGTGGAGATTGTTGCC-3’ and reverse primer 5’-AAGATGGTGATGGGCTTCCCG-3’). 
 
Statistical Analyses 
 Statistical analysis was performed using Student’s t test. Results with P < 0.05 were considered 
statistically significant. Survival in animal experiments was represented with Kaplan-Meier curves, and 
significance was estimated with the log-rank test (GraphPad Prism). 
 
Southern Blot Analysis 
Southern Blot analysis was performed on genomic DNA isolated from mouse ES cell clones using 
standard procedures. For analysis of the integration of the external long arm of the Fbxl4 targeting 
construct, digestion by MscI and a probe generated by forward primer 5’-
AGATGACCACCAGTCTGGCAT-3’ and reverse primer 5’-GGCTAGATGCAGGGTGAATTTTCC -3’ were 
used. 
 
Tandem Affinity Purification 
HEK293T cells transiently transfected to express FBXL4(ΔFbox)-HA-FLAG or empty vector as a 
control (1 x 109 cells per condition) were lysed according to standard procedures in Lysis Buffer (50 mM 
Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, Phosphatase Inhibitor Cocktails 2 and 3 (Sigma Aldrich), 
and Complete Protease Inhibitor (Roche)), supplemented with 1% Trition-X. The cleared lysates were 
incubated with anti-FLAG M2 loaded sepharose beads (Sigma Aldrich) and then extensively washed with 
Wash Buffer (Lysis Buffer supplemented with 0.1% Triton X) at 4°C. Proteins associated with the anti-
Flag M2 beads were eluted by overnight incubation in Wash Buffer and 1 mg/ml Flag Peptide (Sigma 
Aldrich). These eluates were then incubated with anti-HA coupled sepharose beads (Sigma Aldrich), 
washed extensively and subjected to over day elution with Wash Buffer containing 1 mg/ml HA Peptide 
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(Roche Diagnostics). Protein eluates were resolved in 4-12% Bis-Tris gradient gels (Life Technologies) 
and subjected to silver staining according to the manufacturer’s instructions with the SliverQuest Staining 
Kit (Invitrogen). Following TCA precipitation of protein eluates, samples were analyzed by MALDI-TOF 
and ESI-LC-MS/MS mass spectrometry at the Taplin Mass Spectrometry Facility of Harvard University. 
 
Ubiquitin Pull-Down Assays  
HEK293T cells were transfected with His-ubiquitin and the indicated vectors. After 4 hours 10 uM 
of MG132 treatment (Sigma Aldrich), cells were washed with and harvested in ice-cold PBS with 10 mM 
N-ethylmaleimide (NEM; Sigma Aldrich), and a 10% sample was lysed in sample buffer. The remainder 
was lysed in a chaotropic lysis buffer containing 6 M guanidinium-HCl (Sigma Aldrich), 100 mM 
Na2HPO4/NaH2PO4 (P-) buffer, 10 mM Tris-HCl (pH 8.0), 20 mM imidazole, and 10 mM β-
mercaptoethanol. After sonification, lysates were cleared of their residual 16,000 × g centrifugation pellets 
and incubated with nickel sepharose beads (GE Healthcare) for 3 hour in a head-over-head tumbler at 
room temperature. Beads were washed with lysis buffer without imidazole and inhibitors, but with 0.2% 
Triton X-100, then with 8 M urea washing buffers A, B, and C (A, 8 M urea, 100 mM P-buffer, 10 mM Tris-
HCl [pH 8.0], 10 mM β-ME, 0.2% Triton X-100; B, as buffer A, but pH 6.3; C, as B, but with 0.1% Triton X-
100). His-tagged proteins were eluted with two bead volumes of elution buffer (8 M urea, 10 mM Tris-HCl 
[pH 7.0], 100 mM P buffer, and 200 mM imidazole), and 1.5 volumes of Laemmli’s SDS-Sample Buffer 
(Boston BioProducts). (Tauriello, Haegebarth et al. 2010)    
 
Western Blotting and Immunoprecipitation 
Total protein was isolated by standard procedures. Briefly, for Western blotting, cells were lysed 
in RIPA lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP40, 0.5% Sodium Deoxycholate, 0.1% SDS; 
supplemented with Phosphatase Inhibitor Cocktails 2 and 3 (Sigma Aldrich), and Complete Protease 
Inhibitor (Roche)) for 30 minutes on ice and then centrifuged at 13,2000 rpm for 15 minutes to clear the 
lysates. Protein concentrations were quantified using the BCA Kit (Pierce) and a Modulus Microplate 
reader capable of absorbance at 562 nm (Promega). For immunoprecipitation, cells were lysed in Lysis 
Buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, Phosphatase Inhibitor Cocktails 2 and 3 
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(Sigma Aldrich), and Complete Protease Inhibitor (Roche)), supplemented with 1% Trition-X, for 30 
minutes in rotation at 4°C and then centrifuged at 13,2000 rpm for 15 minutes to clear the lysates. Beads 
were washed with Wash Buffer (Lysis Buffer supplemented with 0.1% Triton X) and boiled directly in 2X 
sample buffer (Novex NuPAGE 10X Sample Reducing Agent and Novex NuPAGE 4X LDS Sample Buffer, 
both purchased from Life Technologies). 
Antibodies against NDUFB8 (ab110242), SHDA (ab14715), UQCRC2 (ab103616), ATP5A 
(ab14748), TOMM20 (ab56783), SLC25A4 (ab102032), and AIMF1 (ab32516) were from Abcam. The 
TUBULIN (TU-02) antibody was from Santa Cruz Biotechnology. The GAPDH (D16H11) and COX4I1 
(4844s) antibodies were from Cell Signaling. Antibodies against FBXL4 were obtained from Genetex 
(N1C1 or C1C3). For immunoprecipitation of epitope-tagged proteins, anti-HA or anti-MYC coupled 
sepharose beads were purchased from Sigma Aldrich. For Western Blot analysis of epitope-tagged 
proteins, HA epitope antibody was from Roche, FLAG epitope antibody was from Cell Signaling, and 
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Appendix A. An Activating Intragenic Deletion in NOTCH1 in human T-ALL 
Adapted from Haydu JE et al. An Activating Intragenic Deletion in NOTCH1 in human T-ALL (2012). 




T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic tumor resulting from 
the malignant transformation of immature T-cell progenitors.1,2 Activating mutations in NOTCH1 are a 
hallmark of T-cell transformation and are found in more than half of T-ALL cases.3-5 In the present study, 
we used array comparative genomics hybridization (aCGH) analysis to investigate the possibility that 
focal chromosomal rearrangements involving the NOTCH1 locus could also participate in the 
pathogenesis of human T-ALL.  
Here, we describe a novel mechanism of NOTCH1 activation in T-ALL, where a deletion 
removing the 5’ portion of NOTCH1 abolishes the negative regulatory control of the extracellular domain 
and leads to constitutively active NOTCH1 signaling. Polypeptides translated from truncated transcripts 
encoded by the NOTCH1 deletion allele retain the transmembrane domain of the receptor and are 
constitutively cleaved by the gamma secretase complex, resulting in high levels of NOTCH1 signaling 
which can be effectively blocked by gamma secretase inhibitors. Our results thus expand the spectrum of 
oncogenic lesions activating NOTCH1 signaling in human T-ALL. 
 
 
AA.2. Materials and Methods 
Patient samples 
DNA and lymphoblast samples were provided by the Eastern Cooperative Oncology Group. All 
samples were collected with informed consent in accordance with the Declaration of Helsinki and with 
approval from the Columbia University Medical Center institutional review board.  
Array CGH 
Array CGH of human T-ALL was performed with SurePrint G3 Human CGH 1 × 1M Oligo 





FISH was performed by standard methods in interphase nuclei using the RP11-370H5 and CTD-
3242B16 BAC probes encompassing the NOTCH1 locus as described previously.6 
5′-RACE 
5′-Rapid amplification of cDNA ends (5′-RACE) cDNA synthesis was performed with the 
SMARTer RACE cDNA Amplification Kit (Clontech) using a NOTCH1 exon 28–specific primer (5′-
TGGCCTCAGACACTTTGAAGCCCTCAG-3′) and the GC-RICH PCR System (Roche Applied Science).  
Gamma-secretase inhibitor treatments 
HEK-293T and HeLa cell cultures were treated for 48 hours with the gamma secretase inhibitor 
compound E (250nM; Enzo Life Sciences) in DMSO or with vehicle only.  
NOTCH1 expression plasmids 
The pCDNA3 NOTCH1, pCDNA3 NOTCH1 HD-ΔPEST, pCDNA3 NOTCH1 Jurkat JME17, and 
pCDNA3 NOTCH1 P12 mutant constructs have been described previously.7,8 The pCDNA3 NOTCH1 N-
terminal deletion mutant construct (pCDNA3 NOTCH1 del-N) consists of the ACATGG hexanucleotide, 
followed by the distal part of the NOTCH1 coding cDNA sequence (RefSeq number NM_017617) starting 
at position 4998 and a FLAG epitope coding sequence in the 3′ end.  
Luciferase reporter assays 
NOTCH1 expression plasmids (pCDNA3) were transfected transiently into HeLa cells using 
FuGene (Roche) together with the pGaLUC RBPJ/CSL luciferase reporter construct. A Renilla luciferase–
expressing vector (pRL) was used as an internal control. Luciferase assays were carried out using the 
Dual Luciferase Assay System (Promega) on a Modulus microplate reader.  
Western blotting 
Antibodies against activated NOTCH1 (NOTCH1 Val1774; Cell Signaling Technology), FLAG 
(DYKDDDDK Tag; Cell Signaling Technology), and actin (SC-1615; Santa Cruz Biotechnology) were 








AA.3. Results and Discussion 
 
AA.3.i. A novel 5′ NOTCH1 deletion in human T-ALL  
 
Oncogenic NOTCH1 signaling is a hallmark of T-ALL.3-5,8-12 However, approximately 40% of T-
ALL cases lack genetic alterations involving the NOTCH pathway.3,4,8,9 Based on the strict requirement of 
NOTCH1 for T-cell development13 and the prominent role of NOTCH1 signaling in T-ALL, we 
hypothesized that as-yet-unrecognized genetic alterations involving NOTCH1 may be implicated in the 
pathogenesis of T-ALL. To investigate this possibility, we performed aCGH analysis in 69 adult T-ALL 
samples, which revealed an intragenic deletion encompassing the 5′ region of the NOTCH1 locus in an 
early cortical double-positive (CD1+, CD4+, CD8+, CD3−) T-ALL patient sample (Figure A.1A-B). FISH 
analysis ruled out the presence of a chromosomal translocation involving NOTCH1 in this sample (data 
not shown). Detailed analysis of our aCGH data mapped the telomeric breakpoint of this deletion proximal 
to exon 1 of the NOTCH1 gene and positioned the centromeric deletion breakpoint between exons 24 
and 27. Based on these results, we predicted that this focal deletion could result in the expression of an 
N-terminal truncated form of NOTCH1. To investigate this possibility, we performed 5′-RACE from RNA 
extracted from NOTCH1-deleted tumor cells using a reverse primer located in exon 28 of NOTCH1. This 
experiment resulted in the amplification of a 367-nucleotide band consisting of a NOTCH1 del-N allele 
containing the ACATGG hexanucleotide, followed by the distal part of the NOTCH1 coding cDNA 
sequence starting in exon 26 at position 4998 (RefSeq number NM_017617; Figure A.1C-D). We found 
that a canonical Kozak consensus sequence flanks a potential NOTCH1 del-N translation initiation site 
located at nucleotides 14-16, which encode for a methionine corresponding to codon 1668 in the full-
length NOTCH1 receptor (Figure A.1E). DNA sequencing of exon 34 of NOTCH1 in this patient failed to 
demonstrate the presence of prototypical PEST domain–truncating mutations, but we did detect 2 
nonsynonymous single-nucleotide variants (NOTCH1 C6889A, NOTCH1 T2297P; NOTCH1 G7387T, 
NOTCH1 A2463T) in the PEST domain region of NOTCH1. Therefore, the predicted NOTCH1 del-N–
encoded protein consists of an 887-amino acid polypeptide encompassing the C-terminal HD domain of 
NOTCH1, followed by the juxtamembrane segment, transmembrane region, and intracellular domains of 








AA.3.ii. The NOTCH1 del-N mutant is a constitutively active form of NOTCH1 sensitive to γ-
secretase inhibitors 
 
To determine the functional impact of NOTCH1 del-N, we analyzed the levels of NOTCH1 
signaling using a RBPJ/CSL luciferase reporter assay in cells transfected with NOTCH1 del-N compared 
Figure A.1. Isolation and analysis of a NOTCH1 intragenic deletion in human T-ALL.  
(A) Chromosome 9 ideogram showing deletions identified by aCGH encompassing the 
CDKN2A/B tumor suppressor gene and the NOTCH1 locus in T-ALL. (B) aCGH plot 
showing an intragenic focal deletion of NOTCH1 in chromosome band 9q34. (C) Agarose 
gel electrophoresis of a truncated NOTCH1 cDNA sequence isolated by 5′-RACE using a 
primer located in exon 28 of NOTCH1. (D) Nucleotide sequence of the NOTCH1 5′ RACE 
product. (E) Kozak consensus sequence alignment of the NOTCH1 sequences surrounding 
methionine 1668 located at the N-terminal portion of the NOTCH1 del-N amino acid 
sequence. R indicates purine (adenosine or guanosine).   
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with cells transfected with wild-type NOTCH1 or with a panel of strongly activated NOTCH1 mutants such 
as NOTCH1 L1601P (HD) ΔPEST,8 NOTCH1 Jurkat JME17,7 and NOTCH1 P12.14 These experiments 
showed that expression of NOTCH1 del-N results in high levels (200-fold more than wild-type) of 
activated NOTCH signaling (Figure A.2A). NOTCH1 activation by NOTCH1 del-N was significantly higher 
than that resulting from expression of NOTCH1 HDΔPEST, NOTCH1 Jurkat JME17, or the NOTCH1 P12 
mutant allele (Figure A.2A). Consistent with the high levels of NOTCH1 activation detected in the 
luciferase reporter assay, NOTCH1 del-N induced high levels of expression of activated NOTCH1 protein 
(Figure A.2B). We also investigated the ability of compound E, a highly active and specific γ-secretase 
inhibitor, to inhibit NOTCH1 activation driven by the NOTCH1 del-N allele using a RBPJ/CSL luciferase 
reporter assay and Western blot analysis. These assays demonstrated complete abrogation of NOTCH1 
del-N–driven NOTCH1 signaling and rapid clearance of activated NOTCH1 protein after compound E 











Activating mutations in NOTCH1 are present in more than 60% of human T-ALLs, making 
oncogenic NOTCH1 signaling an attractive target for the development of new, highly specific antileukemic 
drugs.3,4,8,9,15 The NOTCH1 del-N T-ALL allele described herein, which results from an intragenic deletion 
in the NOTCH1 locus and encodes a highly active form of NOTCH1 sensitive to inhibition with γ-
secretase inhibitors, expands the repertoire of genetic alterations resulting in aberrant activation of the 
NOTCH1 signaling pathway in human T-ALL. Similar intragenic deletions in the Notch1 gene resulting in 
high levels of Notch1 activation and expression of 5′-truncated alternative spliced forms of NOTCH1 have 
been reported as common oncogenic alterations in mouse models of T-ALL.16-18 The del-N NOTCH1 
allele is reminiscent of the type II Notch1 intragenic deletions described by Ashworth et al.16 
Nevertheless, this seems to be a rare event in human T-ALL, because RT-PCR and 5′RACE analysis of 
T-ALL samples with PEST-only NOTCH1 mutations failed to detect additional samples expressing 5′-
truncated forms of NOTCH1 (data not shown).  
The identification of NOTCH1 del-N in human T-ALL in the present study highlights the relevance 
of genomic rearrangements activating NOTCH1 signaling in the pathogenesis of human T-ALL, provides 
further insight into the mechanisms of NOTCH1-meditated leukemic transformation, and substantiates the 
value of mouse models of T-ALL harboring activating 5′-truncated forms of Notch1 for the study of T-ALL.  
Figure A.2. The NOTCH1 del-N mutant shows high levels of NOTCH1 signaling and is 
sensitive to inhibition of the γ-secretase complex. (A) CSL luciferase reporter assay of 
ICN1 activity in HeLa cells transfected with empty vector (control) or expressing wild-type 
NOTCH1 (NOTCH1), NOTCH1 del-N deletion mutant (NOTCH1 del-N), NOTCH1 HD 
ΔPEST (HDΔPEST), NOTCH1 Jurkat JME17 (JME17), or NOTCH1 P12 (P12) mutant 
alleles. Reporter activity is shown as the fold change compared with wild-type NOTCH1. 
Error bars represent SD. P values were derived from Student t test. (B) Western blot 
analysis of HEK-293T cells expressing empty vector (Control) or FLAG-tagged forms of 
wild-type and del-N mutant NOTCH1 alleles. ICN1 protein was detected with the NOTCH1 
Val1744 Ab, which specifically recognizes the γ-secretase–cleaved activated form of 
NOTCH1. Total NOTCH1 levels were detected with an anti-FLAG Ab. Actin is shown as a 
loading control. (C) Transactivation activity of NOTCH1 del-N, HDΔPEST, Jurkat JME17, 
and P12 NOTCH1 alleles in a CSL luciferase reporter assay in HeLa cells treated with 
vehicle (DMSO) or a γ-secretase inhibitor (compound E, 250 nM). Reporter activity is shown 
as the fold reduction compared with vehicle-treated cells for each allele. Error bars 
represent SD. (D) Western blot analysis of activated NOTCH1 (ICN1) levels in 293T cells 
treated with compound E (250nM) for 48 hours shows inhibition of NOTCH1 processing and 
clearance of activated intracellular NOTCH1. ICN1 protein was detected with NOTCH1 
Val1744 Ab, total NOTCH1 levels were detected with anti-FLAG Abs, and actin is shown as 
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Empty Vector Reference Protein 
44 53 0 PRKDC_HUMAN PRKDC 
37 53 2+ CALX_HUMAN CANX 
30 40 0 AT1A1_HUMAN ATP1A1 
27 31 0 IMMT_HUMAN IMMT 
26 41 0 SUGT1_HUMAN SUGT1 
26 34 0 HUWE1_HUMAN HUWE1 
24 28 0 NFM_HUMAN NEFM 
23 30 0 TCPB_HUMAN CCT2 
22 30 0 TCPQ_HUMAN CCT8 
20 26 0 RUVB2_HUMAN RUVBL2 
20 25 0 DNJC7_HUMAN DNAJC7 
19 26 0 AIFM1_HUMAN AIFM1 
19 24 1 ATPA_HUMAN ATP5A1 
19 23 2+ TCPE_HUMAN CCT5 
18 26 0 HS105_HUMAN HSPH1 
18 19 1 MAP1B_HUMAN MAP1B 
18 19 0 GCN1L_HUMAN GCN1L1 
17 24 2+ TCPG_HUMAN CCT3 
17 22 0 SC16A_HUMAN SEC16A 
17 20 0 PSMD3_HUMAN PSMD3 
17 17 0 TNR6B_HUMAN TNRC6B 
16 23 0 DNJA1_HUMAN DNAJA1 
15 19 0 HS90A_HUMAN HSP90AA1 
14 22 0 CALU_HUMAN CALU 
14 17 0 CCD47_HUMAN CCDC47 
14 15 2+ TCPD_HUMAN CCT4 
14 15 0 PYR1_HUMAN CAD 
13 21 0 H90B3_HUMAN HSP90AB3P 
13 20 0 DNJA2_HUMAN DNAJA2 
13 18 0 PSMD2_HUMAN PSMD2 
13 17 0 BAG2_HUMAN BAG2 
13 16 0 RUVB1_HUMAN RUVBL1 
13 13 0 SMC2_HUMAN SMC2 
12 17 0 BAG6_HUMAN BAG6 
12 16 0 AT2A2_HUMAN ATP2A2 
Table B.1. Mass spectrometry analysis of the FBXL4 complex. Proteins (bolded) are 
ranked in descending order by the number of unique peptides and total peptides identified in 
the FBXL4ΔFbox HA eluate. Proteins with 2 or more peptides represented in the empty 
vector HA eluate are indicated with gray shading and are excluded from further analysis.  
! 170 
12 16 0 HDX_HUMAN HDX 
12 14 0 TCPA_HUMAN TCP1 
12 14 0 CAB45_HUMAN SDF4 
12 14 2+ TCPH_HUMAN CCT7 
12 13 0 RCN1_HUMAN RCN1 
12 12 0 ATPB_HUMAN ATP5B 
12 12 0 UGGG1_HUMAN UGGT1 
12 12 1 PHB2_HUMAN PHB2 
11 47 0 FBXL4_HUMAN FBXL4 
11 23 0 HSP72_HUMAN HSPA2 
11 14 0 TET2_HUMAN TET2 
11 14 0 ADT1_HUMAN SLC25A4 
11 13 0 MAGD2_HUMAN MAGED2 
11 13 0 PPM1A_HUMAN PPM1A 
11 12 0 MAGD1_HUMAN MAGED1 
11 12 0 MSH6_HUMAN MSH6 
11 11 0 CHCH3_HUMAN CHCHD3 
11 11 0 SMC4_HUMAN SMC4 
11 11 1 CKAP4_HUMAN CKAP4 
10 18 0 HS90B_HUMAN HSP90AB1 
10 17 0 HAX1_HUMAN HAX1 
10 11 0 PSMD6_HUMAN PSMD6 
10 10 0 CHIP_HUMAN STUB1 
10 10 0 UBR5_HUMAN UBR5 
9 18 2+ LAP2A_HUMAN TMPO 
9 12 1 RHG21_HUMAN ARHGAP21 
9 11 0 AT2A1_HUMAN ATP2A1 
9 11 0 PGRC1_HUMAN PGRMC1 
9 10 1 CE170_HUMAN CEP170 
9 10 0 HECD1_HUMAN HECTD1 
9 10 0 DNJB2_HUMAN DNAJB2 
9 10 0 PDIA3_HUMAN PDIA3 
9 9 0 NFL_HUMAN NEFL 
9 9 0 PSMD1_HUMAN PSMD1 
9 9 0 STIP1_HUMAN STIP1 
8 14 0 RCN2_HUMAN RCN2 
8 13 0 MPCP_HUMAN SLC25A3 
8 11 0 XPO1_HUMAN XPO1 
8 11 0 NUP93_HUMAN NUP93 
8 10 0 SMC3_HUMAN SMC3 
8 9 1 GRDN_HUMAN CCDC88A 
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8 9 0 DHE3_HUMAN GLUD1 
8 8 0 PSMD4_HUMAN PSMD4 
8 8 2+ PHB_HUMAN PHB 
8 8 0 PSD11_HUMAN PSMD11 
8 8 1 SLAI2_HUMAN SLAIN2 
8 8 0 PRS4_HUMAN PSMC1 
8 8 0 PRPS1_HUMAN PRPS1 
8 8 0 LMNB2_HUMAN LMNB2 
7 11 0 H90B2_HUMAN HSP90AB2P 
7 10 1 MGAP_HUMAN MGA 
7 9 0 SERA_HUMAN PHGDH 
7 9 0 FAF2_HUMAN FAF2 
7 8 1 IPO8_HUMAN IPO8 
7 8 0 SMC1A_HUMAN SMC1A 
7 8 0 AKP8L_HUMAN AKAP8L 
7 8 0 FANCI_HUMAN FANCI 
7 7 0 ERLEC_HUMAN ERLEC1 
7 7 0 XPO2_HUMAN CSE1L 
7 7 0 SCO2_HUMAN SCO2 
7 7 0 1433E_HUMAN YWHAE 
7 7 0 HSP74_HUMAN HSPA4 
6 9 0 CMC2_HUMAN SLC25A13 
6 9 0 MLF2_HUMAN MLF2 
6 8 0 TBB4A_HUMAN TUBB4A 
6 8 0 TOM70_HUMAN TOMM70A 
6 8 0 PFD2_HUMAN PFDN2 
6 8 0 DIC_HUMAN SLC25A10 
6 7 0 VDAC2_HUMAN VDAC2 
6 7 0 SYEP_HUMAN EPRS 
6 7 0 UBAC2_HUMAN UBAC2 
6 7 1 PRS7_HUMAN PSMC2 
6 7 0 ESYT2_HUMAN ESYT2 
6 7 0 HACD3_HUMAN PTPLAD1 
6 7 0 NU205_HUMAN NUP205 
6 7 0 MOT1_HUMAN SLC16A1 
6 7 0 METH_HUMAN MTR 
6 6 0 SAMH1_HUMAN SAMHD1 
6 6 1 PRS8_HUMAN PSMC5 
6 6 0 AMOT_HUMAN AMOT 
6 6 0 M3K7_HUMAN MAP3K7 
6 6 0 UN45A_HUMAN UNC45A 
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6 6 0 PRS10_HUMAN PSMC6 
6 6 0 GASP2_HUMAN GPRASP2 
6 6 0 GHC1_HUMAN SLC25A22 
6 6 0 PSD12_HUMAN PSMD12 
6 6 0 MARH7_HUMAN MAR7_ 
6 6 1 RS13_HUMAN RPS13 
6 6 0 ATPG_HUMAN ATP5C1 
6 6 0 OXA1L_HUMAN OXA1L 
6 6 0 CLGN_HUMAN CLGN 
6 6 0 PPP5_HUMAN PPP5C 
5 30 1 RL40_HUMAN UBA52 
5 24 0 TBB1_HUMAN TUBB1 
5 20 1 TBB3_HUMAN TUBB3 
5 9 0 PEX19_HUMAN PEX19 
5 7 0 AMFR_HUMAN AMFR 
5 7 0 DNJA3_HUMAN DNAJA3 
5 7 0 PJA1_HUMAN PJA1 
5 7 0 QCR2_HUMAN UQCRC2 
5 7 0 HEAT1_HUMAN HEATR1 
5 7 0 IMB1_HUMAN KPNB1 
5 7 0 PPM1B_HUMAN PPM1B 
5 6 0 AKAP8_HUMAN AKAP8 
5 6 0 BASI_HUMAN BSG 
5 6 0 AMRA1_HUMAN AMBRA1 
5 6 0 RL7_HUMAN RPL7 
5 6 0 TCPZ_HUMAN CCT6A 
5 6 1 2AAA_HUMAN PPP2R1A 
5 5 0 PDS5A_HUMAN PDS5A 
5 5 0 SPTC1_HUMAN SPTLC1 
5 5 0 GCP2_HUMAN TUBGCP2 
5 5 0 LTBP1_HUMAN LTBP1 
5 5 0 GALK1_HUMAN GALK1 
5 5 0 PJA2_HUMAN PJA2 
5 5 0 TIM50_HUMAN TIMM50 
5 5 0 HS74L_HUMAN HSPA4L 
5 5 0 VDAC1_HUMAN VDAC1 
5 5 0 ACADM_HUMAN ACADM 
5 5 0 C1TC_HUMAN MTHFD1 
5 5 1 CAPR1_HUMAN CAPRIN1 
5 5 0 PRS6A_HUMAN PSMC3 
5 5 0 EF2_HUMAN EEF2 
! 173 
5 5 0 AN13A_HUMAN ANKRD13A 
5 5 0 PFD3_HUMAN VBP1 
5 5 0 K1671_HUMAN KIAA1671 
5 5 0 JAK1_HUMAN JAK1 
5 5 0 U520_HUMAN SNRNP200 
5 5 0 BAG3_HUMAN BAG3 
5 5 0 XPOT_HUMAN XPOT 
5 5 0 GCDH_HUMAN GCDH 
5 5 0 RPN2_HUMAN RPN2 
5 5 0 PRS6B_HUMAN PSMC4 
5 5 0 AFG32_HUMAN AFG3L2 
5 5 0 PSD13_HUMAN PSMD13 
4 7 0 TCAL4_HUMAN TCEAL4 
4 6 2+ RUXF_HUMAN SNRPF 
4 6 2+ FA98B_HUMAN FAM98B 
4 6 2+ TIF1B_HUMAN TRIM28 
4 5 2+ IF4E2_HUMAN EIF4E2 
4 5 0 TAB2_HUMAN TAB2 
4 5 0 UBL4A_HUMAN UBL4A 
4 5 2+ HNRPF_HUMAN HNRNPF 
4 5 0 TOIP2_HUMAN TOR1AIP2 
4 5 2+ HNRPD_HUMAN HNRNPD 
4 5 0 SYFA_HUMAN FARSA 
4 5 0 EFTU_HUMAN TUFM 
4 5 0 BRAT1_HUMAN BRAT1 
4 5 0 AAAT_HUMAN SLC1A5 
4 5 0 EIF3B_HUMAN EIF3B 
4 5 0 TRAD1_HUMAN TRAFD1 
4 5 2+ RBM3_HUMAN RBM3 
4 5 2+ RLA2_HUMAN RPLP2 
4 5 0 TSC2_HUMAN TSC2 
4 5 0 P5CS_HUMAN ALDH18A1 
4 5 0 FUBP2_HUMAN KHSRP 
4 5 2+ RAN_HUMAN RAN 
4 5 2+ ERH_HUMAN ERH 
4 4 2+ EIF3C_HUMAN EIF3C 
4 4 2+ DDX17_HUMAN DDX17 
4 4 0 SSRD_HUMAN SSR4 
4 4 0 PHLB3_HUMAN PHLDB3 
4 4 2+ CIRBP_HUMAN CIRBP 
4 4 0 YTHD2_HUMAN YTHDF2 
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4 4 0 FACR1_HUMAN FAR1 
4 4 0 DCTN1_HUMAN DCTN1 
4 4 0 GANAB_HUMAN GANAB 
4 4 0 CMC1_HUMAN SLC25A12 
4 4 0 ATX10_HUMAN ATXN10 
4 4 0 RIF1_HUMAN RIF1 
4 4 2+ ANFY1_HUMAN ANKFY1 
4 4 2+ RL22_HUMAN RPL22 
4 4 0 WIZ_HUMAN WIZ 
4 4 0 ODPB_HUMAN PDHB 
4 4 0 TTC27_HUMAN TTC27 
4 4 0 VIME_HUMAN VIM 
4 4 0 CNOT1_HUMAN CNOT1 
4 4 1 RS15A_HUMAN RPS15A 
4 4 2+ EIF3E_HUMAN EIF3E 
4 4 0 NOM1_HUMAN NOM1 
4 4 0 DNJB1_HUMAN DNAJB1 
4 4 0 BAG5_HUMAN BAG5 
4 4 0 PPM1G_HUMAN PPM1G 
4 4 0 RPB2_HUMAN POLR2B 
4 4 0 OGT1_HUMAN OGT 
4 4 2+ RFA2_HUMAN RPA2 
4 4 0 TECR_HUMAN TECR 
4 4 0 YMEL1_HUMAN YME1L1 
4 4 0 MCM7_HUMAN MCM7 
4 4 0 TAB1_HUMAN TAB1 
4 4 0 DDX20_HUMAN DDX20 
4 4 0 PDXD1_HUMAN PDXDC1 
4 4 0 RM12_HUMAN MRPL12 
4 4 2+ RL7A_HUMAN RPL7A 
4 4 0 LBR_HUMAN LBR 
4 4 0 FKBP8_HUMAN FKBP8 
4 4 0 SE1L1_HUMAN SEL1L 
4 4 0 WRIP1_HUMAN WRNIP1 
4 4 0 TCPW_HUMAN CCT6B 
4 4 1 NS1BP_HUMAN IVNS1ABP 
4 4 0 HIN1L_HUMAN HIN1L 
4 4 0 MLF1_HUMAN MLF1 
4 4 0 THOC2_HUMAN THOC2 
4 4 2+ PRDX1_HUMAN PRDX1 
4 4 0 DJC11_HUMAN DNAJC11 
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4 4 2+ RL12_HUMAN RPL12 
4 4 2+ RL28_HUMAN RPL28 
4 4 0 PSA1_HUMAN PSMA1 
3 6 1 IMA2_HUMAN KPNA2 
3 6 0 COPR5_HUMAN COPR5 
3 5 0 GGT7_HUMAN GGT7 
3 5 2+ ROA1_HUMAN HNRNPA1 
3 5 0 DJB11_HUMAN DNAJB11 
3 5 0 TIM8B_HUMAN TIMM8B 
3 5 0 PP6R3_HUMAN PPP6R3 
3 4 0 PDIA1_HUMAN P4HB 
3 4 0 ALMS1_HUMAN ALMS1 
3 4 0 NFXL1_HUMAN NFXL1 
3 4 0 TM165_HUMAN TMEM165 
3 4 0 PLAP_HUMAN PLAA 
3 4 0 PFD4_HUMAN PFDN4 
3 4 0 NU107_HUMAN NUP107 
3 4 0 S27A4_HUMAN SLC27A4 
3 4 0 ERF_HUMAN ERF 
3 4 0 RS27L_HUMAN RPS27L 
3 4 0 B4DLE8_HUMAN CRYBG3 
3 4 0 BORG5_HUMAN CDC42EP1 
3 4 2+ PDIP3_HUMAN POLDIP3 
3 4 2+ RAM_HUMAN FAM103A1 
3 4 2+ SMD2_HUMAN SNRPD2 
3 3 0 4F2_HUMAN SLC3A2 
3 3 0 TIM13_HUMAN TIMM13 
3 3 0 TBB6_HUMAN TUBB6 
3 3 2+ THOC4_HUMAN ALYREF 
3 3 2+ PAIRB_HUMAN SERBP1 
3 3 0 RNF31_HUMAN RNF31 
3 3 0 DNJB3_HUMAN DNAJB3 
3 3 0 CDC45_HUMAN CDC45 
3 3 0 UBP19_HUMAN USP19 
3 3 0 SYMC_HUMAN MARS 
3 3 0 SRPRB_HUMAN SRPRB 
3 3 0 TOIP1_HUMAN TOR1AIP1 
3 3 0 ATPO_HUMAN ATP5O 
3 3 0 RBP2_HUMAN RANBP2 
3 3 2+ RS20_HUMAN RPS20 
3 3 0 TTK_HUMAN TTK 
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3 3 2+ PRC2B_HUMAN PRRC2B 
3 3 0 STML2_HUMAN STOML2 
3 3 0 AKA11_HUMAN AKAP11 
3 3 0 BAG4_HUMAN BAG4 
3 3 0 FACD2_HUMAN FANCD2 
3 3 0 NDUAD_HUMAN NDUFA13 
3 3 0 PSAL_HUMAN NPEPPSL1 
3 3 0 GPN1_HUMAN GPN1 
3 3 0 APC1_HUMAN ANAPC1 
3 3 0 COPA_HUMAN COPA 
3 3 0 CPSF5_HUMAN NUDT21 
3 3 0 PFD5_HUMAN PFDN5 
3 3 0 DNJB6_HUMAN DNAJB6 
3 3 2+ RFA3_HUMAN RPA3 
3 3 2+ RL11_HUMAN RPL11 
3 3 0 IGBP1_HUMAN IGBP1 
3 3 0 AURKB_HUMAN AURKB 
3 3 0 SRC8_HUMAN CTTN 
3 3 0 MCM3_HUMAN MCM3 
3 3 2+ ILF3_HUMAN ILF3 
3 3 0 PSB2_HUMAN PSMB2 
3 3 0 SDF2L_HUMAN SDF2L1 
3 3 0 AL3A2_HUMAN ALDH3A2 
3 3 0 RAF1_HUMAN RAF1 
3 3 0 2ABA_HUMAN PPP2R2A 
3 3 0 PELO_HUMAN PELO 
3 3 0 NUDC_HUMAN NUDC 
3 3 1 METK2_HUMAN MAT2A 
3 3 0 RS16_HUMAN RPS16 
3 3 0 ELOB_HUMAN TCEB2 
3 3 0 RPN1_HUMAN RPN1 
3 3 0 AIP_HUMAN AIP 
3 3 2+ RL13_HUMAN RPL13 
3 3 2+ ROCK1_HUMAN ROCK1 
3 3 0 TMCO1_HUMAN TMCO1 
3 3 0 MTDC_HUMAN MTHFD2 
3 3 0 COX2_HUMAN MT-CO2 
3 3 0 SPC24_HUMAN SPC24 
3 3 0 NP1L4_HUMAN NAP1L4 
3 3 0 ERLN2_HUMAN ERLIN2 
3 3 0 NDK8_HUMAN NME2P1 
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3 3 0 PSPC1_HUMAN PSPC1 
3 3 0 CN37_HUMAN CNP 
3 3 0 TNPO1_HUMAN TNPO1 
3 3 0 RFOX1_HUMAN RBFOX1 
3 3 0 MMS19_HUMAN MMS19 
3 3 0 1433B_HUMAN YWHAB 
3 3 0 SMG7_HUMAN SMG7 
3 3 0 SFXN1_HUMAN SFXN1 
3 3 0 PSA5_HUMAN PSMA5 
3 3 0 RL18_HUMAN RPL18 
3 3 2+ NPM_HUMAN NPM1 
3 3 0 PCH2_HUMAN TRIP13 
3 3 2+ RM11_HUMAN MRPL11 
3 3 0 SUCB1_HUMAN SUCLA2 
3 3 2+ RS6_HUMAN RPS6 
3 3 0 S61A1_HUMAN SEC61A1 
3 3 0 RN115_HUMAN RNF115 
3 3 0 PSD7_HUMAN PSMD7 
3 3 0 MA7D3_HUMAN MAP7D3 
3 3 0 RL35A_HUMAN RPL35A 
3 3 0 CAZA1_HUMAN CAPZA1 
3 3 2+ RS5_HUMAN RPS5 
3 3 1 PRC2C_HUMAN PRRC2C 
3 3 0 ZC11A_HUMAN ZC3H11A 
3 3 0 TXTP_HUMAN SLC25A1 
3 3 1 3MG_HUMAN MPG 
3 3 0 NU133_HUMAN NUP133 
3 3 0 IQEC1_HUMAN IQSEC1 
3 3 0 PCNA_HUMAN PCNA 
2 5 0 USP9X_HUMAN USP9X 
2 5 1 TBB4B_HUMAN TUBB4B 
2 5 0 AF1Q_HUMAN MLLT11 
2 5 0 ADRM1_HUMAN ADRM1 
2 4 0 TOM1_HUMAN TOM1 
2 4 0 PTSS2_HUMAN PTDSS2 
2 4 0 MAGD4_HUMAN MAGED4 
2 4 0 LAS1L_HUMAN LAS1L 
2 3 2+ LUC7L_HUMAN LUC7L 
2 3 0 1433T_HUMAN YWHAQ 
2 3 2+ SRRT_HUMAN SRRT 
2 3 0 DJC16_HUMAN DNAJC16 
! 178 
2 3 0 TOM22_HUMAN TOMM22 
2 3 0 SKP1_HUMAN SKP1 
2 3 0 FR1OP_HUMAN FGFR1OP 
2 3 0 AT2B1_HUMAN ATP2B1 
2 3 1 RFC3_HUMAN RFC3 
2 3 0 RPAP1_HUMAN RPAP1 
2 3 0 DDX6_HUMAN DDX6 
2 3 0 SQSTM_HUMAN SQSTM1 
2 3 2+ UBAP2_HUMAN UBAP2 
2 3 0 DJB12_HUMAN DNAJB12 
2 3 0 PSDE_HUMAN PSMD14 
2 3 0 SARNP_HUMAN SARNP 
2 3 1 ZN638_HUMAN ZNF638 
2 3 0 MIA40_HUMAN CHCHD4 
2 3 2+ YBOX1_HUMAN YBX1 
2 3 0 LAGE3_HUMAN LAGE3 
2 3 0 ZDBF2_HUMAN ZDBF2 
2 3 0 J3KNL6_HUMAN SEC16A 
2 3 0 CX057_HUMAN CXorf57 
2 3 0 PP6R1_HUMAN PPP6R1 
2 3 2+ G3BP1_HUMAN G3BP1 
2 3 0 SAAL1_HUMAN SAAL1 
2 3 0 GTSE1_HUMAN GTSE1 
2 3 0 RBBP7_HUMAN RBBP7 
2 3 2+ LARP1_HUMAN LARP1 
2 3 0 NDUA4_HUMAN NDUFA4 
2 3 0 ALG1_HUMAN ALG1 
2 3 0 CAND2_HUMAN CAND2 
2 2 1 EIF3H_HUMAN EIF3H 
2 2 2+ TR112_HUMAN TRMT112 
2 2 0 VATA_HUMAN ATP6V1A 
2 2 2+ E9PBV3_HUMAN SBSN 
2 2 0 MDN1_HUMAN MDN1 
2 2 0 IRAK1_HUMAN IRAK1 
2 2 1 FIP1_HUMAN FIP1L1 
2 2 1 LYRIC_HUMAN MTDH 
2 2 0 CDK9_HUMAN CDK9 
2 2 0 INT3_HUMAN INTS3 
2 2 0 BIG1_HUMAN ARFGEF1 
2 2 0 THEM6_HUMAN THEM6 
2 2 0 PRP6_HUMAN PRPF6 
! 179 
2 2 0 VATH_HUMAN ATP6V1H 
2 2 2+ HNRH3_HUMAN HNRNPH3 
2 2 0 VCIP1_HUMAN VCPIP1 
2 2 0 HAUS6_HUMAN HAUS6 
2 2 0 ZWINT_HUMAN ZWINT 
2 2 0 HS902_HUMAN HSP90AA2 
2 2 0 ZCCHV_HUMAN ZC3HAV1 
2 2 2+ CHTOP_HUMAN CHTOP 
2 2 0 LAT1_HUMAN SLC7A5 
2 2 1 PTPS_HUMAN PTS 
2 2 2+ DHX15_HUMAN DHX15 
2 2 0 TAF4_HUMAN TAF4 
2 2 0 KIRR1_HUMAN KIRREL 
2 2 0 PCBP1_HUMAN PCBP1 
2 2 2+ ATD3B_HUMAN ATAD3B 
2 2 1 1433Z_HUMAN YWHAZ 
2 2 0 RL23_HUMAN RPL23 
2 2 0 E41L3_HUMAN EPB41L3 
2 2 0 IPO9_HUMAN IPO9 
2 2 0 AKAP1_HUMAN AKAP1 
2 2 0 GOGA2_HUMAN GOLGA2 
2 2 0 ETFA_HUMAN ETFA 
2 2 0 NOP14_HUMAN NOP14 
2 2 0 HTF4_HUMAN TCF12 
2 2 0 PABP4_HUMAN PABPC4 
2 2 0 NDUF4_HUMAN NDUFAF4 
2 2 0 TIDC1_HUMAN TIMMDC1 
2 2 1 ACTB_HUMAN ACTB 
2 2 1 MAX_HUMAN MAX 
2 2 2+ RU17_HUMAN SNRNP70 
2 2 0 TMX3_HUMAN TMX3 
2 2 2+ EIF3D_HUMAN EIF3D 
2 2 0 APOOL_HUMAN APOOL 
2 2 0 WIBG_HUMAN WIBG 
2 2 0 OS9_HUMAN OS9 
2 2 2+ ROA3_HUMAN HNRNPA3 
2 2 0 EAA1_HUMAN SLC1A3 
2 2 2+ F263_HUMAN PFKFB3 
2 2 0 ASHWN_HUMAN C2orf49 
2 2 0 AGK_HUMAN AGK 
2 2 2+ ZN598_HUMAN ZNF598 
! 180 
2 2 2+ ACAP2_HUMAN ACAP2 
2 2 0 TADBP_HUMAN TARDBP 
2 2 0 CBWD1_HUMAN CBWD1 
2 2 0 ZYX_HUMAN ZYX 
2 2 0 DAPLE_HUMAN CCDC88C 
2 2 0 HSPB1_HUMAN HSPB1 
2 2 0 KANK2_HUMAN KANK2 
2 2 0 SV2A_HUMAN SV2A 
2 2 0 RS9_HUMAN RPS9 
2 2 1 PRP8_HUMAN PRPF8 
2 2 1 IF4G1_HUMAN EIF4G1 
2 2 0 PREB_HUMAN PREB 
2 2 0 SPG20_HUMAN SPG20 
2 2 0 UBP15_HUMAN USP15 
2 2 0 LARP4_HUMAN LARP4 
2 2 0 COG2_HUMAN COG2 
2 2 0 OSGEP_HUMAN OSGEP 
2 2 0 TMM33_HUMAN TMEM33 
2 2 0 NCLN_HUMAN NCLN 
2 2 0 EXOC4_HUMAN EXOC4 
2 2 0 PFD1_HUMAN PFDN1 
2 2 0 TRABD_HUMAN TRABD 
2 2 0 VDAC3_HUMAN VDAC3 
2 2 0 IPO7_HUMAN IPO7 
2 2 2+ CEP70_HUMAN CEP70 
2 2 0 ERLN1_HUMAN ERLIN1 
2 2 0 ECHB_HUMAN HADHB 
2 2 0 OPA1_HUMAN OPA1 
2 2 0 UBQL1_HUMAN UBQLN1 
2 2 0 DSG2_HUMAN DSG2 
2 2 0 AT5F1_HUMAN ATP5F1 
2 2 1 RBM39_HUMAN RBM39 
2 2 2+ H12_HUMAN HIST1H1C 
2 2 1 CLPX_HUMAN CLPX 
2 2 0 STT3A_HUMAN STT3A 
2 2 2+ ROA0_HUMAN HNRNPA0 
2 2 2+ EIF3G_HUMAN EIF3G 
2 2 0 DHB12_HUMAN HSD17B12 
2 2 0 SYNRG_HUMAN SYNRG 
2 2 2+ CPSF6_HUMAN CPSF6 
2 2 1 COA3_HUMAN COA3 
! 181 
2 2 0 MOGS_HUMAN MOGS 
2 2 0 DRS7B_HUMAN DHRS7B 
2 2 0 HEAT2_HUMAN HEATR2 
2 2 0 PSB5_HUMAN PSMB5 
2 2 0 NELFE_HUMAN RDBP 
2 2 0 ERAL1_HUMAN ERAL1 
2 2 0 SLIK5_HUMAN SLITRK5 
2 2 2+ HEMH_HUMAN FECH 
2 2 2+ RS18_HUMAN RPS18 
2 2 2+ MAP7_HUMAN MAP7 
2 2 0 UBP54_HUMAN USP54 
2 2 0 CDC73_HUMAN CDC73 
2 2 0 FAS_HUMAN FASN 
2 2 0 ECHA_HUMAN HADHA 
2 2 0 CHCH1_HUMAN CHCHD1 
2 2 0 DNJB5_HUMAN DNAJB5 
2 2 0 EI2BG_HUMAN EIF2B3 
2 2 0 CHCH6_HUMAN CHCHD6 
2 2 0 EPN4_HUMAN CLINT1 
2 2 0 DHCR7_HUMAN DHCR7 
2 2 0 CDC5L_HUMAN CDC5L 
2 2 0 BRCA2_HUMAN BRCA2 
2 2 1 BYST_HUMAN BYSL 
2 2 0 GLMN_HUMAN GLMN 
2 2 1 RA1L2_HUMAN HNRNPA1L2 
2 2 1 CDC37_HUMAN CDC37 
2 2 0 PSA4_HUMAN PSMA4 
2 2 0 XRCC5_HUMAN XRCC5 
2 2 0 SSRG_HUMAN SSR3 
2 2 0 RL37A_HUMAN RPL37A 
2 2 0 UFD1_HUMAN UFD1L 
2 2 0 RL4_HUMAN RPL4 
2 2 2+ H11_HUMAN HIST1H1A 
2 2 0 ATG9A_HUMAN ATG9A 
2 2 0 RBP10_HUMAN RANBP10 
2 2 0 ZC3H4_HUMAN ZC3H4 
2 2 0 TRI32_HUMAN TRIM32 
2 2 0 DNJB4_HUMAN DNAJB4 
2 2 0 CLPB_HUMAN CLPB 
2 2 0 TTC4_HUMAN TTC4 
2 2 0 PM14_HUMAN SF3B14 
! 182 
2 2 0 SC61B_HUMAN SEC61B 
2 2 0 RL9_HUMAN RPL9 
2 2 0 SYIC_HUMAN IARS 
2 2 0 GTPB3_HUMAN GTPBP3 
2 2 0 S35E1_HUMAN SLC35E1 
2 2 0 PFD6_HUMAN PFDN6 
2 2 0 UCRIL_HUMAN UQCRFS1P1 
2 2 0 EXO1_HUMAN EXO1 
2 2 0 TOM20_HUMAN TOMM20 
2 2 0 NAV1_HUMAN NAV1 
2 2 2+ DHX9_HUMAN DHX9 
2 2 0 ATPF1_HUMAN ATPAF1 
2 2 0 CYBP_HUMAN CACYBP 
2 2 2+ SLIRP_HUMAN SLIRP 
2 2 0 RNF12_HUMAN RLIM 
2 2 0 C1TM_HUMAN MTHFD1L 
2 2 0 HIG1A_HUMAN HIGD1A 
2 2 0 NDUS3_HUMAN NDUFS3 
2 2 0 GCP4_HUMAN TUBGCP4 
2 2 0 MD2L2_HUMAN MAD2L2 
2 2 0 SAM50_HUMAN SAMM50 
2 2 0 E2AK3_HUMAN EIF2AK3 
2 2 0 MD2L1_HUMAN MAD2L1 
2 2 2+ EIF3F_HUMAN EIF3F 
2 2 2+ RS10_HUMAN RPS10 
 
